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Abstract 
 
Inflammatory bowel disease (IBD) is idiopathic in origin and is associated with damaged 
mucosa which may bleed and result in anaemia. Iron deficiency is common in IBD and has 
been shown to be involved in the pathogenesis of the anaemia of patients with IBD. 
Treatment of iron deficiency with oral iron supplementation may intensify inflammation and 
tissue damage, and there is evidence that iron supplementation induces inflammation both 
in normal rats and in rodent models of IBD. 
 
The intestinal microbiota is considered to play a vital role in the pathogenesis of IBD, and 
various studies have confirmed the presence of intestinal dysbiosis in IBD patients compared 
to healthy controls. Furthermore, iron supplementation has been shown to influence 
microbial diversity. This thesis studies the effect of iron on gut microbial composition in the 
presence of mucosal inflammation. 
 
These aims were addressed using acute and chronic (DSS) murine models of IBD using wild-
type C57BL/6 mice receiving diets differing in iron content. Bacterial gDNA was extracted from 
faeces, and the microbiota composition was determined by sequencing the V4 region of 16S 
rDNA on the Illumina MiSeq platform. DSS-induced colitis in all treated mice, but a low iron 
consumption was clinically (body weight (p<0.001) and histology (p<0.0001)) more influential 
on colitis. Whereas, high iron intake was more prominent regarding intestinal microbiota 
disturbance (reduction in Bacteroidetes and Firmicutes and an increase in Proteobacteria and 
Actinobacteria).  
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This thesis demonstrates that changes in nutritional luminal iron (100ppm and 400ppm iron) 
exacerbate colitis and cause dysbiosis in mice with acute or chronic colitis. Iron, therefore, 
appears to contribute to the dysbiosis which is associated with IBD.  
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1.1 Inflammatory bowel disease  
 
Inflammatory bowel disease (IBD) is a group of disorders affecting the gastrointestinal tract 
(GIT). Ulcerative colitis (UC) and Crohn’s disease (CD) represent the principal types of 
inflammatory bowel disease (IBD), and they are idiopathic in nature. In general, IBD patients 
complain of abdominal pain, diarrhoea, weight loss, and rectal bleeding. Chronic 
inflammation of the intestinal tract is the main feature of IBD. UC and CD are manageable, 
but incurable diseases. They often begin in patients in their teens to 20s, and then they 
frequently show a relapsing and remitting clinical course 1.  
 
At present, the prevalence of IBD in the UK is 0.5–1%, with an estimated 620 000 people 
believed to be affected. Men and women are diagnosed in similar numbers. The rising 
incidence of the condition, young age of onset and severe nature mean that treatment of IBD 
has significant implications 2, 3. 
 
In Crohn’s disease, the inflammation may occur anywhere along the digestive tract, whereas 
in UC the colon is the only affected site. The inflammation disturbs the mucosal layer only in 
UC, whereas CD shows transmural involvement 4.  
 
IBD patients go through numerous investigations and procedures to make the diagnosis 
before they can receive appropriate treatment. Medical management of inflammatory bowel 
disease seeks to induce and maintain remission using corticosteroids, immunosuppressive 
and biologic agents. As a result of their symptoms, their medication and its side effects, 
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patients often lack confidence and face significant impacts on their lives, such as loss of jobs, 
disrupted education and health insurance issues.  
 
1.1.1 Aetiology and pathogenesis  
 
1.1.1.1 Aetiology 
 
IBD is characterised by immunoregulatory defects in the mucosa. Some theories have been 
proposed regarding the causes of IBD, such as a dysfunctional immune host response to 
normal intestinal luminal microbes; infection with a particular pathogen; and an impaired 
mucosal barrier to luminal antigens. Immune responses to the intestinal microbiota in 
inflamed tissues are thought to result from a failure of tolerance to the commensal 
microbiota. A dysregulated and inappropriately persistent inflammatory response is central 
to the development of both types of IBD 5, 6. 
 
1.1.1.2 Pathogenesis  
 
Inflammation is advantageous when it is physiological and stops spontaneously without 
causing any tissue damage, clearing the trigger of that inflammation. However, in IBD the 
inflammation is pathological, chronic, and out of control 7. 
 
Existing aetiological concepts of IBD focus on environmental causes (microbial factors), 
genetic influences, and immunoregulatory defects as it’s shown in figure 1-1. 
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                          Figure 1-1: The factors contributing to the development of IBD (adapted from 8) 
 
 
The concept of the impact of environmental factors in IBD came from epidemiologic studies: 
changes in diet, smoking, alterations in sunlight, pollution, and industrial chemicals are 
important influences 8. Hygiene and exposure to infection are risk factors. Poor sanitation 
seems to protect against IBD since the prevalence of UC and CD in higher socioeconomic 
communities is greater than in poorer communities. UC and CD are more common in white-
collar workers compared with those with blue-collar jobs, and mortality from IBD is low 
among farmers and builders 9. Researchers in a German study proposed that working 
outdoors and physical activity may protect against IBD. Such hypothesis may explain why IBD 
is more common in northern latitudes and among immigrants from developing countries 10. 
 
Diet is considered to have a major influence on the gut microbiota 11. A diet rich in high fatty 
acids increases the risk of IBD, and fast-food consumption causes a 3-4 fold greater risk for 
IBD 12. 
 
IBD 
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Smoking is the strongest environmental risk factor for IBD. Smoking has the opposite effect 
on each form of IBD; for example, non-smoking is a feature of UC, whereas smoking is a risk 
for CD 13. Moreover, smoking can aggravate the clinical and endoscopic recurrence of CD as 
well as affecting disease activity (37% among non-smokers, 46% of patients who smoked less 
than 10 cigarettes/d, and 48% among heavy smokers) after surgery 14. Maintenance 
treatment with azathioprine is also more effective in non-smokers than smokers with CD 
(Figure1-2) 13. 
 
The elements in tobacco that cause these effects are undefined. A modulatory effect of 
nicotine on immune reactions in vitro has previously been detected, so the different 
association between UC and CD, in particular, is mystifying and may be related to differences 
in the pathogenesis of the two illnesses 15, 16. 
 
 
 
Figure 1-2: Cumulative probability of recurrence depending on the preventive use of azathioprine 
and active smoking (Reproduced with permission from the author 12) 
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1.1.1.2.1 Genetic factors  
 
Genetic factors are important in the susceptibility to IBD. UC and CD are polygenic diseases 
sharing some but not all susceptibility loci 17. There is an increased rate of IBD in first- and 
second-degree relatives of patients and a higher relative risk among siblings. The occurrence 
of IBD among family members ranges from 20% to 30% in referral-based studies and from 5% 
to 10% in population surveys 17. The increased risk of IBD in the Jewish community also 
supports the role of genetic factors in the aetiology of IBD 18. 
 
In families with a high incidence of IBD among first-degree relatives, 75% of those affected 
are concordant for either UC or CD, whereas 25% are discordant, with some members having 
UC and others having CD; this finding indicates that the genetic factors may overlap 17. 
Furthermore, there is a greater concordance in monozygotic twins with CD or UC, compared 
with dizygotic twins 19. Interestingly, immunologic abnormalities, for example, antibodies to 
Escherichia coli O: 14 antigens and intestinal epithelial antigens occur in healthy first-degree 
families of IBD patients 20, 21.  
 
In fact, there are no individual genes that can cause either CD or UC, although many 
predisposing genes have been identified. A recent study identified about 163 genes that 
contribute to the risk of IBD 22. A genome-wide meta-analysis study found 39 loci involved in 
Crohn's disease-relevant pathways such as IL-10, IL-27 and TYK2, which emphasises the 
significant genetic overlap with loci involved in other immune-related diseases 23. By contrast, 
another meta-analysis revealed 29 loci containing genes that strengthen the role of epithelial 
barrier function, intracellular defence and cytokine-dependent signalling in UC, as well as 
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showing a genetic overlap with Crohn’s disease. Besides looking at some complex diseases, 
genome-wide association studies have identified 99 non-overlapping genetic risk loci, 
including 28 that are common to Crohn’s disease and ulcerative colitis 24. 
 
1.1.1.2.2 Immune response  
 
It is proposed that impaired regulation of the mucosal intestinal immune cascade could be a 
factor in the development of IBD. Intestinal epithelial cells (IECs) provide a single superficial 
layer on the intestinal mucosa and act as the first defensive barrier against the luminal 
content of the gut and protector of the underlying tissues. IECs have important roles, 
secreting antimicrobial substances [defensins] and communicating with intestinal immune 
cells through soluble mediators, chemokines and cytokines 25, 26. In patients with IBD a 
disruption in function of the epithelial and mucosal barrier occurs; ultimately this will cause 
chronic recurrence of inflammation in the intestinal mucosa. It has become evident that IECs 
play a significant part as the first line of defence and as a signal inducer for underlying immune 
cells. One of the most important features of IECs is the tight regulation of pro- and anti-
inflammatory signalling, which is defective in the case of chronic intestinal inflammation 27. 
 
1.1.1.2.3 Microbiota (Bacteria mainly) 
 
Gut bacteria are an ecosystem, which changes over time, as the diet changes, and as general 
health changes. The colon harbours a complex microbial population of approximately 1011 
microorganisms per gram of intestinal content: and most of these bacteria are anaerobic. The 
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most dominant bacteria are Bacteroides, Bifidobacterium, Lactobacillus, Clostridium, 
Eubacterium, Escherichia, Enterococcus, Streptococcus, and Klebsiella. Bifidobacterium and 
Lactobacillus are thought to be the most important health-beneficial bacteria for the human 
host 28. The microbiota has many important biological functions such as tissue repair, 
digestion and protection against pathogens (colonisation resistance), by challenging for space 
and making anti-bacterial substances such as bacteriocins. The primary function of the helpful 
bacteria is the synthesis of (SCFA) short-chain fatty acids, which are considered to be essential 
as a source of energy. The intestinal microbiota plays a key role in the production of essential 
vitamins such as B groups and K and preserve the acidic environment, aiding immune 
functions 29. 
 
However, not all intestinal microbes are beneficial. Others are pathogenic for example; some 
Clostridia, Staphylococci, Coliforms, and yeasts or fungi 28. Some non-pathogenic microbes 
may also contribute to diseases such as IBD 30. It is still not proven that IBD develops as a 
result of infection i.e. that there is an association between a single microorganism and 
inflammation 31.  
 
Most bacterial pathogens enter the host body via mucosal surfaces, as in the gastrointestinal 
tract. There are many mechanical as well as immunological barriers that protect mucosal 
surfaces from infection. Colonisation resistance is an additional important protective 
mechanism 29.  
 
Ordinary gut epithelium contains proinflammatory luminal bacteria, without neutrophil 
recruitment. About 50% of these bacteria may activate neighbouring gut-specific 
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macrophages: thus, in the presence of intestinal inflammation, these bacteria may augment 
degranulation and secretion of proinflammatory cytokines, which result from activating 
TREM-1 (the receptor expressed on myeloid cells). TREM-1 is a cell surface molecule existing 
on neutrophils, monocytes, and macrophages within the intestinal lamina propria. Less than 
10% of macrophages express TREM-1, suggesting that this is a system to avoid extreme 
inflammatory reactions 32.  
 
There is little information about colonisation resistance at the molecular level, and how 
pathogenic bacteria overcome this process. However, recent research in IBD and animal 
models of enteric disease has found some answers to colonisation resistance. Perturbations 
of gut microbiota (dysbiosis) can result from gut disturbance, which upsets colonisation 
resistance and increases pathogen survival 28.  
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1.2 Anaemia in IBD 
 
Anaemia is a common blood disorder with either too little haemoglobin in the red blood cells 
or too few red blood cells. Anaemia has a prevalence of around 3% in middle-aged men and 
14% in middle-aged women in the United Kingdom, but it is more common in the developing 
world 33. Anaemia-specific symptoms include fatigue, breathlessness, headache, dizziness, 
and palpitations. Iron deficiency (ID)-associated symptoms include impaired nail growth, skin 
defects, sleeping disorders, loss of libido and erectile dysfunction 34. There are several kinds 
of anaemia, and they can be classified by morphology or aetiology as shown in Table 1-1. 
 
 
(a) Morphology of RBCs  (b) Underlying aetiology (pathogenic) 
Normocytic: MCV 80-100 fl Excessive blood loss (haemorrhage). 
Microcytic: MCV < 80 fl Excessive RBC destruction (haemolysis). 
Macrocytic: MCV > 100 fl A defect in blood cell production mechanism 
(haematopoiesis). 
 
Table 1-1: Classification of anaemia per (a) morphology and (b) aetiology 
 
 
Anaemia is a common manifestation of inflammatory bowel disease (IBD) affecting about 
one-third of patients 34. There are four types of anaemia in IBD patients; iron deficiency, 
vitamin B12 deficiency, folate deficiency, and anaemia of chronic disease (ACD). Together iron 
deficiency anaemia (IDA) and anaemia of chronic disease (ACD) are the most common types 
of IBD-associated anaemia, and these two disorders often coexist 35. 
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Iron deficiency is the most common cause of anaemia in IBD, as it results not only from 
constant or repeated blood loss from ulceration of the bowel mucosa but also from decreased 
iron intake or malabsorption which causes a negative iron balance leading to iron deficiency 
anaemia 35.  
 
In chronic inflammatory diseases, such as IBD, cytokines, interleukin-1 (IL-1), interleukin-6 (IL-
6), tumour necrosis factor-α (TNF-α), and interferon-ɣ (IF-ɣ) concentrations may be elevated, 
causing adverse effects at different stages of erythropoiesis and inhibition of erythropoietin 
(EPO) production. In addition, there is retention of iron within macrophages and monocytes 
(the reticuloendothelial system) because of hepcidin effects (Figure 1-3). The result of this 
process is termed “anaemia of chronic disease (ACD)” 36, 37. 
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Figure 1-3: Pathophysiological mechanisms of anaemia in IBD patients. Cytokines induce the formation of hepcidin which 
then blocks cellular iron (Fe2+) export via ferroportin (FPN) from macrophages and inhibits the transfer of absorbed iron 
from the intestine to the circulation. This will result in a drop of circulating iron and limits its availability for erythroid 
progenitors, thus blocking erythropoiesis. Some cytokines, such as tumour necrosis factor (TNF)-α and interferon (IFN)-ɣ, will 
restrict iron in macrophages by stimulating iron uptake, promoting phagocytosis and inhibit iron export via repression of 
ferroportin transcription. Iron deficiency can also worsen by chronic luminal blood loss in active IBD cases. Further inhibition 
of the erythropoiesis will further occur due to a reduction in erythropoietin (Epo) formation along with some vitamins 
deficiencies that can impair erythroid differentiation (adapted from 35). 
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1.2.1 Treatment of anaemia in IBD 
 
The persistence of anaemia associated with impaired cardiac and renal function will cause 
decreased systemic oxygen delivery, reduced physical activity, fatigue, and a declining quality 
of life. The quality of life in anaemic patients with CD may be the same as that in those who 
suffer from advanced cancer 38. Treatment of IBD-associated anaemia should be taken 
seriously as its correction will improve the quality of life. The best therapy for anaemia of 
chronic disease (ACD) is to cure the underlying disease. However, this may not always be 
possible 35.  
 
1.2.1.1 Iron therapy  
 
1.2.1.1.1 Oral iron preparations 
 
There are two types of oral iron supplements; ferrous salts (ferrous sulphate, ferrous 
gluconate, and ferrous fumarate) and iron polysaccharides (iron polymaltose complex). Oral 
iron supplementation is frequently used to treat IDA because of its relative safety, efficacy, 
and cost. However, compliance often declines with time because of gastrointestinal side 
effects. Patients frequently complain of gastrointestinal symptoms such as nausea, bloating, 
diarrhoea, constipation and upper abdominal pain. However, the exact cause of these 
symptoms is still not completely understood; it may be due to the intestinal formation of free 
oxygen radicals 33. The goal is to replenish iron stores as well as to treat the anaemia 37. 
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1.2.1.1.2 Intravenous iron preparations 
 
The parenteral route may be used to avoid the issues with oral iron supplementation. 
Intravenous iron should be given slowly to avoid cellular toxicity of iron salts 39. There are 
several products available.  
 
1- Iron dextran: this is a stable form of parenteral iron product that may be given as a 
single dose. This product has a molecular weight (MW) of 100-500 KD; its plasma half-
life is 3-4 days, and it has high structural homogeneity. Iron dextran complexes are 
taken up by the reticuloendothelial system (RES) cells such as macrophages, through 
phagocytosis, where intracellular degradation occurs and releasing iron into the 
plasma. The dextran molecule can, however, cause dextran-induced anaphylactic 
reactions. 
 
2- Iron sucrose: this has the same molecular weight as iron saccharate (30-100 KD). It is 
partially stable and has a half-life of about 90 minutes. Cells of the RES and additionally 
apotransferrin or apoferritin might take up iron sucrose. It is less likely to lead to an 
allergic reaction than iron dextran. 
 
3- Iron gluconate: this type of intravenous iron product is unstable with fast dynamic 
degradation and direct uptake of plasma proteins (apotransferrin, apoferritin, others). 
Iron gluconate may also be toxic due to oversaturation of transferrin (Tf) binding 
capacity. 
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4- Ferumoxytol: this is used for the treatment of iron deficiency anaemia in adult 
patients with chronic kidney disease (CKD). 
 
Iron preparation Brand name Recommended dose 
Oral Iron 
 
   Ferrous sulphate 
Feospan, ironorm  
Drops, ferrogard 
300mg (60mg elemental iron) three times a day 
Ferrous 
gluconate 
Non-proprietary 300mg (35mg elemental iron) three times a day 
Ferrous fumarate 
Fersaday, Fersamal,  
Galfer  
 
200mg (65mg elemental iron) three times a day  
 
Intravenous iron   
   Iron sucrose 
 
Venofer                 
  
2% (20mg/ml) of iron by slow IV injection or IV 
infusion, calculated according to body weight and 
iron deficit. 
   Iron dextran 
 
CosmoFer (Vitaline) 
5% (50mg/ml) of iron by slow IV injection or IV 
infusion, calculated according to body weight and 
iron deficit. 
Ferric 
carboxymaltose 
 
  Ferinject                                   
5% (50mg/ml) of iron by slow IV injection or IV 
infusion, calculated according to body weight and 
iron deficit. 
 
Table 1-2: Iron formulations adapted from BNF 
 
The amount of iron needed to correct anaemia and the best way to administer it is still a 
subject of debate. Both routes of administration can effectively increase the haemoglobin 
level in an iron-deficient patient; however, there is no evidence to show that intravenous iron 
is superior to oral iron. Some side effects of oral iron may result from the high doses 
prescribed, and a lower iron dose has been suggested to have equal benefits along with fewer 
side effects 40. In conclusion, both oral iron and intravenous iron supplements are very 
effective in IBD 41. 
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1.2.2 Iron homoeostasis and metabolism 
 
Iron is an essential metal that is required by all organisms. Iron has a transition ability between 
2 redox states, which makes it very helpful as a catalyst. Biological functions that require iron 
include DNA synthesis, oxygen and electron transport, and respiration. The same 
characteristics that make iron useful also make it toxic. Unbound (free) iron can produce free 
oxidative radicals, which may damage lipids, proteins, and DNA 42. In many organisms, iron 
uptake and storage is regulated by the iron load. In humans, this regulation happens between 
the amounts of iron that are absorbed, rather than the amount that is excreted. Any 
disruption will result in anaemia or iron overload 43. 
 
Iron homoeostasis happens mainly in the epithelial cell layer of the duodenum, where about 
1-2mg of iron is absorbed from gut each day: iron passes through the apical and basolateral 
membranes of the enterocytes of the duodenum and upper jejunum. 1-2mg of iron is lost by 
the skin and gut epithelial turnover process. This mechanism maintains iron balance in the 
body. The iron, when it is absorbed, will bind to transferrin (Tf) in the plasma. It is 
subsequently released in the bone marrow for erythropoiesis. The amount of free iron in 
plasma is very low (3.5-5 mg) compared with the total body amount. Most iron is attached to 
haemoglobin 43. 
 
Transferrin has two binding sites for iron; about 30-40% of these are occupied under normal 
physiological conditions. Iron binds to Tf, and it is then taken up by the Tf Receptor (TfR) into 
target cells by the process of endocytosis and subsequently, at a low pH, disassociation 
occurs. Iron is then released to perform its functions, which include acting as a cofactor for 
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many enzymes and intracellular proteins (Figure 1-4) 43. TfR can be detected in human serum 
after cleavage of its cytoplasmic and transmembrane domains. This soluble form of TfR (sTfR) 
is produced when TfR leaves the cell surface. An increase in sTfR level indicates iron deficiency 
and a high-rate of erythropoiesis. Consequently, sTfR may be used to distinguish between 
iron deficiency (ID) alone and a combination of ID and ACD 43. 
 
When intracellular iron decreases, TfR expression is upregulated. However, TfR expression is 
controlled by the interaction of iron regulatory protein (IRP) and iron-responsive element 
(IRE) post-transcriptionally at the 3`-untranslated region of its mRNA. The affinity of IRP 
binding to IRE changes with the intracellular concentration of iron, i.e. when iron 
concentration is low, affinity is high and vice versa. So, binding of IRP to IRE at the 3`-
untranslated end of TfR mRNA saves it from degradation and enhances TfR expression. 
However, binding of IRP to IRE at the 5`-untranslated end of ferritin or 5-aminolevulinic acid 
(ALA-S) will inhibit the translation and stop protein synthesis. In the case of high intracellular 
iron, TfR degradation occurs causing an induction of ferritin and ALA-S expression 40. 
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Figure 1-4: Iron homoeostasis and metabolism. Once dietary is iron absorbed from the intestine, it is stored 
as ferritin in the intestinal epithelial cells or conveyed to plasma as transferrin. Haemoglobin synthesis 
happens when erythroid progenitors attain iron either from plasma transferrin or reutilizing iron of old 
erythrocytes which destroyed by macrophages in bone marrow, spleen, and liver. When iron quantity is 
more than its requirement, it is then stored in macrophages as ferritin, which is then oxidised to 
hemosiderin. These stores will be released from macrophages in times of need (increased erythropoiesis) 
adapted from 44. 
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There is a linear relationship between intracellular and circulating ferritin, which reflects the 
iron resources. During inflammation or neoplasia serum ferritin levels are increased, giving 
ferritin the characteristics of an acute phase protein. Thus, in inflammation, a rise in serum 
ferritin concentrations may obscure iron deficiency 45. 
 
Iron molecules are essential for haemoglobin (Hb) synthesis which depends on the availability 
of intracellular iron in erythroid precursor cells (Figure 1-4). Haemoglobin holds about 60% of 
total body iron. Haemoglobin biosynthesis does not begin until the intracellular iron 
concentration is high. Iron controls the synthesis of some associated proteins, and its 
metabolism can be detected by measurement of these proteins, which include Hb, Tf, sTfR, 
and ferritin. Plasma iron concentration on its own is often unhelpful 46. 
  
Preservation of cellular iron homoeostasis is also essential for many vital biological processes, 
the development of many microorganisms, and for immune functions. Both iron deficiency 
and iron overload can apply indirect effects on immune status by changing the proliferation 
of T and B cells 47. 
 
Immunological properties of iron can be seen in macrophage-mediated cytotoxicity by 
catalysing the construction of reactive oxygen species (ROS); in contrast, oxidative stress and 
nitric oxide (NO) excite the binding of IRP to IRE process and interact with an expression of 
TfR and ferritin. Iron-rich macrophages similarly demonstrate a reduction in interferon-ɣ 
responsiveness, TNF-α production, and (NO) formation 47, 48. 
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IBD patients have a combination of IDA and ACD because of chronic intestinal blood loss 
during flares of their disease. Sometimes iron absorption may be impaired in the duodenum 
and upper jejunum in CD, but in general iron absorption in both CD and UC is normal. 
However, when chronic intestinal bleeding exceeds the body’s absorptive capacity, a negative 
iron balance will result in 43. 
 
When total body iron has decreased, chronic inflammation triggers iron trapping from the 
plasma pool. This reaction is an acute response, which will provoke up-regulation of ferritin 
and down-regulation of Tf assembly. This will reduce Tf-bound plasma iron, which is referred 
to as a functional iron deficiency. This term means a failure of iron transport to supply an 
adequate amount of iron from the storage pool to the bone marrow 49. 
 
1.3 Bacteria, iron, and pathogenicity 
 
Over the last decade, there have been many publications on microbial iron metabolism. These 
have shown the role that iron plays in the in vivo growth of infectious pathogens. For many 
microorganisms, it is vital that they acquire iron to maintain themselves within animals. 
Without this ability, they will be unable to grow, and eventually, they will be eradicated by 
the host, or die from nutrient starvation. 
 
Not all bacteria are pathogenic, but they can become so when they find a suitable 
environment in which to grow within the animal. Bacteria need warmth and nutrients that 
are necessary for their growth. The human ‘host’ may provide warmth and nutrients, 
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including organic carbon, which can found in body fluids and tissues. These molecules are 
easy for bacteria to use, but iron cannot be found freely in the body 50. 
 
In the human body, iron can be present in two forms, the ferric form (Fe III) and ferrous form 
(Fe II). In an aerobic environment, iron exists in the oxidised, ferric form. The concentration 
of free iron in solution at pH 7.0 is usually very low (10-18 M), so pathogens have to find a 
specific mechanism to obtain iron from their host 50. 
 
Generally, in human and other developed vertebrates, iron from the diet is absorbed by 
mucosal cells of the jejunum then passed into the circulation via attachment with a 
glycoprotein transferrin (Tf) 34. There are three types of Tf; serum transferrin 
(serotransferrin); Lactoferrin (Lf) or lactotransferrin, which is found in several extracellular 
fluids; and ovotransferrin, previously called conalbumin, which was, initially, discovered in the 
albumen of eggs. All three types of Tf convey iron to different cells to be used in the synthesis 
of certain proteins. All kinds of Tf have two similar binding sites for iron; these sites have a 
binding constant for iron of ~1020. Ideally, this binding capacity should not be fully saturated: 
leaving some “spare capacity” is essential to take up any extra iron into the blood during 
infection. This surplus iron-binding capacity of Tf then ensures that no free iron is left in the 
circulation 34, 51.  
 
The withholding of iron from infecting bacteria is a significant means of host protection, and 
the virulence of numerous pathogens (investigational infections) has been noticeably 
enhanced in the laboratory by injecting iron into host animals. A list of such organisms 
includes Aeromonas spp., Clostridium spp., Corynebacterium spp. and Enterobacteria spp. 
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Escherichia coli, Klebsiella spp., Salmonella spp., Listeria spp., Neisseria spp., Pasteurella spp., 
Pseudomonas spp., Staphylococcus spp., Vibrio spp., and Yersinia spp. Mycobacterium avium 
and Mycobacterium tuberculosis 52, 53 may also be added to this list. 
 
Pathogenic bacteria cannot multiply in vivo because of the “iron-withholding” defence 
mechanism of the infected host. If pathogenic bacteria grow in the host, this suggests that 
they have developed methods to obtain iron from available sources. For example, bacteria, 
may bind to transferrin and/or lactoferrin to use the iron associated with these proteins. 
Bacteria may also obtain iron from haemoglobin (by the destruction of erythrocytes) or 
ferritin 54. 
 
The main iron storage complex is ferritin. Ferritin is not confined to animals but also occurs in 
plants (phytoferritin) and many microorganisms (as bacterioferritin). Bacterioferritins can 
also be found in fungi. Ferritin, characteristically, is composed of 24 protein subunits that 
form a hollow sphere that can house > 4000 atoms of Fe (III). However, bacterioferritin differs 
from ferritins and phytoferritin, by possessing haem groups that store iron in iron-replete cells 
and make it available to the cell whenever it is needed 55. 
 
Bacteria can use two methods to obtain iron from their host tissues. The first is direct contact 
with iron sources such as Tf or iron proteins (haem and haem proteins) where the iron is then 
removed by reduction and uptake. In the second, microorganisms, such as bacteria and fungi, 
synthesise an ultra-high-affinity composite that has a superior binding strength. This binding 
capacity can physically capture iron from the host protein (ferritin or Tf): such compounds, 
known as siderophores, play key roles in the microbial iron acquisition. These two methods 
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are crucial to the understanding of the relationship between the host’s response to infection 
and iron metabolism disturbance 55, 56. 
 
1.4 Iron supplements and IBD activity  
 
Oral iron supplements can increase intestinal tissue injury by catalysing the production of 
reactive oxygen species (ROS). Inflamed intestinal mucosa contain activated neutrophils 
which produce ROS in excess which in turn aggravates the injured mucosal tissues. As free 
iron is considered to be a strong catalyst for ROS production, oral iron therapy such as ferrous 
sulphate tablets may be harmful to IBD patients. Oral ferrous sulphate tablets are poorly 
absorbed and lead to a high faecal iron concentration where it will be ready for catalytic 
activity 57. 
 
It is believed that many iron supplements can affect the immune system as well as intestinal 
inflammation in IBD. Iron inhibits interferon ɣ (INF-ɣ) activity which has disabling effects on 
macrophage function and T helper one cell (Th1) reaction. Therefore, giving parenteral iron 
will reduce Th1-driven intestinal inflammation in Crohn’s disease 38. 
 
1.5 Human-associated microbiota 
 
The human body is home to multiple groups of microbes. It is an ecosystem of many different 
niches or a metacommunity. Human-associated microorganisms are estimated to number 
1014 in total; this is about ten times the number of human cells per individual. These microbial 
 
 
51 
 
populations reside in the mouth, nose, ears, vagina, skin, and in the intestinal tract. As an 
ecosystem, it is comparable to ecological sources where microbes are present, for example, 
seawater and soil. Each anatomical site has unique physiochemical features, and each 
location is occupied by specific types of microbes 58. The mainstream of the human-associated 
microbes and the most diverse community is in the intestinal tract, where microbial 
abundance increases from the stomach to the colon. The highest number of microbes is found 
in the stool (1011 per mL), in which the complex ecosystem contains bacteria, archaea, yeasts, 
and other eukaryotes 59. 
 
1.5.1 Composition and function 
 
Human microbiota is a term referring to the total number of microorganisms. These microbes 
include bacteria, fungi, yeast, and archaea, in different abundances and diversities, depending 
on location and local environment. A study of the human skin bacteria found that the greatest 
numbers of types were allocated to the Actinobacteria, Firmicutes, and Proteobacteria phyla. 
However, in the same study, the structure of the skin microbiota was the same between 
samples from the left and right forearm of most participants, but highly variable at different 
time-points and between different individuals 60. 
 
The idea that all microbes are harmful to humans has been replaced by the concept that the 
majority of microbe-host interactions are non-pathogenic, i.e. commensal where 
microorganisms benefit without causing any harm to human, or, mutualistic, in which both 
partners benefit. How extra-intestinal microbes may be beneficial is unknown. According to 
many recent studies, it is clear that the gut microbiota benefits the host in several different 
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ways. Intestinal symbionts have been shown to have important roles in nutrient digestion and 
synthesis, vitamin synthesis, energy metabolism, epithelial development, and immune 
responses. In turn, the intestinal bacteria are provided with steady growth conditions and a 
continuous stream of nutrients 59. 
 
The human vagina is occupied by a range of microbes from a pool of over 50 species. 
Lactobacilli are very common, mostly in healthy women. Changes in the microbiota can cause 
infection such as bacterial vaginosis (BV); this condition is characterised by a depletion of the 
lactobacillus population. However, in vitro studies have found that Lactobacillus strains can 
interrupt BV and yeast biofilms and prevent the growth of urogenital pathogens 61. 
 
1.5.2 Gut microbiota 
 
The gut microbiota, previousely known as the gut flora, consists of trillions of microorganisms 
in human intestines; these microbes participate in some metabolic activities like those of an 
organ. Gut microbiota also contributes to immune system development: changes in its 
composition can be associated with many chronic diseases including obesity and diabetes 11. 
However, it is possible that around 99% of the bacteria come from 30 or 40 species. Moreover, 
fungi, protozoa, virus and archaea also make up a part of the gut microbiota, but their 
activities are still not fully understood 62. 
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1.5.2.1 Normal gut microbiota 
 
The oral microbiota has been linked to local (periodontal) as well as systemic diseases such as 
bacterial endocarditis and preterm labour. The composition of the oral microbiota varies 
depending on the site as well as between individuals. The most abundant genera found 
include Streptococcus, Gemella, Granulicatella, and Veillonella 63. 
 
A study of bacteria present in the oesophagus of four healthy participants showed the 
presence of nearly 100 bacterial species. The upper oesophagal microbiota was similar to 
those in the oral cavity (Streptococcus, Prevotella, and Veillonella). In the lower part of the 
oesophagus, the microbiota was closer to that found in the stomach despite its high acidic 
environment. Helicobacter pylori (H. pylori) may reside in the stomach and play a role in the 
development of many gastric diseases. A study analysing the bacterial 16S rDNA of gastric 
biopsies in 23 individuals found 128 phylotypes. The majority of the sequences belonged to 
Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, and Fusobacteria phyla, suggesting 
that the human stomach harbours a distinct microbiota 64. 
 
Regarding the microbiota in the large intestine and faeces, around 395 phylotypes were 
identified from 11,831 bacterial 16S rDNA sequences in an extensive study which analysed 
multiple colonic sites and the faeces of three healthy individuals. However, there was only 
one phylotype, Methanobrevibacter smithii that was detected among the 1524 sequences 
amplified with archaeal primers. The majority of phyla were assigned to the Firmicutes and 
Bacteroidetes; while the minor phyla were Proteobacteria, Actinobacteria, Fusobacteria, and 
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Verrucomicrobia. The intersubject variation was greater than that between different sites 
within a single individual 65. 
 
1.5.2.2 Intestinal microbiota and disease 
 
To understand the intestinal microbiota and its role in human health and disease, we should 
increase our knowledge of the function and composition of the human-associated microbiota 
as well as the consequences of its perturbation on the host and its symbionts.  
 
For example, a connection between intestinal microbiota and obesity has been reported; the 
faeces of an obese mouse model has a lower energy value than that of a wild-type mouse, 
signifying that the obese mouse is better able to extract energy from its diet. The gut 
microbiota of obese mice was given to germ-free (GF) mice, and this resulted in weight 
increase, although repeating the same experiment using gut microbiota from lean mice 
caused no reduction of the weight of GF obese mice. The intestinal microbiota of obese mice 
demonstrated fewer Bacteroidetes and more Firmicutes; similar findings occur in lean and 
obese humans 66, 67. 
 
Recent studies in rodents have shown changes in bacterial composition in the case of colonic 
inflammation and infection. Advanced molecular techniques have demonstrated changes in 
mucosal bacterial composition and faecal microbiota in patients with Crohn’s disease and 
ulcerative colitis. There is a decrease in specific phyla in CD and UC such as Bacteroidetes and 
Firmicutes 68.  
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1.5.2.3 Physiological interactions between the microbiota and host 
 
In the healthy intestine, commensal gut microbiota contributes to homeostatic responses by 
epithelial cells and different types of immune cells such as macrophages, dendritic cells (DC), 
T lymphocytes, and B cells, thus allowing cohabitation with potentially toxic microbial 
products. The most important homeostatic responses include down-regulating bacterial 
receptors, promoting intracellular and secreted molecules that stop adaptive and innate 
immune responses and stimulating protective fragments that facilitate mucosal barrier 
function. Bacteria have unique ways of entering cells i.e. transmembrane design recognition 
receptors, such as intracellular nucleotide-binding oligomerization domain (NOD) receptors, 
Toll-like receptors (TLR) and, NOD-like receptor (NLR) family. The central signalling cascade 
starts once these bacterial receptors have been occupied. The recognition cascade is inhibited 
by stimulation of interferon (IFN), interleukin (IL)-10, and transforming growth factor (TGF). 
In order to regulate such inhibition, paracrine exchanges between epithelial cells and lamina 
propria regulatory lymphocytes that secrete TGF and IL-10 are needed (Figure 1-5) 69-71. 
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Figure 1-5: Possible mechanisms of inducing chronic immune-mediated intestinal injury by enteric bacteria. (A) A common 
pathogen or dysbiosis will increase bacterial stimulation of innate and adaptive immune responses. (B) a reduction in the 
bacteria that produce SCFA such as butyrate may increase mucosal permeability to toxic metabolites such as hydrogen 
sulphide (H2S). (C) inadequate secretion of antimicrobial peptides or secretory IgA will cause bacterial mucosal overgrowth 
creating flawed killing of phagocytosed bacteria increasing mucosal permeability. (D) Failed down-regulation of innate 
immune response in epithelial and antigen-presenting cells (APC), can stimulate inflammation. However, dysfunction of 
regulatory T cells or APC will aggravate T cells response to universal microbial antigens (i.e., loss of tolerance) (Adapted 
from 69) 
 
 
 
57 
 
1.5.2.4 Flawed bacterial killing mechanism in Crohn’s disease 
 
There are pathophysiologic similarities between CD and chronic granulomatous diseases, 
such as defective phagocyte function and polymorphisms of genes that regulate the clearance 
of intracellular pathogens. There are defects in innate antimicrobial function in subtypes of 
CD triggered by defective clearance of commensal, opportunistic or pathogenic bacteria. This, 
followed by initiation of compensatory antibacterial effector T cells resulting in tissue damage 
71.  
 
Some of the genetic polymorphisms that are found in CD are associated with failed killing and 
include autophagy-related protein 16-1 (ATG16L1) and immunity-related GTPase family M 
protein (IRGM), NOD2, and Neutrophil cytosol factor 2 (NCF2) 72. Deletion of the autophagy 
gene ATG16L1 results in Paneth cell morphologic changes and reduced expression of 
antimicrobial peptides (Figure 1-6). A reduction in antimicrobial peptide secretion might 
cause bacterial overgrowth, the rise of mucosal adherent bacteria and translocation of 
commensal bacteria, whereas a defective clearance of invasive or phagocytized bacteria 
encourages persistence of viable intracellular bacteria. These two mechanisms increase 
antigenic stimulation of pathogenic TH1/TH17 cells and promote chronic granulomatous 
inflammation and increase susceptibility to infection by opportunistic pathogens 73. 
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Figure 1-6: Flawed control of commensal bacteria in IBD. (Adapted from 73). 
 
 
 
Crohn’s disease associated genetic mutations may impair bacterial recognition potentially 
leading to the poor control of commensal bacteria. An increase in mucosal bacterial growth 
may result from the defective secretion of antimicrobial peptides (NOD2 and ATG16L1 
polymorphisms) or secretory IgA. However, a reduction in bacterial killing (NOD2, ATG16L1, 
NCF4 and IGRM polymorphisms) can cause intracellular bacteria to persist and the 
unsuccessful clearance of bacterial antigens. When mucosal permeability is increased, an 
overwhelming exposure to bacterial TLR ligands and antigens occurs, which then activates 
pathogenic innate and T-cell immune responses 74. 
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1.6 The relationship between iron and gut microbiota 
 
Iron is a growth-limiting nutrient for many gut bacteria, which compete for unabsorbed 
dietary iron in the colon 75. Lactobacilli, considered to be beneficial barrier bacteria, do not 
require iron. Lactobacilli play a significant role in the inhibition of colonisation by enteric 
pathogens 76. For other bacteria, acquiring iron is an essential step for their virulence; such 
bacteria include Gram-negative bacteria (Salmonella, Shigella, or pathogenic Escherichia coli) 
77. In animal studies, increasing amounts of iron in diets causes a linear rise in diarrhoea. The 
proportion of Bifidobacterium and Lactobacilli to Enterobacteria can be a guide to gut health: 
a higher proportion of Bifidobacterium and Lactobacilli is associated with resistance to 
infection. Consequently, an increase in unabsorbed dietary iron in humans could alter the 
composition of the colonic microbiota and favour the growth of pathogenic strains over 
barrier strains 78. 
 
1.7 Murine models of IBD (colitis) 
 
There are many different animal models of IBD, which are valuable tools for examining factors 
that are involved in IBD pathogenesis. Recent studies have used 20 experimental models with 
a diverse range of clinical features similar to human IBD. These models have contributed 
advances to the understanding of the pathogenesis of IBD. These models support the idea 
that the induction of IBD is affected by environmental factors in genetically susceptible 
individuals 79.  
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The animal model used should, ideally, display structural changes, inflammation, symptoms 
and signs, pathophysiology, and disease course comparable to those observed in human IBD. 
The animal used should also have a distinct and defined genetic background.  
 
Animal models of IBD are classified into four broad classes (examples of which in mice are 
shown in Table 1-3). The majority of these models are based on chemical induction, free cell 
transfer or gene targeting. However, in some models, the illness is spontaneous 80, 81. 
 
Model Pathology Site Pathogenesis Cost 
1- Spontaneous colitis: 
SAMP/Yit 
 
Chronic 
 
Ileum 
Activation of Th1 T cells toward 
luminal antigen in ileum only 
 
High 
2- Inducible colitis: 
 
DSS 
 
 
 
 
TNBS 
 
 
 
 
Acute/Chronic 
Mainly 
mucosal 
 
 
 
Acute/Chronic 
Transmural 
 
Colon 
 
 
 
 
 
Colon 
 
Toxic intestinal damage plus 
activation of the mucosal 
immune system (TH1/TH2). 
The addition of azoxymethane 
induces cancer. 
 
Activation of the immune 
system (TH1-mediated; 
hapten-specific). Optimisation 
of TNBS dosage is required in 
certain strains. 
 
 
Low 
 
 
 
 
Low 
3- Adoptive transfer: 
    CD45RB CD62L+ 
    cell transfer into SCID 
    Mice 
 
Acute/Chronic 
Transmural 
 
Colon/ 
duodenum 
 
IL-12 driven TH1 T cells. 
Induction of colitis requires 6-
12 weeks. Animal facility for 
SCID mice required. 
 
High 
4- Genetically modified: 
     
IL-2 knockout mice 
 
 
 
 
STAT-4 transgenic 
 
 
Acute/Chronic 
Mucosal 
 
 
 
Acute/Chronic 
Transmural 
 
 
Colon 
 
 
 
 
Colon/ 
Ileum 
 
 
IFN-gamma production T cells. 
Colitis develops 6-15 weeks 
after birth, variability between 
mice. 
 
TH1 T cells in response to 
bacterial antigens. Requires 
immunisation of mice. 
 
 
Medium 
 
 
 
Medium 
 
Table 1-3: Types of animal models of IBD (adapted from 79, 80). 
 
 
61 
 
DSS-induced colitis model has some advantages in comparison with others. For example, it is 
relatively simple, has similarity to human IBD and has acute/chronic or relapsing variants 
which can be produced easily by changing the concentration of DSS and numbers of cycles 
administered to mice and rats. 
 
Also, dysplasia, similar to that in human UC, occurs frequently in the chronic phase of DSS-
induced colitis 82. DSS models respond to some of the therapeutic agents that are used to 
treat human IBD, suggesting that DSS-induced colitis is an appropriate model for many 
experimental purposes 83. 
 
1.7.1 Dextran sulphate sodium (DSS) colitis 
 
DSS is a colitogenic chemical with anticoagulant properties. It is a sulphated polysaccharide 
with a highly variable molecular weight, ranging from 5KDa to 1400KDa. The molecular weight 
is a critical factor in the induction of colitis or colitis-induced dysplasia (carcinogenicity) 84, 85. 
 
There are numerous elements peculiar to the DSS including concentration, duration, 
frequency, molecular weight, manufacturer and batch. Murine factors also influence 
response: these include genetic modification, strain, substrain and gender. C57BL/6J mice 
have a more severe IBD phenotype following DSS than other mice 86. Furthermore, the 
intestinal microbiota may influence DSS-induced colitis 87.  
 
The severity of both colitis and dysplasia differs according to the use of DSS of different 
molecular weights. There is a failure of induction of colitis when high molecular weight 500 
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KDa DSS is used. The location of colitis can also be affected by the molecular weight of DSS. 
For example, 40KDa DSS causes colitis in the distal colon whereas 5KDa DSS causes patchy 
lesions more proximally in the colon 84. The peak of carcinogenic activity of DSS occurs with 
54KDa DSS, while DSS of smaller or larger molecular weights has no carcinogenic activity 85. 
DSS is mainly excreted in the urine and faeces as it is resistant to degradation by the intestinal 
microbiota and pH 88. 
 
1.7.2  Initiation of colitis using DSS  
 
In the DSS model, mice are given drinking water supplemented with DSS for several days. This 
is believed to be directly toxic to colonic epithelial cells. Treatment with 3.5% to 5% DSS 
causes a rapid loss of body weight. Due to the severity of the 5% DSS model, saline is 
administered intravenously on day-10 to treat dehydration; saline administration is not 
required in the ≤3.5% DSS model. The procedures for acute DSS colitis can be completed in 
about two weeks, but the protocol for chronic DSS colitis takes around two months 89.  
 
Acute colitis can be induced by giving DSS [molecular weight 36,000–50,000 KDa (MP 
Biomedicals, LLC, UK) in acidified drinking water [2–2.5% (wt. /v)] for 4 to 5 days followed by 
5-7 days of plain drinking water (Figure 1-7). By contrast, chronic colitis can be induced by 
administering 3-4 DSS cycles of 5 days with intervals of 5 to 16 days between cycles when 
plain drinking water is administered. The acute DSS colitis model, despite its limitations, has 
increased our understanding of the pathophysiology of intestinal inflammation. The chronic 
DSS model represents a powerful means with which to study the impact of recurrent episodes 
of inflammation in IBD 89. 
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Mice are weighed on arrival and then daily after the DSS cycle has been initiated. Both weight 
loss and later weight gain are useful indicators of DSS-induced colitis and recovery. Mice are 
observed daily and clinical measurements, including an IBD severity scoring, are conducted 
twice weekly. The IBD scoring system contains severity scores of zero to three for three 
parameters: 
 
1. Stool consistency                     
2. Faecal blood                          
3. Anal prolapse 
 
 
                                                                                                                   Water 
 
                                                  0                                            5                                             10 
 
 
 
1.7.3 Clinical and histological signs of DSS colitis 
 
In all animals, body weight, rectal bleeding, stool consistency and survival should be 
monitored daily. Intestinal bleeding can be detected by using a Hem-occult test (Beckman 
Coulter, Inc., Fullerton, CA) as well as by watching for signs of bleeding at the anus or indeed 
the presence of gross bleeding. Disease activity index (DAI) can be calculated as shown in 
Table 1-4. The scores are combined then divided by three to obtain the final disease activity 
index. Depending on DSS colitis type, whether it is acute or chronic, 10 to 30 days following 
DSS 
Figure 1-7: Study timeline for acute DSS induction 
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disease induction, the mice are euthanised, and the large intestine is collected and evaluated 
for colonic length and microscopic colonic changes 90. 
 
Score Weight loss Stool consistency Bleeding 
0 None Normal - 
1 1-5% Loose - 
2 5-10% Loose + 
3 10-15% Diarrhoea + 
4 >15% Diarrhoea Gross bleeding 
 
Table 1-4: DAI Scoring System adapted from 89 
 
Acute histological changes in the colon can be seen as mucosal erosions or destruction and 
inflammatory cell infiltration. Chronic DSS colitis results in mononuclear leukocyte infiltration, 
crypt architectural disarray and a widening of the gap between the base of the crypt and 
muscularis mucosae with deep mucosal lymphocytosis also commonly observed 91. 
 
Assessment of colonic histological damage can be made from distal colonic tissues after 
processing them by standard methods, embedding them in paraffin wax before staining them 
with haematoxylin-eosin (H&E). Total histology scores are calculated according to the scale 
shown in Table 1-5. The two equally weighted subscores (cellular infiltration and tissue 
damage) are added, and the combined histological colitis severity score is reported ranging 
from zero to six. 
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Table 1-5: Colitis Scoring System adapted from 90 
 
 
1.7.4  Significance of iron on DSS-induced colitis 
 
A short-term study was performed to investigate the consequences of alimentary iron 
supplementation on DSS-induced acute colitis in 2002 by Seril et al. Acute DSS (1%) colitis was 
used to induce mild to moderately severe colitis. This acute colitis was enough to allow 
evaluation of the influence of iron on inflammation. Colons underwent histopathology scoring 
to assess the changes. The study found that iron given in the diet significantly increased DSS-
induced acute colitis severity. Colons from animals given 2, 5, or 10-fold increased oral iron 
displayed more severe inflammation and more extensive areas of inflammation (more than 
50% of the colorectal mucosa) than those fed the control diet. However, colons from the 
control mice administered a 10-fold enhanced iron containing diet without 1% DSS were 
normal. The authors concluded that the effect of iron supplementation on acute DSS colitis is 
dose-dependent 92. 
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In another study, iron supplementation increased disease activity in DSS-induced colitis: it 
was linked with oxidative stress, neutrophilic infiltration, augmented cytokines and activation 
of NF-κB. However, this damaging effect was moderately reduced by vitamin E 93. 
 
1.8  Bacterial life characteristics 
 
Bacteria are present everywhere - in the air, soil, water, inside an animal’s body and on its 
skin. They have a habit of multiplying rapidly under favourable conditions, creating colonies 
of millions or even billions of organisms within a space as small as a drop of water. Bacteria 
assemble in various distinctive ways. Most microbes are one of three common shapes: a rod 
(bacillus), round (coccus), or winding (spirillum). An additional group, vibrios, show up as 
incomplete spirals. A cell wall encompasses the cytoplasm and plasma film of most bacterial 
cells; further characterisation of microbes depends on cell wall features (e.g. using a Gram's 
stain). Aerobic bacteria are metabolically active in oxygen; anaerobes require no oxygen. 
  
1.8.1 Symbiosis 
 
Humans are colonised by four groups of commensal organisms (Eubacteria, Archaebacteria, 
Fungi and Protista) of the six kingdoms of life (Figure 1-8). The human gastrointestinal tract 
houses helpful and theoretically pathogenic microorganisms. Symbiosis is a constant 
beneficial interaction between two or more organisms. The most prominent human symbiont 
is Bacteroides fragilis, which protects animals from experimental colitis 94. In typical 
environments, microbiota survives in a state of symbiotic tolerance (eubiosis) with its host 
and stays fairly constant over time 95.  
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Figure 1-8: Kingdoms of life 
 
 
 
1.8.2  Dysbiosis 
 
Changes in bacterial populations within the gut will cause imbalances in the composition of 
the bacterial microbiota, a condition known as dysbiosis. The change in the normal gut 
microbiome associated with a failure of host- microbial mutualism may represent what 
happens in IBD. It is established that there is a shift from main “symbiont” bacteria to 
potentially harmful “pathobiont” bacteria 96. These changes in microbiota are thought to be 
a major factor in human illnesses such as inflammatory bowel disease 97. Some of these 
alterations in the gut microbiota have been identified in the common subgroup of IBD 
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patients: some changes have been particularly defined either in CD or UC patients. The most 
distinct alteration in IBD patients is the reduction in Firmicutes abundance 96. 
 
Different agents may cause dysbiosis e.g. continuous and improper antibiotic use, alcohol 
abuse, or a change in diet. A recent study revealed that taurine-conjugated bile acids, 
produced by an interaction between milk (fats) and bile acids, increased the intraluminal 
growth of Bilophilia wadsworthia. This bacterium induces macrophages and dendritic cells to 
release immune cytokines, which stimulate bacterial-antigen-specific TH1 cells to secrete 
interferon-gamma (IFN-ɣ) causing colitis 97. Another pathway that may include B. 
wadsworthia may lead to deconjugation of taurine and hydrogen sulphide formation. 
Hydrogen sulphide production may interfere with the mucosal barrier and inhibit colonic 
epithelial metabolism (Figure 1-9). In inflammatory bowel disease, dysbiosis may be a key 
component in immunopathogenesis by disrupting the host immune defences against 
commensal microbes at the mucosal border 97. 
 
Immunomodulators, dietary contributions, and exposure to antibiotics disturb the gut 
microbiome to a varying extent. However, antibiotics have the most significant outcome on 
microbial community assembly 97. 
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Figure 1-9: Diet promotes dysbiosis and colitis in susceptible hosts (adapted from 94) 
 
 
 
 
1.8.3  Diversity and abundance 
 
The variety of microorganisms in a specific anatomical body site can define the number and 
abundance distribution of discrete types of microbes. A reduction in diversity is associated 
with many human systemic illnesses, such as obesity and inflammatory bowel disease 98. 
 
Alterations in microbial composition in inflammatory bowel disease patients occur during 
disease activity. They are more marked in CD than in UC 99. 
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1.9 The Great Anomaly 
 
In 1985, Staley and Konopka established that the biodiversity of a complex microbial 
community observed by microscopy was greater than that by culturing it on agar plates. 
Therefore, they called this phenomenon The Great Anomaly. More recently, as a 
consequence of the widespread usage of PCR and DNA sequencing, 16S ribosomal DNA 
(rDNA) sequencing has played an essential role in the precise identification of bacterial 
isolates and the discovery of novel microscopic organisms in clinical microbiology research 
facilities 100. 
 
1.9.1 16S rRNA  
 
16S rDNA genes code for 16S rRNA. 16S rDNA is around 1,500 bp long and represents one of 
the components of the small subunit (30S) of prokaryotic ribosomes. These genes are very 
useful for evaluating phylogenetic relationships among microorganisms, as the degree of 
conservation varies significantly. All bacteria share the conserved regions, whereas the 
variable regions contain specific sequences which are characteristic to individual bacteria. 
This uniqueness enables taxonomic identification (Figure 1-10) 101. Regarding the microbial 
diversity of the gastrointestinal tract, through a random sequencing of 16S rRNA genes, Hold 
et al. 2002 102 showed in a study that only 25% of sequences were > 97% sequence identity 
with current species type strains, and 28% were < 97% linked to any database entry, which 
indicating our incomplete knowledge of bacterial diversity in the colon. Also, Hold observed 
a sequence identity was above 97% of 21 out of the 110 of the colonic 16S rDNA sequences 
with butyrate-producing strains that been extracted from human faeces 102. 
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1.9.2 Variable regions 
 
Bacterial 16S ribosomal RNA (rRNA) genes cover nine “hypervariable regions” (V1 – V9), which 
have significant sequence diversity between different bacteria. Species-specific sequences in 
a given hypervariable region are useful targets for diagnostic assays and other scientific 
investigations. However, there is no single region that can distinguish all bacteria; so 
numerous systematic studies that associate the relative advantage of each region with 
specific diagnostic goals have been performed 101. 
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                Conserved regions (undefined uses) 
                   Variable regions (cluster or species –specific uses) 
 
 
1.9.3 V4 region 
 
The most widely used variable region of 16S rRNA is V4. It is around 291 bp in size. The 
disadvantage of V4 is that it is a small fragment. V4 primers could be designed to suit the best 
arrangement/library when sequencing is performed. For instance, utilising MiSeq Illumina 
needs 250bp every route (forward and reverse), so the V4 region is suitable for this machine. 
However, adding adapters and barcodes should also be taken into consideration (Table 1-6).  
 
Figure 1-10: 16S ribosomal DNA gene 
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Region Product size 
(bp) 
+ 150 adapters + 
barcodes 
V4 291 441 
 
Table 1-6: V4 primer size 
 
 
1.10 Sequencing an amplicon library 
 
The processing and sequencing of amplicons are entirely adaptable and allow for a broad 
range of experimental designs. Variables include the number of amplicons pooled together, 
the length of amplicons, the number of reads required for a given amplicon pool, and whether 
to read from the A end, the B end or both. So each project will have its specific variables as 
well as objectives. 
 
The choice of 16S rRNA region to sequence is an area of discussion, and the area of interest 
might vary depending on experimental objectives, design, and sample type. The protocol in 
Figure 1-11 illustrates a strategy for preparing samples for sequencing the variable V4 region 
of the 16S rRNA gene. This protocol can similarly be applied to different sequencing regions 
with various region‐specific primers. This protocol combined with a benchtop sequencing 
framework, on board initial analysis, and secondary analysis using MiSeq Reporter or Base 
Space, provides a comprehensive workflow for 16S rRNA amplicon sequencing.  
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Figure 1-11: 16S library preparation workflow (reproduced with permission from CGR) 
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1.11 Hypothesis  
 
 
 
 
 
 
The hypothesis under investigation is that iron supplementation (and or bleeding) in IBD 
patients can change the composition of the gut microbiota and influence the natural history 
of IBD. 
 
 
 
 
 
 
IBD
iron 
supplements
gut bacterial 
dysbiosis
Internal 
luminal bleeds
IDA
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1.12 Aims and objectives 
 
1.12.1 Aims 
 
The purpose of this research project is to investigate the influence of iron on the gut 
microbiota in inflammatory bowel disease (IBD).  
 
1.12.2 Objectives  
 
To characterise the intestinal microbiota in murine models of inflammatory bowel disease, 
and in mice given different doses of iron supplements. 
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2 Materials and methods 
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2.1 Mice 
 
Unless otherwise mentioned, all mice were purchased from Charles River Laboratories 
(Margate, UK). 
 
2.1.1 Animal conditions 
 
All mice used in animal experiments were wild-type C57BL/6 female mice, aged 8-9 weeks 
old, purchased from Charles River Laboratories (Margate, UK). They were acclimatised under 
typical animal house conditions for at least seven days before the experiments began. The 
mice were fed standard mice chow pellets (during the acclimatisation period only) and water 
ad libitum. They were individually caged in a room with controlled temperature, humidity and 
a pre-set dark-light cycle (12 h: 12 h).  
 
2.2 Experimental procedures  
 
For each group of experiments, mice were matched for age, sex, and body weight. The care 
of, and experimentation on, mice was carried out in accordance with the UK Home Office 
regulations. The animal work was done under a project licence as specified by the Animals 
(Scientific Procedures) Act 1986, as well as with institutional guidelines under protocols 
approved by the Biomedical Services Unit (BSU) at the University of Liverpool for the proper 
use of animals in biomedical research. The author as a UK Home Office personal licence holder 
conducted every animal procedure. 
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2.2.1 Dietary intervention and group classification  
 
Unless otherwise stated, the animals were administered chow pellets throughout the 
experiments (all diets purchased from Special Diets Services [SDS], Witham, Essex, UK). 
 
2.2.1.1 Dietary intervention 
 
The conventional breeding diet utilised in the Biomedical Services Unit (BSU) at the University 
of Liverpool is the Rat and Mouse Breeder and Grower Pelleted CRM (P). It contains 200ppm 
[part per million] iron and appears as a 10mm compression pellet. These pellets were used 
for all experiments which required a normal iron diet. There were two modifications of this 
diet: the first was CRM (P) 100ppm iron Fe (P) where the CRM (P) formulation was used but 
had reduced iron content (0.01% Fe). This was called the low iron diet (100ppm iron). The 
second was CRM (P) 400ppm iron Fe (P): again the CRM (P) formulation was used, but the 
iron content was increased (0.04% Fe). This was called the high iron (400ppm iron) as shown 
in Figure 2-1.  
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Figure 2-1: Mice dietary modifications. 
 
 
 
 
2.2.2 Induction of colitis 
 
Dextran sulphate sodium (DSS) was used to induce colitis: this being a commonly used murine 
model of human ulcerative colitis. Usually, only the acute phase is used to study the innate 
immune response, but CD and UC are chronic pathologies, and so chronic intestinal 
inflammation was induced by the used of repeated cycles of DSS, thus enabling the study of 
the adaptive immune system. 
 
2.2.2.1 Acute DSS  
 
Mice were given a 2% solution [1000ml sterile water + 20g DSS] of dextran sulphate sodium 
(M.W. 36,000 – 50,000Da; Catalogue number: 160110; Lot number: 6683K; MP Biomedicals, 
LLC, UK) in their drinking water for 5 days to induce colitis (~150ml/mouse over 5 days), 
Normal iron 
diet
200ppm iron
High iron diet
400ppm iron
Low iron diet
100ppm iron
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followed by another 5 days of DSS-free water. Mice were euthanised on day-10, measured 
from the start of the experiment. The gastroenterology research team at the University of 
Liverpool approved this protocol (Acute DSS cycle). Mice were monitored daily for signs of 
disease (clinical observation), and their body weight was recorded as illustrated in Figure 2-2. 
 
 
Day -7 to -1 1 2 3 4 5 6 7 8 9 10 
Procedure Acclimatisation DSS treatment Recovery period (plain water) 
 
 
 
Figure 2-2: Induction of acute colitis protocol using DSS 
 
 
 
2.2.2.2 Chronic DSS  
 
Chronic colitis can be induced by applying 3-4 cycles of 5 days of DSS treatment with intervals 
of between 5 to 16 days when plain drinking water is provided. Mice were given 1.25% DSS 
solution [1000ml sterile water + 12.25g DSS (as above)] to drink for 5 days to induce acute 
colitis (~150ml/mouse over 5 days), followed by 16 days of DSS-free water (full recovery 
period). The cycles were repeated twice to give 3 cycles of 21 days each (total 63-days) as 
illustrated in Figure 2-3. The gastroenterology team approved this protocol (Chronic DSS). All 
mice were euthanised on day-63 counting from the start of the experiment. During the whole 
period (63 days) mice were weighed and monitored daily for any signs of disease by clinical 
observation. 
 
Colon 
collection 
Body Weight (BW) BW 
 
BW 
 
Clinical observation 
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Figure 2-3: Chronic DSS schedule 
 
2.3 Tissue sampling and preparation 
 
Mice were killed by using a CO2 chamber with 2 cycles of 60% CO2 for 5 minutes, followed by 
100% CO2 for 1 minute to enable blood extraction by cardiac puncture. Death was then 
confirmed by a neck dislocation technique (this is a Home Office approved Schedule 1 
procedure). Subsequently, after spraying with 70% ethanol, a ventral midline incision was 
performed. The colon was grasped with forceps and pulled until the caecum could be 
identified. The colon, from the colocaecal junction to the anal verge, was removed: particular 
care was taken as the inflamed colon of DSS-treated animals is delicate, shortened and 
attached to surrounding tissues. Colonic faecal contents were removed by squeezing the 
colon, using a pair of forceps, onto a clean histology slide before transferring the contents 
into a 2ml Eppendorf tube containing stool stabiliser (supplied from Startec Kit [PSP® Spin 
Stool DNA Plus Kit]).  
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2.3.1 Fixation / Preservation 
 
Fixation is a major step in histological specimen preparation. The intestine was rinsed (dipped 
in a dish) with cold (4°C) Phosphate-buffered saline (PBS) and then wrapped in filter paper 
and fixed in freshly prepared 4% formalin solution for a maximum of 24hrs. The tissue was 
then stored in 70% ethanol before the bundling step.  
 
2.3.2 Gut bundling and processing 
 
Tissues were removed from the ethanol and rinsed with cold (4°C) PBS, and divided into 2 
parts: proximal and distal colon. The distal colon tissue segment, located approximately 10 
mm, from the anal verge was identified and cut into 2-3 small parts before being placed into 
loops of 3M Micropore surgical tape in a process called ‘gut bundling’. After bundling, the 
tape around the tissues was squeezed to hold the tissues in loops together, and the bundles 
were trimmed by removing excess tissues and any extra tape using a Swann-Morton size 22-
scalpel blade (VWR International Ltd, Lutterworth, UK) 103. Each bundle was placed 
individually into a histology cassette, and this was stored in 70% ethanol until the processing 
step. All of the cassettes were placed in the processor machine [Thermo Shandon 
Hypercentre] overnight.  
 
Figure 2-4: Schematic diagram for gut bundling 103. 
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2.3.3 Embedding in paraffin and cutting  
 
After retrieving cassettes from the processor, the paraffin-embedding stage was begun. 
Tissues were held in a vertical position in the centre of a stainless steel or plastic mould, to 
enable transverse section during tissue cutting, before pouring the melted paraffin wax and 
then allowing the blocks to cool and harden. Finally, transverse tissue sections of 4μm 
thickness were obtained by cutting the paraffin blocks using a manual microtome (Leica 
RM2235 manual microtome). Tissue sections were then placed on glass microscope slides. 
Slides were drained vertically for a brief time to get rid of excess water before they were 
placed in an oven (at 37°C for 24hrs).  
 
2.3.4 Haematoxylin and eosin staining  
 
Paraffin is poorly permeable to stains, so the slide was de-waxed using fresh Xylene I for 5 
minutes and fresh Xylene II for another 5 minutes. The sections were then transferred 
through a series of alcohol gradients starting with absolute ethanol and finishing with distilled 
water to avoid diffusion currents.  
 
Slides were placed in haematoxylin (Sigma-Aldrich Co, Dorset, UK) for 3 minutes and then 
rinsed in tap water for 10 minutes. The slides were placed in eosin (Sigma-Aldrich Co, Dorset, 
UK) for 4 minutes, before dipping them in tap water several times. Sections were then 
dehydrated by immersion in 95% ethanol and (twice) in 100% ethanol.  
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After dehydration, slides were cleared using Xylene I and II for 5 minutes each. Finally, the 
slides were removed from the rack, wiped, and mounting medium (DPX) and coverslips were 
applied. Air bubbles were removed using tweezers or a pipette tip. The slides were allowed 
to cool for 10 minutes at room temperature and were then examined under a light 
microscope. 
 
2.3.5 Masson’s trichrome staining  
 
Intestinal fibrosis in chronic DSS-induced colitis was investigated by staining the sections with 
the Masson’s trichrome method: NovaUltraTM Masson’s Trichrome Stain Kit 
(Fisher Scientific UK Ltd) was utilised. The sections were dipped in 2 Xylene dishes [I and II] 
for 5 minutes each to remove paraffin; then the slides were rehydrated in 2 changes of 100% 
alcohol for 5 minutes each, 95% and 70% alcohol for 1 minute each. Then the slides were 
rinsed in distilled water before staining them in a dish filled with Weigert's Iron Haematoxylin 
Solution for 10 minutes. The slides were then placed in running tap water for 10 minutes, 
before being washed with distilled water and stained in Biebrich Scarlet-Acid Fuchsin Solution 
for 10-15 minutes, before being washed again in distilled water. The sections were then 
placed in phosphomolybdic-phosphotungstic (PP) Acid Solution for 10-15 minutes to 
differentiate or until the red colour of the collagen disappeared. At that time, the sections 
were laid into aniline blue solution, without rinsing, and stained for 5-10 minutes and rinsed 
briefly with distilled water and acetic acid solution for 2-5 minutes, before washing again in 
distilled water.  
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This was followed by quick dehydration using 95% alcohol, two changes of 100% alcohol for 
1 minute each to wash off the Biebrich Scarlet-Acid Fuchsin stain before, finally, clearing the 
slides again using 2 changes of xylene, 5 minutes each, before mounting medium and 
coverslips were applied. Slides were allowed to cool before being visualised using the 
microscope. 
 
2.4 Faecal bacterial DNA extracted from mouse pellets 
 
The intestinal microbiota is considered to play a vital role in the pathogenesis of IBD, and 
various studies have confirmed the presence of intestinal dysbiosis in IBD patients compared 
to healthy controls 68. Furthermore, iron supplementation has been shown to influence 
microbial diversity, and therefore this should be considered when studying the intestinal 
microbiota 104. This research aimed to assess the relationship between the faecal microbiota 
and the presence of gastrointestinal mucosal inflammation. 
 
There are significant differences in relative abundance of bacteria when DNA is extracted 
using different techniques from mock groups of bacteria and measured by 16S rRNA 
sequencing 105. However, in another study, reported differences in the yield and relative 
abundance of main bacterial families for different kits used to extract bacterial DNA from 
faeces. This highlights the importance of ensuring that all samples are prepared with the same 
DNA extraction technique (kit), and careful consideration when comparing studies that have 
used different approaches 106. 
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Therefore, in this research, to evaluate bacterial diversity in faeces, bacterial DNA was 
extracted using the Startec Kit [PSP® Spin Stool DNA Plus Kit] throughout the study. The 
extracted DNA was sent to the Centre for Genomic Research (CGR) at the University of 
Liverpool to carry out 16S Metagenomic Sequencing Library Preparation. Data was extracted 
from the sequencing machine [Miseq] followed by bioinformatics analysis.  
 
2.4.1 Faecal sampling 
 
In the murine studies, to avoid cross-contamination between samples, each mouse was put 
in a bowl previously wiped with 70% ethanol. The presence of the animal in the bowl for a 
couple of minutes was usually sufficient for it to excrete 5-6 faecal pellets. This amount is 
sufficient for DNA extraction. The faecal samples were placed into 2ml Eppendorf tubes filled 
with a stool stabiliser (supplied with the extraction kit) using sterile forceps.  
 
 
 
 
 
Figure 2-5: Stool Stabilizer Tube 
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2.4.2 PSP® Spin Stool DNA Plus Kit 
 
This kit is a combined kit for the collection, transportation and storage of faecal samples and 
consequent DNA purification; it is designed for the separation of DNA from microorganisms, 
as well as from the host organism. The PSP® Spin Stool, DNA Plus Kit (Figure 2-6), delivers fast 
and easy purification of DNA from frozen or fresh stool samples using Invisorb® technology. 
The kit utilises a stabilising reagent (Stool DNA Stabilizer in tubes; Figure 2-4) for collection, 
storage and stabilisation of the stool sample to prevent DNA degradation, prelysing bacteria 
and stopping further bacterial growth, thus preserving the microbial community. The kit is 
effective for both Gram positive and negative bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6: PSP® Spin Stool DNA plus 250 extractions Kit 
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2.4.3 Assay procedure 
 
1. The required amount of the stool sample was collected and transferred to the stool 
collection tube, which contained stool DNA stabiliser. The tube was closed, and the 
contents were mixed by shaking. 
2. 1.4ml of the stabilised stool sample was pipetted into a 2.0ml Safe-Lock Tube. 
3. The sample was incubated for 10 minutes at 95°C on a thermomixer, then shaken at 900 
rpm. 
4.  5 Zirconia Beads II was added, the sample was vortexed for 2 minutes, then centrifuged 
at 11.000 x g for 1 minute. 
5. The supernatant was transferred to the InviAdsorb-Tube before mixing by vortex for 15 
seconds. 
6.  The sample was incubated for about 1 minute at room temperature then centrifuged 
again for 3 minutes at full speed (15.000 x g). 
7. The supernatant was transferred to a new 1.5ml receiver tube before being centrifuged 
again at full speed for 3 minutes. 
8.  800µl of the sample supernatant was added to a new 2.0ml Safe-Lock-Tube, 25µl 
Proteinase K was added, and this was mixed briefly by vortexing. 
9. The sample was incubated for 10 minutes at 70°C on a thermomixer while shaking (900 
rpm). 
10.  400µl of Binding Buffer A was added to the sample, and this was mixed by pipetting up 
and down. 
11. The whole mixture was transferred to the RTA Spin Filter and was incubated at room 
temperature for about 1 minute.  
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12. The RTA Spin Filter was centrifuged at 11.000 x g for 2 minutes before disposing of the 
filtrate and the RTA Receiver Tube. 
13.  The RTA Spin Filter contents were placed in a new RTA Receiver Tube, 500µl of Wash 
Buffer I was added to the RTA-Spin Filter, and this was then centrifuged at 11.000 x g for 
1 minute before discarding the flow-through and the RTA Receiver Tube. 
14. Again, the RTA Spin Filter was placed in a new RTA Receiver Tube and 700µl Wash Buffer 
II was pipetted onto the RTA Spin Filter, then this was centrifuged at 11.000 x g for 1 
minute before disposing of the flow-through and reusing the RTA Receiver Tube. 
15.  An additional centrifuge step for 4 minutes at maximum speed was applied to remove 
any traces of ethanol. 
16. After centrifugation, the RTA Receiver Tube was removed, and the RTA Spin Filter was 
placed into a new 1.5ml Receiver Tube. 100-200µl of elution buffer, heated up to 70°C 
(Stuart Scientific heater block) was added to the centre of the membrane of the filter 
before it was incubated for 1 minute at room temperature. 
17.  The tube was then centrifuged at 11.000 x g for 1 minute; the RTA-Spin Filter was removed, 
and two aliquots were prepared for use. One aliquot was placed directly into a refrigerator 
and the second was stored in the freezer at –20°C. 
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2.5 ELISA for faecal calprotectin analysis 
 
ELISA (enzyme-linked immunosorbent assay) is a plate-based assay procedure aimed 
at finding and measuring elements such as peptides, proteins, antibodies, and 
hormones. In ELISA assay, an antigen is immobilised on a solid surface and then 
complexes with an antibody linked to an enzyme. Detection is achieved by evaluating 
the conjugated enzyme activity via incubation with a substrate to produce a 
measurable product. Calprotectin is a calcium-binding protein which is secreted 
predominantly by neutrophils and monocytes. It is a marker for neoplastic and inflammatory 
gastrointestinal diseases such as IBD. 
Sample 
Homogenisation and 
prelysis 
Removal of PCR  
    Inhibitors Second Sample Clean-up 
Proteinase 
K digestion  
Binding of the 
DNA 
Washing steps 
[Wash buffer 1 and 2] 
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then DNA elution 
  Bacterial DNA  
enrichment 
Figure 2-7: Scheme of the PSP® Spin Stool DNA plus Kit 
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2.5.1 S100A8/S100A9 ELISA [Murine] 
 
The S100A8/S100A9 ELISA by Immundiagnostik Germany is designed for experimental animal 
studies i.e. mouse or rat and is not suitable for human samples. This ELISA kit was designed 
for the quantitative determination of calprotectin S100A8/S100A9 (Calprotectin, MRP (8/14)) 
in stool, urine, plasma, serum, tissue samples and cell culture. 
 
 
                Figure 2-8: S100A8/S100A9 ELISA Kit 
                 
                        
 
 
2.5.1.1 Faecal samples prepared and stored for analysis 
 
Mouse faecal samples (pellets) were allowed to thaw slowly at 2–8°C, if they were frozen, and 
were warmed to room temperature before analysis. For long term storage of up to 
12 months, samples were stored at -20°C and repeated freezing and thawing of the sample 
was avoided as much as possible. Each faecal sample was extracted 1:50 in extraction buffer 
(e.g. 100mg faeces + 5ml extraction buffer), then centrifuged for 10 minutes at 3000 x g. 
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2.5.1.2 Assay procedure 
 
100µl of the supernatant was pipetted into each well. All reagents and samples were brought 
to room temperature (15–30°C) and mixed well. The experiments were performed in 
duplicate, and the assay procedure steps were completed according to the protocol supplied 
with S100A8/S100A9 ELISA kit. First, each well in the plate was washed 5 times by dispensing 
250µl of diluted WASHBUF (wash buffer) using an automatic microplate washer (Mikura 
Autura 1000), then residual buffer was removed by tapping the plate on absorbent paper. 
100µl of STD (Standard) SAMPLE (Sample/supernatant) CTRL (Controls) was pipetted into 
each corresponding well. An adhesive plastic sheet was placed to cover the plate tightly 
before it was incubated for 1 hour at 37°C on a single plate horizontal shaker (Mikura Orbis). 
The contents of each well were removed, then washed again 5 times with diluted WASHBUF 
(wash buffer) before tapping the plate on absorbent paper to remove residual buffer. 100µl 
of diluted AB (detection antibody) was added to each well, the strips covered firmly, and this 
was re-incubated again for 1 hour at 37°C on a horizontal shaker.  
 
The plate’s content was discarded, and it was washed 5 times again with 250µl wash buffer 
and slapped four times onto absorbent paper. 100µl of diluted CONJ (conjugate) was pipetted 
into each well then the plate was covered tightly before being re-incubated once more for 1 
hour at 37°C on a horizontal shaker. Similarly, the contents of each well were removed and 
washed another 5 times, with diluted wash buffer, and then the plate cleaned using the same 
tapping technique. 
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100µl of SUB (substrate) was pipetted into each well, however, this time, the plate was 
incubated for 10–20min at room temperature (15–30°C) in the dark. Lastly, 100µl of STOP 
(stop solution) was added to each well, and this was mixed before the absorption was 
measured immediately with an ELISA reader (TECAN Sunrise™) at 450nm.  
 
 
2.5.1.3 Calprotectin results filtered and analysed 
 
The absorbance was measured directly at 450nm only as no reference wavelength was 
available on the ELISA reader (TECAN Sunrise™). For a 4-parameter algorithm, a logarithmic 
abscissa was used for the concentration and a linear ordinate for the optical density. 
However, using a logarithmic abscissa, the zero standards were specified with a value less 
than 1 (e.g. 0.001). All data from the ELISAs were reduced using special software either 
MasterPlex ReaderFit (Hitachi Solutions America, Ltd. USA) or [Gen5 Image+ (BioTek 
Instruments, Inc., USA)].  
 
The reduced data from the calprotectin test used the dilution factor 50. However, as the 
standards are ng/ml but were reported in ug/g, the following calculation was applied to the 
observed result: 
  
 
(Result x 5000 = Final concentration in ng/ml)     = Final result in µg/g 
                                                1000 
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Figure 2-9: Standard curve using MasterPlex ReaderFit Software [(a) the minimum value that can be obtained, (d) 
the maximum value that can be obtained (i.e. what happens at infinite dose), (c) the point of variation (i.e. the 
point on the S-shaped curve halfway between a and d) and (b) Hill’s slope of the curve (i.e. this is related to the 
sharpness of the curve at point c) 
 
       450                                  = Absorbance reading at 450nm 
[Concentration]                = Calculated concentration in ng/ml  
                                                (I.e. concentration before applying the dilution factor of 0.05) 
[Concentration] x Dil.      = Calculated concentration in ug/g  
                                                 (I.e. concentration after applying the dilution factor of 0.05) 
 
 
 
2.6 Faecal iron concentration 
 
Iron deficiency anaemia (IDA) is common in inflammatory bowel disease (IBD). Iron plays a 
critical role in numerous biological pathways. The biological action of iron is largely governed 
by its transition ability: redox reactions control its ferric (Fe3+) and ferrous (Fe2+) forms. Free 
reduced iron is toxic as it reacts with hydrogen peroxide (H2O2) or lipid peroxide to produce 
highly reactive radicals that can damage lipids, proteins, and nucleic acids. In inflammatory 
bowel disease, reactive oxygen species (ROS) are formed by neutrophils in inflamed intestinal 
mucosa which participate in the mechanism of tissue injury: free iron is a strong catalyst for 
ROS production 107, 108.  
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There is some doubt about how to treat patients with iron deficiency, who have haemoglobin 
readings in the normal range. Oral iron supplementation usually consists of ferrous (Fe2+) 
salts, which are linked to gastrointestinal side effects, often resulting in poor compliance. 
Treatment with oral ferrous salts may even be harmful to IBD patients as they are poorly 
absorbed and lead to an increase in faecal iron concentration. A significant portion of faecal 
iron will be available for catalytic activity when iron reaches the inflamed intestinal mucosa 
causing more ROS production and thus aggravating tissue damage 109. 
 
2.6.1 Faecal iron immunoassay 
To calculate faecal iron concentration, an iron assay kit [MAK025, Sigma-Aldrich Company Ltd. 
Dorset, England] was utilised. This assay gives the option to measure Fe2+ directly or to 
measure total iron (Fe2+ and Fe3+). Iron is released by adding an acidic buffer; freed iron reacts 
with a chromogen causing in a colorimetric (593 nm) product, proportional to the amount of 
iron present. The MAK025 Assay Kit, therefore, offers a suitable means of calculating iron in 
diverse biological samples (tissues, cells, serum and other liquids). 
 
 
 
Figure 2-10: Iron assay kit.                                                                                                                                                                                     
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2.6.1.1 Storage and preparation of samples 
 
Fresh specimens [mouse faecal samples (pellets)] were used and stored correctly until used, 
then allowed to thaw slowly at 2–8°C from frozen, and warmed to room temperature before 
analysis. To calculate the best size for the faecal sample, three weights (10, 20 and 30mg of 
fresh specimens) were used to ensure that readings were within the linear range of the 
standard curve. The best reading (standard curve) was found to be with 20mg samples. 
Therefore all faecal iron immunoassay tests (animal) used this weight of starting material. 
20mg of faecal samples were added to a 2ml Eppendorf tube with 5 mm stainless steel beads 
and 100µl of Iron Assay Buffer. For rapid homogenisation, a bead beater (TissueLyser II/ 
QIAGEN) was used at frequency 30 1/S for about 2 minutes; then the tubes were centrifuged 
at 13,000 x g for 10 minutes at 4°C to remove any insoluble material. 
 
2.6.1.2 Assay procedure 
 
This assay was performed in triplicate for all wells (samples and standard) using 96 well clear 
flat-bottom plates.  
 
1) 0, 2, 4, 6, 8, and 10µl of the 1 mM standard solution were added into a 96 well plate 
to create 0, 2, 4, 6, 8, and 10 nmol/well standards, then Iron Assay Buffer was added 
to each well to bring the volume to 100µl.  
2) 20µl of the samples (homogenised) was added into respective wells, before adding 
Iron Assay Buffer to each well to bring the volume to 100µl.  
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3) To measure total iron, 5µl of Iron Reducer was added to each of the wells (sample and 
standard) to reduce Fe3+ to Fe2+. 
4) Solutions were pipetted up and down to mix all the contents in each well before the 
plate was incubated for 30 minutes at room temperature.  
5) 100µl of Iron Probe was added to each well and samples were then mixed well by 
pipetting, and the reaction was re-incubated for about 60 minutes at room 
temperature. The plate was wrapped in aluminium foil to protect it from light during 
each incubation. 
6)  The absorbance was measured using a spectrophotometric multi-well plate reader 
(TECAN Sunrise™) at 593 nm (A593). 
 
 
Figure 2-11: An example of a standard iron curve in 96-well plate assay (the 
calibration curve obtained by plotting the absorbance of identified 
concentrations) 
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Figure 2-12: Standard curve and dilution optimization               Figure 2-13: Assay micro-plate model 
 
 
98 
 
Iron changes colour by reduction during the reaction. The different oxidation states have the 
following colours, Fe2+ (Very pale green) to Fe3+ (Very pale violet (as in the standard)/brown). 
Then, once chloride ions bind Fe3+ in a complex, it forms a yellow/brown colour. These 
colorimetric products are followed by measuring absorbance at 593 nm. 
 
2.6.1.3 Faecal iron results and analysis 
 
It is important to have a blank (0) for the iron standard for use as a background for the assay. 
The background is removed from the sample values by deducting the 0 (blank) value from all 
readings. A standard curve was prepared from a known concentration of iron. A new standard 
curve was made for each assay run.  
 
                                                                       Sa (Amount of iron in unknown sample (more) from standard curve) 
Concentration of iron in sample (C) =  
                                                                       Sv (Sample volume (µl) added into the wells) 
 
Example for sample calculation:  
Assuming the amount of iron (Sa) = 5.84 moles (from standard curve) and the sample volume 
(Sv) = 100µl, then by applying the equation above. 
                       Concentration of iron in sample = 5.84 nmole/100µl = 0.0584 nmol/µl 
Now converting from nmol/µl to ng/µl by multiplying the concentration of iron in sample by 
the iron atomic mass is 55.85 g/mole 
                                                    0.0584 nmole/µl x 55.85 ng/nmole = 3.26 ng/µl 
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2.7 Microbiome studies 
 
Metagenomic studies are accomplished by analysing the prokaryotic 16S ribosomal RNA gene 
(16S rRNA), which is around 1,500 bp long and covers nine variable regions sprinkled between 
conserved regions. Variable regions of 16S rRNA are often used in phylogenetic classifications 
such as genus or species in diverse microbial populations.  
 
Previous animal research has shown that there are changes in bacterial composition with 
colonic inflammation and/or infection 30. Current molecular techniques have enabled the 
description of the change in the composition of the faecal microbiota, as well as mucosally-
associated bacteria, in patients with CD and UC. This research has explored the impact of 
disease activity and iron on the faecal microbiota. The mucosal microbiota play a crucial role 
in maintaining microbiome equilibrium, however in this research it was difficult to obtain 
samples (mucosal) from day-1 without killing the animals, as the aim is to compare pre- and 
post-treatment samples together. 
 
2.7.1 DNA sample preparation and storage  
 
Bacterial DNA was extracted from murine faecal samples using the Startec Kit [PSP® Spin Stool 
DNA Plus Kit]. To validate the efficiency of the PCR assay for detection of the presence of the 
prokaryotic V4 region (16S rDNA), the DNA extracted was quantified by Qubit® 2.0 
Fluorometer [Invitrogen by life technologies] to 1 ng/µl into Aliquots of 50µl. 
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2.7.1.1 DNA samples were quantified using Qubit® 2.0 Fluorometer 
 
 Aliquot 199 x n µl of Quant-iTTM Buffer was added into the 45ml tube, and 1 x n µl for 
the Quant-iTTM Reagents to make Quant-iTTM Working Solution (master mix). [n= 
number of Standards plus number of Samples].  
 Aliquot 199µl of Quant-iTTM Working Solution was added into 0.5ml tubes (molecular 
probe tubes for the Qubit) for the samples, and 190µl was added to the two standards. 
 1µl of the sample was added and 10µl of the standards to a separate 0.5ml tube. 
 The samples and standards were mixed by vortex. 
 The samples and standards were incubated for 2 minutes at RT in the dark. 
 The Qubit machine was switched on then standards were placed in for calibration 
before the samples were placed in for reading. All the reading data were recorded in 
an Excel file. 
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*n = number of Standards plus number of Samples 
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Figure 2-14: Qubit’s process 
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2.7.1.2 Assessing DNA quality 
 
To assess the quality of the extracted DNA before sequencing, a basic PCR was performed to 
detect the V4 region band on an agarose gel. This was done for one out of every five DNA 
extracted samples. V4 primers [Forward: F515: 5’-GTG-CCA-GCM-GCC-GCG-GTA-A-3’, and 
Reverse: 806R: 5’-GGA-CTA-CNN-GGG-TNT-CTA-AT-3’] were used. A 
KAPA HiFi HotstartReadyMix PCR Kit [Kapabiosystems, Boston, Massachusetts, United States] 
was used as recommended by the CGR (Centre for Genomic Research). 
 
Reaction 
component 
Final 
concentration 
Per 25µl 
reactions 
PCR grade water _ Up to 25µl 
KAPA HiFi Hot start 1x 12.5µl 
Fw V4 primer 0.3µM 1.5µl 
Rv V4 primer 0.3µM 1.5µl 
Template DNA 1 ng/µl 1.5µl 
 
Table 2-1: KAPA HiFi reaction setup for routine high-fidelity PCR 
 
Reactions were performed using a MultiGene™ OptiMax Thermal Cycler (Labnet 
International, Inc.) under the cycling conditions listed in Table 2-3, below. 
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Cycling step Temperature and Time 
Initial denaturation 2 min at 95°C 1 
Denaturation 20 sec at 98°C  
X 30 cycles Annealing 15 sec at optimal 60°C 
Extension 40 sec/kB at 72°C 
Final extension 1 min at 72°C 1 
 
Table 2-2: KAPA HiFi cycling parameters for routine high-fidelity PCR 
 
 
 
To detect the amplified band, a 2% agarose gel was placed in a bath of running buffer ((Tris-
acetate-EDTA) TAE 1x) with 5µl of Hyperladder IV and 12.5µl of PCR product. The gel was run 
for 2 hours at 80 Volts. After 90 minutes, it was possible to visualise the gel in a ChemiDoc™ 
MP System (BIO-RAD) where the band size should be around 300 bp. 
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Figure 2-15: example of 2% agarose gel showing V4 bands [-ve CTR. (water), +ve CTR (healthy control), 
DNA 1, 2, 3 and 4 (IBD samples)] all samples are faecal bacterial DNA from humans 
 
 
Once the DNA quality had been assured, 96 well plates were prepared with 25µl of quantified 
samples (genomic DNA) per well. Negative controls were also applied.  
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2.7.2 16S Metagenomics Sequencing Library Preparation  
 
All of the following work was done at the Centre for Genomic Research labs and by their staff. 
 
The Centre for Genomic Research (CGR) used a standard protocol as shown in Figure 2-16 for 
preparing samples and sequencing the variable V4 region of the 16S rRNA gene. This protocol 
combined with a benchtop sequencing system, initial onboard analysis, and secondary 
analysis using MiSeq Reporter, provided a comprehensive workflow for 16S rRNA amplicon 
sequencing.  
 
 
 
 
 
Figure 2-16: V4 sequencing protocol (2-steps PCR Dual Indexes)                      
1st round PCR
[V4 (F515, 806R) primers]
•Amplicon PCR to identify V4 band.
•Cleaning up using Ampure beads.
2nd round PCR
[N501 Rev 701 barcodes]
•PCR with barcodes.
•Cleaning up using Ampure beads.
Quantity and quality 
check
•Measuring DNA quanity using Qubit.
•Check DNA quality by runing on Bioanalyzer.
Pooling and size
selection
•According to results from Bioanalyzer stage, measuring 
average fragment length then select DNA size using PIPPIN 
PREP.
•Cleaning up using Ampure beads.
Q-PCR
•Another quantity and quality check [Qubit/Bioanalyzer].
•Q-PCR.
Sequencing •Fill out LIMS website.
•MiSeq illumina sequencing.
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2.7.2.1 Amplicon PCR 
 
In this step, PCR was used to amplify DNA of interest using specific primers with extended 
adapters attached. 
1.  The following components of DNA, 2 x KAPA HiFi Hot Start Ready-mix, and primers were 
added together to make a reaction mix of 25μl per each sample: 
 
Reaction components Volume 
Microbial DNA (5 ng/μl) 2.5μl 
V4 Forward Primer 1μM 5μl 
V4 Reverse Primer 1μM 5μl 
2x KAPA HiFi Hot Start Ready-mix 12.5μl 
Total 25μl 
 
2.  25μl of each reaction components (each sample) was added to a 96-well PCR plate. The 
plate was then sealed, and the PCR reaction was performed in a thermal cycler using the 
following program: 
 
Cycling step Temperature and Time 
Initial denaturation 3 min at 95°C 1 
Denaturation 30 sec at 95°C  
X 25 cycles Annealing 30 sec at optimal 55°C 
Extension 30 sec/kB at 72°C 
Final extension 5 min at 72°C 1 
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The size was verified by running 1μl of the PCR product on a Bioanalyzer DNA 1000 chip using 
the V4 primer pairs in the protocol. The expected size on a Bioanalyzer trace after the 
Amplicon PCR step was ~550 bp. 
 
 
Figure 2-17: Example of Bioanalyzer trace after Amplicon PCR Step 
 
 
 
2.7.2.2 PCR Clean‐Up 1 
 
In this step, AMPure XP beads were used to purify the 16S V4 amplicon away from free 
primers and primer dimer species. The kit was prepared by bringing the AMPure XP beads to 
room temperature. 
 
Consumables 
Item Quantity 
10 mM Tris pH 8.5 52.5μl per sample 
AMPure XP beads 20μl per sample 
96‐well 0.2ml PCR plate 1 plate 
Freshly Prepared 80% Ethanol (EtOH) 400μl per sample 
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2.7.2.2.1 Procedure 
1) The Amplicon PCR plate was centrifuged at 1,000 × g at 20°C for 1 minute. 
2) Then the AMPure XP beads were vortexed for 30 seconds to make sure that the beads were 
evenly dispersed before adding some to a trough.  
3) About 20μl of AMPure XP beads was added to each well of the Amplicon PCR plate; this 
was then mixed by pipetting up and down a few times before incubating at room 
temperature for 5 minutes. 
4) The plate was placed on a magnetic stand for 2 minutes until the supernatant had cleared. 
5) While the Amplicon PCR plate was on the magnetic stand, the supernatant was removed 
and discarded using a pipette. 
6) The beads were washed with freshly prepared 80% ethanol while the Amplicon PCR plate 
was on the magnetic stand. First, 200μl of freshly prepared 80% ethanol was added to each 
sample well. Next, the plate was incubated on the magnetic stand for 30 seconds. Then, the 
supernatant was removed and discarded. 
7) Again, the second ethanol wash was performed while the Amplicon PCR plate was on the 
magnetic stand. So, 200μl of freshly prepared 80% ethanol was added to each sample 
well. Next, the plate was incubated on the magnetic stand for 30 seconds. Then the 
supernatant was removed and discarded before removing excess ethanol with pipette 
tips. 
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8) The beads were allowed to air‐dry for 10 minutes then the Amplicon PCR plate was 
removed from the magnetic stand before 52.5μl of 10 mM Tris pH 8.5 was pipetted into 
each well of the Amplicon PCR plate. 
9) Gentle mixing was performed by pipetting up and down 10 times, before incubation at 
room temperature for 2 minutes. 
10) The plate was placed on the magnetic stand for 2 minutes or until the supernatant had 
cleared. 
 11) 50μl of the supernatant was transferred from the Amplicon PCR plate into a new 96 well 
PCR plate. 
 
 
 
 
 
Figure 2-18: Standard workflow of AMPure XP reagents (adapted from manufacturer's catalogue) 
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2.7.2.3 Index PCR 
 
In this step dual indices and Illumina sequencing adapters were attached using the Nextera 
XT Index Kit. 
 
Consumables 
 
Item Quantity 
2x KAPA HiFi Hot Start Ready-mix 25μl per sample 
Nextera XT Index 1 Primers (N7XX) 5μl per sample 
Nextera XT Index 2 Primers (S5XX) 5μl per sample 
PCR Grade Water 10μl per sample 
TruSeq Index Plate Fixture (FC‐130‐
1005) 
1 
96‐well 0.2ml PCR plate 1 plate 
Microseal 'A' film 1 
 
Table2-3: Nextera XT Index Kit contents 
                                                      
 
 
 
2.7.2.3.1 Procedure 
 
1)  About 5μl of suspended PCR product DNA was transferred from each well to a new 
96-well plate. 
2)          The Index 1 and 2 primers were positioned in a rack (i.e. the TruSeq Index Plate Fixture) 
as follows: 
              [a]  Index 2 primer tubes (white caps, clear solution) were placed vertically, 
aligned with rows A-H. 
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             [b]  Index 1 primer tubes (orange caps, yellow solution) were placed horizontally, 
aligned with columns 1-12. 
3)  The 96-well PCR plate containing the 5μl of DNA had been put in the TruSeq Index 
Plate Fixture.  
 
 
 
 
 
 
 
 
 
 
 
 
 
4) The following components of DNA, Nextera XT Index Primers [1 (N7xx), 2 (S5xx)], 2x 
KAPA HiFi Hot Start Ready-mix, and PCR Grade water were added together to make a 
reaction mix of 50μl per each sample: 
 
Reaction components Volume 
DNA 5μl 
Nextera XT Index Primer 1 (N7xx) 5μl 
Nextera XT Index Primer 2 (S5xx) 5μl 
2x KAPA HiFi Hot Start Ready-mix 25μl 
PCR Grade water 10μl 
Total 50μl 
 
A Index 2 primers (white caps) 
B Index 1 primers (orange caps) 
C 96-well plate 
Figure 2-4: TruSeq Index Plate Fixture 
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5)  All components were mixed by pipetting up and down; then the plate was covered 
with micro seal 'A' before it was centrifuged at 1,000 × g at 20°C for 1 minute. 
6)  PCR reaction was performed in a thermal cycler using the following cycling conditions: 
 
 
 
Cycling step Temperature and Time 
Initial denaturation 3 min at 95°C 1 
Denaturation 30 sec at 95°C  
X 8 cycles Annealing 30 sec at optimal 55°C 
Extension 30 sec/kB at 72°C 
Final extension 5 min at 72°C 1 
 
 
2.7.2.4 PCR Clean‐Up 2 
 
In this step, AMPure XP beads were used again to clean up the last library before 
quantification. 
 
Consumables 
 
Item Quantity 
10 mM Tris pH 8.5                                                           27.5μl per sample 
AMPure XP beads 56μl per sample 
96‐well 0.2ml PCR plate 1 plate 
Freshly Prepared 80% Ethanol (EtOH) 400μl per sample 
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2.7.2.4.1 Procedure 
 
1)  The Index PCR plate was centrifuged at 280 × g at 20°C for 1 minute to gather 
condensation. 
2)  The AMPure XP beads were vortexed for 30 seconds to make sure that the beads were 
evenly dispersed before adding some to a trough.  
3)  Around 56μl of AMPure XP beads was added to each well of the Index PCR plate, mixed 
by pipetting up and down few times before incubating at room temperature for 5 
minutes. 
4)  The plate was placed on a magnetic stand for 2 minutes until the supernatant had 
cleared. 
5)  While the Amplicon PCR plate was on the magnetic stand, the supernatant was 
removed and discarded using a pipette. 
6)  The beads were washed with freshly prepared 80% ethanol while the Amplicon PCR 
plate was on the magnetic stand. First, 200μl of freshly prepared 80% ethanol was 
added to each sample well; the plate was placed on the magnetic stand for 30 seconds 
before the supernatant was removed and discarded. 
7)  Again, another ethanol wash was performed during the Amplicon PCR plate on the 
magnetic stand. 200μl of freshly prepared 80% ethanol was added to each sample 
well; then the plate was placed on the magnetic stand for 30 seconds before the 
supernatant was removed and discarded and any excess ethanol was removed with 
fine pipette tips. 
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 8)  The beads were allowed to air-dry for 10 minutes before the Amplicon PCR plate was 
removed from the magnetic stand. 27.5μl of 10 mM Tris pH 8.5 was added to each 
well of the Amplicon PCR plate. 
9)  Gentle mixing by pipetting up and down 10 times, before incubating at room 
temperature for 2 minutes. 
10)  The plate was placed on the magnetic stand for 2 minutes or until the supernatant had 
cleared. 
11)  25μl of the supernatant was transferred from the Index PCR plate to a new 96-well 
PCR plate.  
 
2.7.2.5 Library Quantification, Normalization, and Pooling 
 
Illumina recommends quantifying libraries using a fluorometric quantification method that 
uses dsDNA-binding dyes. 
The following equation is used to calculate DNA concentration in nM, based on the size of 
DNA amplicons as determined by an Agilent Technologies 2100 Bioanalyzer trace: 
                                                    
                                  
                                        (Concentration in ng/µl) 
                           (660 g/mol x average library size) x 106 = concentration in nM 
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The concentrated final library was diluted by using Resuspension Buffer (RSB) or 10 mM Tris 
pH 8.5 to 4 nM, then 5μl of diluted DNA from each library was aliquoted, and all aliquots for 
pooling libraries were mixed with unique indices. 
  
However, depending on coverage needed, up to 96 libraries can be pooled for one MiSeq run. 
In the case of metagenomics samples, >100,000 reads per sample are adequate to survey the 
bacterial composition fully. This number of reads permits sample pooling to the maximum 
level of 96 libraries, given the MiSeq output of > 20 million reads. 
 
2.7.2.6 Library Denaturing and MiSeq Sample Loading 
 
To prepare a cluster generation and sequencing, pooled libraries were denatured with NaOH, 
diluted with hybridization buffer, and then heated before MiSeq sequencing. To each run, a 
minimum of 5% PhiX was added to serve as an internal control for these low diversity libraries. 
 
Consumables 
 
Item Quantity 
10 mM Tris pH 8.5 or RSB (Resuspension Buffer) 6μl 
HT1 (Hybridization Buffer) 1540μl 
0.2 N NaOH (less than a week old) 10μl 
PhiX Control Kit v3 (FC‐110‐3001) 4μl 
MiSeq reagent cartridge 1 cartridge 
1.7ml microcentrifuge tubes 3 tubes 
2.5 L ice bucket  
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Before denaturing the DNA, a heat block suitable for 1.7ml microcentrifuge tubes sat at 96°C. 
Then the MiSeq reagent cartridge was thawed at room temperature. Finally, an ice‐water 
bath in an ice bucket was prepared by combining 3 parts ice and 1 part water. 
 
2.7.2.6.1 Denature DNA 
 
1)  5μl of 4nM pooled final DNA library and 5μl of freshly diluted 0.2 N NaOH were 
combined in a microcentrifuge tube. 
2)  The remaining dilution of 0.2 N NaOH was retained to prepare a PhiX control within 
the next 12 hours. 
3)  The sample solution was mixed by vortex, and centrifuged for 1 minute at 280 × g, 
before being incubated for 5 minutes at room temperature to denature the DNA into 
single strands. 
4) 990μl of the pre‐chilled HT1 was added to a tube containing 10μl of the denatured 
DNA. Consequently, adding the HT1 resulted in a 20 pM denatured library in 1 mM 
NaOH, this denatured DNA was then placed on ice until proceeding to final dilution. 
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2.7.2.6.2 Dilute Denatured DNA 
 
1)  Dilution of the denatured DNA to the preferred concentration used the following 
example: 
Final concentration 2 pM 4 pM 6 pM 8 pM 10 pM 
20 pM denatured library 60μl 120μl 180μl 240μl 300μl 
Pre‐chilled HT1 540μl 480μl 420μl 360μl 300μl 
 
2) The DNA solution was mixed by inverting the tubes several times and pulse 
centrifuging and then placing the denatured and diluted DNA on ice. 
 
2.7.2.6.3 Denature and Dilution of PhiX Control 
 
This step was to denature and dilute the 10 nM PhiX library to the same loading concentration 
as the Amplicon Library. However, the final library mixture must contain at least 5% PhiX. 
1)         2μl of the 10 nM PhiX library was added to 3μl of 10 mM Tris pH 8.5 to dilute the PhiX 
library to 4 nM. 
2)  Then 5μl of the 4 nM PhiX library was added to 5μl of the 0.2 N NaOH in a 
microcentrifuge tube. 
3)  About 2 nM PhiX library solution was mixed gently by vortex before the solution was 
incubated for 5 minutes at room temperature to denature the PhiX library into single 
strands. 
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4)  990μl of pre‐chilled HT1 was added to the tube containing 10μl of the denatured PhiX 
library to result in a 20 pM PhiX library. 
5)  The denatured 20 pM PhiX library was diluted to the same loading concentration as 
the Amplicon Library using the same example above. 
 6)  The DNA solution was mixed by inverting the tubes several times and pulse 
centrifuging and then placing the denatured and diluted Phix on ice. 
 
2.7.2.6.4 Combine Amplicon Library and PhiX Control 
 
1) 30μl of the denatured and diluted PhiX control was added to 570μl of the denatured 
and diluted amplicon library in a microcentrifuge tube. 
2)  The combined sample library and PhiX control were placed on ice until it was time to 
denature the mixture, immediately before loading it onto the MiSeq v3 reagent 
cartridge. 
3) The combined library and PhiX control tube were incubated in a heat block at 96°C for 
2 minutes. 
4)  After incubation, the solution was mixed by inverting the tube a couple of times, and 
this was immediately placed in ice water for about 5 minutes. 
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2.7.2.7 MiSeq Reporter Metagenomics Workflow 
 
Once the samples had been loaded, a secondary analysis was provided by the MiSeq system 
using the MiSeq Reporter software (MSR). This software provides several selections for 
analysing MiSeq sequencing data. Therefore, for the 16S protocol, the Metagenomics 
workflow was selected. 
 
By following this protocol, the Metagenomics workflow classifies organisms from a V4 
amplicon using a database of 16S rRNA data. The classification will be based on the 
Greengenes database (http://greengenes.lbl.gov/). The production of this workflow is a 
ranking of reads at several taxonomic levels: Kingdom, phylum, class, order, family, genus, 
and species.  
 
This analysis includes: 
1-  Clusters Graph – displays numbers of the raw cluster, clusters passing filter, clusters 
that did not align, clusters not related with an index, and duplicates. 
2-  Sample Table – summarises the sequencing outcomes for each sample. 
3-  Cluster Pie Chart – a graphical illustration of the classification breakdown for each 
sample. 
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2.8 Statistical analysis of physiological and microbiota data 
 
To test the statistical significance of the physiological and biochemical data, normally 
distributed data were assessed by analysis of variance followed by multiple comparisons 
Dunn’s test, whereas not normally distributed data were assessed by Kruskal-Wallis test 
followed by multiple comparisons Dunn’s test (StatsDirect version 3.0.171). Differences 
were considered significant when P<0.05.  
 
For the bioinformatic analysis of microbiota data, Welch’s t-test was used in acute DSS 
experiments, and Kruskal-Wallis H-test was used in chronic DSS experiments (the software 
[STAMP] guidelines recommendations). The false discovery rate (FDR) Storey’s (multiple 
correction tests) was used to produce a prioritised list of OTUs that summarise observed 
differences between two user-defined populations. The q-value is the adjusted p-value based 
on FDR calculation, where statistical significance was declared at P<0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
121 
 
 
3 The effect of different iron diets on acute course of 
dextran sulphate sodium (DSS)‐induced colitis in wild‐
type mice C57BL/6 
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 3.1 Introduction 
 
Iron deficiency is common in IBD. Iron supplementation appears to exacerbate symptoms: 
this may be because all ferrous compounds are oxidised and release activated hydroxyl 
radicals (reactive oxygen species (ROS)) within the lumen of the gut or the mucosa. These 
particles will damage the intestinal wall and produce a variety of gastrointestinal symptoms 
and discomfort 110.  
 
There is a dysbiosis in patients with IBD. Also, there is a possibility that components of the 
normal intestinal microbiota might cause, activate, or in some way contribute to IBD 111. 
Variations in microbial ecology among people with UC and CD and normal individuals have 
been demonstrated by recent studies, in which the diversity of bacteria is changed 112. The 
gut microbiota of healthy individuals is occupied by Firmicutes and Bacteroidetes, and contain 
less Proteobacteria, Actinobacteria and Verrucomicrobia 99. However, in IBD patients, 
Firmicutes appear to be reduced 113, 114, 115 whereas Gammaproteobacteria was increased 116, 
117. In CD patients there was a reduction in the Clostridia cluster IV group, in 
particular Faecalibacterium prausnitzii 118, 119. Some members of Clostridia group XIVa 
(Roseburia genus), also appear to be reduced in all IBD patients 119. In addition to these 
alterations in relative abundances of specific phylotypes, there appears to be a general 
reduction in biodiversity in IBD patients 120, 121. 
 
Most invading pathogens require iron for rapid growth during infection. Consequently, most 
mammals aim to resist infection by reducing (sequestering) free iron: this tight regulation 
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protects the body during infection 111. Increasing available iron, by iron supplementation, 
increases the growth of Escherichia coli, Salmonella enterica serovar, Yersinia enterocolitica, 
Typhimurium and Staphylococcus epidermidis 122. Therefore, regulating free iron may be used 
to control the constitution of the microbiome. 
 
The take-up of iron from dietary components occurs in the small intestine: however excess 
iron in the diet remains in the small intestine and passes into the colon. There is a correlation 
between the amount of dietary iron consumed and faecal iron excretion in healthy individuals 
123. 
 
This study investigated the hypothesis that changing the amount of dietary iron would 
influence the development of IBD in a murine model. Dietary iron was both increased and 
decreased in groups of mice in which DSS-induced colitis was induced. This chapter reports 
the impact of different oral iron diets on colitis features in wild-type mice. 
 
 
3.2 Aims  
 
The aims were to investigate the impact of varying dietary iron on acute DSS-induced colitis 
in mice. 
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3.3 Preliminary experiments 
 
36 individually housed, wild-type C57BL/6 female mice aged 8-9 weeks were divided into 6 
groups of 6 mice. Group (A) mice were given a 100ppm iron diet; Group (B) a 200ppm iron 
diet and Group (C) a 400ppm iron diet. All groups were given 2% DSS treatment. Control mice 
were given distilled water without DSS; Group (D) had a 100ppm iron diet; Group (E) a 
200ppm iron diet and Group (F) mice a 400ppm iron diet (Figure 3-1). 
    
Figure 3-1: Different diet groups with and without DSS treatment 
 
3.3.1 Induction of Colitis in three different iron diet groups  
 
The 2% DSS colitis model (5 days DSS in drinking water) induces disease that may be 
recognised by the development of the clinical signs such as loss of body weight, loose 
faeces/watery diarrhoea and faecal blood/rectal bleeding. This colitis model, established in 
our department, has been documented in previous publications 124. 
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DSS-treated animals (Group (A) 100ppm iron, (B) 200ppm iron and (C) 400ppm iron) were fed 
each corresponding diet from day-1 until day-10 of the DSS cycle. All mice were administered 
2% DSS in distilled water as the sole source of drinking fluid for 5 days, and then normal 
drinking water for the subsequent 5 days (the 10-day period was defined as an acute DSS 
cycle as illustrated in Figure 2-2, Chapter 2). During the entire 10-day experiment the mice 
were caged separately and placed on paper bedding, which was changed daily to collect fresh 
samples and observe any signs of colonic bleeding. Daily body weight was recorded in 
addition to any clinical observations at the end of the experiment (day-10) when all mice were 
euthanised using a schedule 1 method. 
 
3.3.1.1 The effect of dextran sulphate sodium (DSS) on the body weight of wild-type C57BL/6 
mice in DSS-treated mice supplemented with different iron diets 
 
The body weight of the DSS-treated mice was recorded daily to monitor the percentage of 
body weight change as outlined in Figures 3-2, 3-3 and 3-4. Strikingly, mice on 400ppm iron 
only lost 2.3% of their starting body weight on day-9; this was significantly less than mice 
taking 100 and 200ppm iron diets which lost 9% and 5% of their starting body weight, 
respectively on day-8. However, the mice on 400 and 200ppm iron both showed a significant 
increase in the percentage of body weight gain compared to 100ppm iron mice on day-10. In 
other words, 400 and 200ppm iron mice showed 8.3% and a 2.8% weight gain while 100ppm 
iron mice showed a 0.03% weight gain on day-10 (Figures 3-2, 3-3 and 3-4). Control mice 
group (E), taking a 200ppm iron diet without DSS treatment had a steady increase in body 
weight during the 10-day period (Figure 3-5). 
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Figure 3-2: Percentage of weight change in mice received 100ppm iron diet 
during 2% DSS-induced colitis. Data are presented as mean (solid line) ± 
standard error of the mean, maximum (dotted line) and minimum (dashed 
line). 
 
 
 
Figure 3-3: Percentage of weight change in mice received 200ppm iron. 
Data are presented as mean (solid line) ± standard error of the mean, 
maximum (dotted line) and minimum (dashed line). 
 
 
 
Figure 3-4: Percentage of weight change in mice received 400ppm iron. 
Data are presented as mean (solid line) ± standard error of the mean, 
maximum (dotted line) and minimum (dashed line). 
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Figure 3-5: Percentage of weight change in mice received 200ppm iron diet 
during the 10-day period. Data are presented as mean (solid line) ± 
standard error of the mean, maximum (dotted line) and minimum (dashed 
line). 
 
 
Acute colitis was induced in the mice that received 2% DSS in their drinking water for 5 days, 
and they recovered during the following 5 days on plain drinking water. All DSS-treated mice 
lost body weight from day-6 with the maximal loss occurring on day-8. Group (A) 100ppm iron 
mice lost significantly more weight than other groups (Figure 3-6).  
 
 
Figure 3-6: Percentage of weight change in mice (100 (blue), 200 (red), and 400ppm iron (green)) during dextran sulphate sodium-
induced colitis and mice receiving 200ppm (orange) iron diet without DSS treatment during the 10-day period. Data are presented as 
a mean ± standard error of the mean. Statistical differences were assessed by Kruskal–Wallis test followed by Dunn’s multiple 
comparison tests (*P<0.05). (n=6 female mice per group).  
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3.3.1.2 The influence of different iron diets on the body weight of wild-type C57BL/6 mice 
without DSS treatment 
 
Control mice (Groups D-F) received drinking water without DSS, but with varying amounts of 
dietary iron, as described above. Daily observations and measures were completed in the 
same way as for the mice receiving DSS. 
 
Group (E) mice (200ppm iron) were euthanised at day-10 to allow comparison with the DSS-
treatment groups. However, the rest of the untreated mice (Group D (100ppm iron) and 
Group F (400ppm iron)) were maintained on their diets for a total of 28 days. They were then 
euthanised using a Home Office approved schedule 1 method. 
 
 
Figure 3-7: Percentage of weight change in mice (100 (blue), 200 (orange), and 400ppm iron (green)) without DSS treatment during 
the 10-days for 200ppm and 28-days for 100 and 400ppm iron groups. Data are presented as a mean ± standard error of the mean. 
Statistical differences were assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests. (n=6 female mice per 
group).  
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3.3.2 Histopathological changes resulted from colonic inflammation following dextran 
sulphate sodium administration 
 
The colons of the mice were examined for the features of colitis by light microscopy after 
staining with haematoxylin and eosin (H&E). 
 
3.3.2.1  100ppm iron diet DSS-treated mice displayed more severe colonic inflammation 
compared with mice receiving 200 and 400ppm iron diets  
 
After 10 days of DSS administration, all DSS-treated mice along with the 200ppm iron diet 
controls were killed by exposure to rising concentrations of CO2. A specimen of the whole 
distal colon was removed, fixed in 4% neutral buffered formalin, dehydrated, and wax-
embedded and was then cut into 4μm sections. The sections were stained with haematoxylin 
and eosin (H&E) to observe under light microscopy. Untreated mice distal colon showed no 
colitis features at all i.e. had similar histological findings to normal with normal crypts and no 
inflammation (Figure 3-8 I, II and III). In contrast to this, all the mice that were treated with 
2% DSS developed bloody diarrhoea within the last 5 days of the study, but there was no 
mortality. Histological examination established the presence of DSS-induced colitis, which 
was mainly located in the distal part of the colon. Histological features included areas of 
mucosal loss, increased muscle thickness, oedema and inflammatory cell infiltration (Figure 
3-8 IV, V and VI). 
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Using the histological inflammatory scoring system (Table 3-1) 91, H and E stained slides were 
scored in a blinded fashion by two investigators; the researcher and an accredited veterinary 
pathologist Jonathan Williams (Diplomate of the European College of Veterinary 
Pathologists). Histological damage was scored using the criteria of Bauer 91, which considers 
the loss of mucosal architecture and cellular infiltration (maximum score = 6). 
 
The 100ppm iron + DSS mice showed a significant increase in intestinal inflammation 
(significant increase in the colitis score) compared with the DSS + 400 or 200ppm iron diet 
groups.  
 
Score Cell infiltration Tissue damage 
0 None None 
1 Focally increased numbers of 
inflammatory cells in the lamina 
propria 
Discrete epithelial lesions 
2 Confluence of inflammatory cells 
extending into the submucosa 
Mucosal erosions 
3 Transmural extension of the infiltrate Extensive mucosal damage and/or 
extension through deeper structures of 
the bowel wall 
 
Table 3-1: Colitis scoring system adapted from 91 
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                                 DSS-treated 
 
Figure 3-8: Representative H&E-stained sections of distal colon from untreated and 2% DSS-treated mice (6 mice per group). Mice 
received either water (control) (I, II, III) or 2% DSS for 5 days followed by another 5 days on plain drinking water (IV, V, VI) before all 
mice were euthanised on day-10. Arrowheads highlight submucosal oedema; arrows highlight almost complete loss of colonic 
epithelium. (20x magnification). 
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Figure 3-9: Inflammation (colitis) scores for all groups, DSS-treated and untreated (controls) 
mice on different iron diets. Horizontal lines at the median. Differences tested by One-way 
ANOVA followed by multiple comparisons Dunn’s test. * P<0.05, **P<0.01 (vs. 200ppm iron). 
 
 
 
3.3.3 Faecal calprotectin in colitis and its role as an inflammatory marker 
 
Faecal calprotectin is a sensitive and non-invasive biomarker to identify active inflammation 
in the gastrointestinal tract of IBD patients and to distinguish IBD from irritable bowel 
syndrome (IBS) 125. Calprotectin represents about 60% of the neutrophil cytosolic proteins 
which are present in all body fluids. Its concentration is directly proportional to the amount 
of neutrophil migration into the intestinal tract (at sites of inflammation) 126. 
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3.3.3.1 Assessing the degree of gut inflammation at the molecular level by measuring faecal 
calprotectin in wild-type (C57BL/6) DSS-treated mice during the 10-day course 
 
Faecal calprotectin was measured by an ELISA designed for animals such as mice 
(S100A8/S100A9 ELISA). Initially, a standard test was performed, and data for 4 parameter 
logistics were plotted (Figure 3-10).                               
 
 
 
 
Figure 3-10: Standard curve using MasterPlex ReaderFit Software [(a) the minimum value that can 
be obtained, (d) the maximum value that can be obtained (i.e. what happens at infinite dose), (c) 
the point of variation (i.e. the point on the S-shaped curve halfway between a and d) and (b) Hill’s 
slope of the curve (i.e. this is related to the sharpness of the curve at point c)  
 
 
Faecal pellets (6) were collected from the cage of each mouse in all groups at day-1 and day-
10. Faecal calprotectin was measured by the S100A8/S100A9 ELISA kit using 100µl per sample 
where the final concentration was applied in ng/ml. The difference between samples taken 
at two different time points, for example at day-1 the start of the diet and DSS treatment and 
at day-10 after the onset of the experiments, reflects the degree of inflammation in DSS-
a
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treated animals. However, the difference in untreated groups would show the impact of the 
diet on intestinal cells and their response (Figure 3-11). 
 
 
   
Figure 3-11: Faecal calprotectin concentrations at two different time points (day-1 and 10) for six 
groups (n=6 mice each), three DSS-treated and three untreated. Data are presented as a mean ± 
standard error of the mean. Differences were tested by Kruskal–Wallis test followed by multiple 
comparison Dunn’s test. * P<0.05. 
 
 
The figure shows that the standard iron diet (200ppm iron) for DSS-treated mice resulted in 
a statistical difference in between day-1 and day-10 (P<0.05). However, low and high iron diet 
DSS-treated and all untreated mice did not show any significance (Figure 3-11), although the 
degree of variability between mice was high in some groups. 
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3.3.3.2 The influence of different iron diets (100 and 400ppm iron) on faecal calprotectin 
concentration in untreated mice during 28-day course 
 
Faecal pellets were collected at day-1 and day-28 from untreated mice taking low (100ppm 
iron) and high (400ppm iron) iron diets. The samples were analysed with the same ELISA kit 
as described above using 100µl per sample. The result showed that there was no significant 
difference between the two different time points in either group (Figure 3-12).  
 
 
 
Figure 3-12: Faecal calprotectin concentrations at day-1 and day- 
28 in two untreated groups (100 and 400ppm iron) 6 mice each. 
Data are presented as a mean ± standard error of the mean. 
Differences were tested by Kruskal–Wallis test followed by 
multiple comparison Dunn’s test. 
 
 
 
There was no statistical significance found in day-1 vs. day-28 for 100 and 400ppm iron 
untreated groups (Figure 3-12), although the faecal calprotectin concentration at day-28 in 
the low iron diet appeared to have increased.  
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3.3.4 The importance of dietary iron and its effect on intestinal inflammation as well as its 
impact on the gut microbiota  
 
One possible source of iron to the intestinal microbial community is likely to be excess iron 
that is not absorbed from the diet. Thus, changes in luminal iron concentrations will 
potentially have an impact on intestinal microbiome structure 127. Iron replacement therapy 
is a common treatment in patients with anaemia and IBD such as Crohn’s disease. Oral iron 
supplements are sometimes less well tolerated, and may also influence intestinal 
inflammation as well as intestinal microbial community structure and function 93. 
 
3.3.4.1 Total faecal iron concentrations in DSS-treated and untreated mice during 10-day 
course 
 
Measuring faecal iron concentrations would help to assess the severity of inflammation 
(bleeding) during colitis. However, it is hard to distinguish between the iron that comes from 
the diet and that which has been released from RBCs during luminal bleeding during colitis. 
Therefore, we collected faecal pellets at different time points from each mouse and calculated 
the total iron (ferric and ferrous) (dietary and bleeding source) and compared the results 
between groups (treated and untreated). To use the correct amount of samples we initially 
tested standard curves using three sample concentrations (5, 10 and 20µl), at six different 
dilutions. The 20µl volume gave the best standard curve (Figure 3-13).   
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Figure 3-13: Iron standard curve at six dilutions points using 20µl volume 
of the raw sample 
 
 
Faecal pellets were collected from the cage of each mouse in all groups at day-1 and day -10. 
The total faecal iron concentration was measured using an iron immunoassay kit [MAK025, 
Sigma-Aldrich]. The difference between samples taken at two different time points, day-1 at 
the start of the diet and DSS treatment and day-10 after the completion of the experiment 
can reflect colitis severity (luminal bleeding) in DSS-treated animals. However, the difference 
in untreated groups will show the change in faecal iron as a result of dietary 
depletion/supplementation (Figure 3-14).  
 
 
Figure 3-14: Faecal iron concentration at two different time points (day-1 and 10) for six groups 
(n=6 mice each) three DSS-treated and three untreated. Data are presented as a mean ± 
standard error of the mean. Differences were tested by Kruskal–Wallis test followed by multiple 
comparison Dunn’s test. * P<0.05. 
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The 100ppm iron DSS-treated group showed a significant difference (P<0.05) between day-
10 and day-1. By contrast, the 200 and 400ppm iron DSS-treated and all untreated groups did 
not show any statistical differences (Figure 3-14).  
 
3.3.4.2 Total faecal iron concentration in untreated (100 and 400ppm iron) mice during 28-
day course 
 
Faecal pellets were also collected at day-1 and day-28 from untreated mice (100 and 400ppm 
iron) to investigate the effect of iron diet modification on faecal iron concentration. The 
samples were analysed with the same iron assay kit above using 20µl per sample. The result 
showed a significant increase (P<0.05) between day-1 and 28 for the 400ppm iron mice 
(Figure 3-15).  
 
 
Figure 3-15: Faecal iron concentration at day-1 and day-28 in 
untreated groups (100 and 400ppm iron) n=6 mice each. Data are 
presented as a mean ± standard error of the mean. Differences 
were tested by Kruskal–Wallis test followed by multiple 
comparison Dunn’s test. *P<0.05. 
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3.4 Investigating the effect of different iron diets during 8-day course of 
dextran sulphate sodium  
 
The clinical signs [loss of body weight, loose faeces and rectal bleeding] that develop after 
exposure to DSS for 5 days have been established in previous work. The most weight loss and 
histological changes were found at day-8 (as it been shown in Figure3-6 and 3-9). In order to 
confirm results from previous work, four groups of C57BL/6 female 8-9-week-old mice (N=8 
per group) were therefore used in a second experiment. Three DSS-treated groups (100, 200 
and 400ppm iron) received 2% DSS in their drinking water for 5 days followed by 3 days on 
plain drinking water. The control group took a 200ppm iron diet and received plain drinking 
water for all 8-days of the experiment (Figure 3-16). 
 
 
 
 
Figure 3-16: Different diet groups with and without DSS treatment during 8-day course 
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3.4.1 The effect of iron modification diets on the body weight of wild-type mice (C57BL/6) 
during 8-day period of dextran sulphate sodium (DSS) induced colitis course 
 
The body weight of the DSS-treated mice was recorded daily (8-day course) (Figures 3-17, 3-
18 and 3-19). All DSS-treated mice developed colitis and lost weight from day-5 until the day-
8, when all animals were culled. The most significant weight loss was recorded for mice on 
100ppm iron followed by 400ppm iron and 200ppm iron diets: weight loss was 18%, 14% and 
12% of their starting body weight, respectively. However, the (control group) mice on 200ppm 
iron without DSS treatment showed a steady increase in body weight during the 8-day period 
(Figure 3-20). 
 
Figure 3-17: Percentage of weight change in mice that received 100ppm 
iron diet during 2% DSS-induced colitis. Data are presented as mean (solid 
line) ± standard error of the mean, maximum (dotted line) and minimum 
(dashed line). 
 
 
Figure 3-18: Percentage of weight change in mice that received 200ppm 
iron diet during 2% DSS-induced colitis. Data are presented as mean (solid 
line) ± standard error of the mean, maximum (dotted line) and minimum 
(dashed line). 
-30
-25
-20
-15
-10
-5
0
5
10
15
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8
%
 C
h
an
ge
 in
 b
o
d
y 
w
ei
gh
t
2% DSS + low iron diet (100ppm iron)
Mean
Min
Max
-25
-20
-15
-10
-5
0
5
10
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8
%
 C
h
an
ge
 in
 b
o
d
y 
w
ei
gh
t
2% DSS + normal diet (200ppm iron)
Mean
Min
Max
  
141 
 
 
 
 
Figure 3-19: Percentage of weight change in mice that received 400ppm 
iron diet during 2% DSS-induced colitis. Data are presented as mean (solid 
line) ± standard error of the mean, maximum (dotted line) and minimum 
(dashed line). 
 
 
 
 
 
Figure 3-20: Percentage of weight change in mice that received 200ppm 
iron diet without DSS induction. Data are presented as mean (solid line) ± 
standard error of the mean, maximum (dotted line) and minimum (dashed 
line). 
 
 
 
All weight changes in each group are summarised in Figure 3-21.  
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Figure 3-21: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red) and 400ppm (green) iron diet) 
during dextran sulphate sodium-induced colitis and mice receiving 200ppm iron (orange) diet without DSS treatment during 
the 8-day period. Data are presented as a mean ± standard error of the mean. Statistical differences were assessed by 
Kruskal– Wallis test followed by multiple comparison Dunn’s test (*P<0.05, **P<0.01). (N=8 female mice per group). 
 
 
 
 
3.4.2 100ppm iron and 400ppm iron diet DSS-treated mice displayed more severe colonic 
inflammation compared with mice on 200ppm iron diet 
 
After 8-days of DSS administration, all mice were killed, and tissues were obtained and 
processed using the same methods as have been described above. The untreated mice had 
no features of colitis (Figure 3-22 a). In contrast with this, all mice treated with 2% DSS 
developed bloody diarrhoea within the 8-day study duration, but again there was no 
mortality. Histological examination showed DSS-induced colitis, which was mainly located in 
the distal part of the colon with areas of loss of mucosal architecture and inflammatory cell 
infiltration (Figure 3-22 b, c and d).  
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The same scoring method was used as has been described above 91 (Section 3.3.2.1: Table 3-
1). All mice treated with DSS showed a significant increase in intestinal inflammation 
compared with the untreated mice. The low (100ppm iron) iron group had the most severe 
colitis among all groups.             
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Figure 3-22: Representative H&E-stained sections of distal colon from untreated and 2% DSS-treated mice (8 mice 
per group). Mice receiving either water (control) (a) or 2% DSS for 5 days and followed by another 3 days on plain 
drinking water (b, c, d) before all mice were sacrificed on day-8. Arrowheads indicate submucosal oedema; arrows  
indicate almost complete loss of colonic epithelium. (20x magnification). 
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Figure 3-23: Inflammation (colitis) scores for all DSS-treated mice and untreated (controls) 
mice. Horizontal lines at the median. The score of low (100ppm iron) iron DSS mice was 
significantly worse than that 200ppm iron DSS-treated mice, whereas all DSS-treated mice were 
statistically significantly different compared to untreated mice. Differences tested by Kruskal-
Wallis followed by multiple comparisons. ** P<0.01, *** P<0.001, **** P<0.0001 versus control 
(200ppm iron). 
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3.4.3 Assessing the degree of gut inflammation by measuring faecal calprotectin in wild-type 
(C57BL/6) DSS-treated and untreated mice during the 8-day course 
 
Faecal calprotectin was measured using the S100A8/S100A9. Once again, a standard test 
was run, and 4 parameter logistics were plotted (Figure 3-24). 
 
 
 
Figure 3-24: Standard curve using MasterPlex ReaderFit Software [(a) the minimum value that 
can be obtained, (d) the maximum value that can be obtained (i.e. what happens at infinite 
dose), (c) the point of variation (i.e. the point on the S-shaped curve halfway between a and 
d) and (b) Hill’s slope of the curve (i.e. this is related to the sharpness of the curve at point c). 
 
 
 
  
 
Faecal pellets were collected from the cages of each mouse in all groups at day-1 and day-8. 
The difference between samples taken at two different time points, day-1 at the start of the 
diet and DSS treatment and day-8, when mice were euthanised, can reflect the degree of 
inflammation in DSS-treated animals. However, the difference in untreated mice used as 
control will explain the dietary effects of standard diet (200ppm iron) on intestinal cells and 
their response as it is shown in Figure 3-25. 
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Figure 3-25: Faecal calprotectin concentrations at two different time points (day-1 and 8) for four 
groups of mice (n=8 each) three DSS-treated and one untreated. Data are presented as a mean ± 
standard error of the mean. Differences were tested by Kruskal– Wallis test followed by multiple 
comparison Dunn’s test. * P<0.05. 
 
 
The high iron diet (400ppm iron) DSS-treated mice showed a statistical difference in faecal 
calprotectin concentration between day-1 and day-8 (P<0.05). However, the low (100ppm 
iron) and standard (200ppm iron) iron diet DSS-treated mice and 200ppm iron untreated mice 
did not show any significant difference between these two time points (Figure 3-25). 
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3.4.4 Measurement of total faecal iron concentration in DSS-treated and untreated mice 
during 8-day course 
 
Faecal iron concentrations were measured using the same kit [MAK025, Sigma-Aldrich] and 
technique as described above. A new standard curve was created (Figure 3-26).   
 
 
 
Figure 3-26: Iron standard curve at six dilution points using 20µl volume of 
the raw sample. 
 
 
Faecal pellets were collected from the cages of each mouse in all groups at day-1 and day-8. 
The difference between samples taken at two different time points, day-1 at the start of diet 
and DSS treatment and day-8 where mice were euthanised can reflect colitis severity (luminal 
bleeding) in DSS-treated animals. However, any difference in untreated mice can be used as 
a control as illustrated in Figure 3-27. 
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Figure 3-27: Faecal iron concentration at two different time points (day-1 and 8) for four groups 
of mice (n=8 each) three DSS-treated and one untreated control. Data are presented as a mean ± 
standard error of the mean. Differences were tested by Kruskal– Wallis test followed by multiple 
comparison Dunn’s test * P<0.05, ** P<0.01, *** P<0.001. 
 
 
 
The 400ppm iron DSS-treated group showed the highest significant difference (P<0.001) 
between day-8 and day-1 readings. The 100ppm iron and 200ppm iron DSS groups also 
showed significant differences (P<0.01 and P<0.05 respectively). However, the untreated 
group did not show any significant difference between the two times points tested (Figure 3-
27).  
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3.5 The influence of iron modifications on weight changes in DSS-treated mice 
 
A larger third study was subsequently performed to validate the findings from all previous 
preliminary experiments (changes in luminal iron exacerbates colitis mainly for low iron 
group). Therefore, 14 groups of 4 mice (female wild-type C57BL/6 mice aged 8-9 weeks) were 
individually housed and divided into two bigger sets of seven groups each. Set 1 consisted of 
Groups (A and E) containing mice on  a 100ppm iron diet; Groups (B and F) contained mice on 
200ppm iron diet and Groups (C and G) consisted of mice on a 400ppm iron diet. All these 
mice received 2% DSS treatment. The control Group (D) were given only distilled water and 
200ppm iron diet (for 10-days). Set 2 was a repeat of set 1 with the experiment being 
conducted two weeks later (see Figure 3-28). DSS groups A, B and C were treated with 2% DSS 
for 5 days followed by another 5 days on normal drinking water and were euthanised at day-
10. Groups E, F and G were treated with 2% DSS for 5 days followed by 3 days on normal 
drinking water only and were euthanised at day-8. 
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Figure 3-28: Classification of all animal experiments (DSS-treated and control groups). 14 groups of 
mice 4 mice per group. Two sets; 1 and 2 each consisted of 7 groups of mice. 4 groups underwent a 
10-days DSS experiment and 3 groups underwent an 8-days DSS experiment. Group D received no 
DSS. 
 
 
 
 
As mentioned in the paragraph above, each set of animal groups was experimented upon 
separately. Two weeks later the second experiment started. All data and results were 
combined (set 1 and 2) and the final data analysis and results are presented in the following 
pages. 
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3.5.1 The effect of different iron diets on the body weight of wild-type C57BL/6 mice treated 
with dextran sulphate sodium (DSS) during a 10-day course 
 
The body weight of the DSS-treated mice was recorded daily (Figures 3-29). All DSS-treated 
mice developed colitis. Weight loss was seen from day-6 and was most significant at day-8, 
especially for group A (100ppm iron) (Figure 3-29).  
 
 
Figure 3-29: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red) and 400ppm iron (green)) during 
dextran sulphate sodium-induced colitis and mice receiving 200ppm (orange) iron diet without DSS treatment during the 10-
day period. Data are presented as a mean ± standard error of the mean. Statistical differences were assessed by Kruskal– 
Wallis test followed by multiple comparison Dunn’s test (*P<0.05, **P<0.01) (N=8 female mice per group). 
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3.5.2 The effect of different iron diets on the body weight of wild-type C57BL/6 mice treated 
with dextran sulphate sodium (DSS) during an 8-day course 
 
The most significant weight loss was recorded for mice on 100ppm iron followed by 400ppm 
iron and 200ppm iron-diets with 14%, 12% and 11% loss, respectively. As expected, the 
control group, consuming 200ppm iron without DSS treatment, showed a steady increase in 
body weight during the same 8-day period (Figure 3-30). 
 
 
 
Figure 3-30: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red) and 400ppm iron (green)) during 
dextran sulphate sodium-induced colitis and mice receiving 200ppm (orange) iron diet without DSS treatment during the 8-
day period. Data are presented as a mean ± standard error of the mean. Statistical differences were assessed by Kruskal– 
Wallis test followed by multiple comparison Dunn’s test (*P<0.05, **P<0.01, ***P<0.001). (n=8 female mice per group). 
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3.5.3 100ppm iron diet DSS-treated mice displayed severe colonic inflammation compared 
with mice on 200ppm iron diet for 10-day course treatment 
 
After 10-days of DSS administration, tissues were harvested at necropsy following carbon 
dioxide euthanasia and were processed as described above. The slides were inspected by light 
microscopy, and in untreated mice, the distal colon showed no features of colitis (Figure 3-31 
II). On the other hand, all the mice that had been treated with 2% DSS developed bloody 
diarrhoea within the 10-days’ study duration. Again, there was no mortality. Histological 
examination established the presence of DSS-induced colitis, with areas of loss of mucosal 
architecture and inflammatory cell infiltration (Figure 3-31 I, III and IV). 
 
 
 
                        
 
                         
Figure 3-31: Representative H&E-stained sections of distal colon from untreated and 2% DSS-treated mice 
(8 mice per group). Mice received either water (control) (II) or 2% DSS for 5 days, and this was followed by 
another 5 days on plain drinking water (I, II and IV) before all mice were killed on day-10. Arrowheads 
highlight submucosal oedema; arrows highlight almost complete loss of colonic epithelium. (20x 
magnification). 
100ppm iron + 2% DSS 200ppm iron  
200ppm iron + 2% DSS 400ppm iron + 2% DSS 
I II 
III IV 
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Using the histological inflammatory scoring system (Table 3-1) 91, H and E stained slides were 
scored in a blinded fashion by the researcher (Figure 3-32). Histological damage was scored 
using the criteria of Bauer 91, which considers the loss of mucosal architecture and cellular 
infiltration (maximum score = 6).  
 
 
 
 
 
           
 
 
 
 
All DSS-treated mice showed significant differences compared with the untreated mice. 
Again, the 100ppm iron DSS-treated group showed the most marked difference compared to 
controls (P<0.0001). 
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Figure 3-32: Inflammation (colitis) scores for all groups DSS- treated and untreated (controls) 
mice on different iron diets (10-day course). Horizontal lines at the median. Differences tested by 
One-way ANOVA followed by multiple comparisons Dunn’s test. *** P<0.001, **** P<0.0001 
versus control (200ppm iron). 
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3.5.4 100ppm iron diet DSS-treated mice displayed more severe colonic inflammation 
compared with mice on 200ppm iron diet for 8-day course of treatment 
 
After 5-days of DSS administration and 3 days on normal drinking water, all mice were  
euthanised, and tissues were obtained and stained (H&E) using the same method mentioned 
previously. The slides were inspected by light microscopy and again the untreated mice distal 
colon showed no features of colitis (Figure 3-33 II). On the other hand, all the mice that had 
been treated with 2% DSS developed bloody diarrhoea. Histological examination showed the 
presence of DSS-induced colitis, with areas of loss of mucosal architecture and inflammatory 
cell infiltration (Figure 3-33 I, III and IV). 
 
 
 
                           
 
                            
Figure 3-33: Representative H&E-stained sections of distal colon from untreated and 2% DSS-treated mice 
(8 mice per group). Mice received either water (control) (II) or 2% DSS for 5 days followed by another 3 days 
on plain drinking water (I, II and IV) before all mice were euthanised on day-8. Arrowheads highlight 
submucosal oedema; arrows highlight almost complete loss of colonic epithelium. (20x magnification). 
100ppm iron + 2% DSS 200ppm iron  
200ppm iron + 2% DSS 400ppm iron + 2% DSS 
I II 
III IV 
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Using the histological inflammatory scoring system (Table 3-1) 91, H and E stained slides were 
scored in a blinded fashion by the researcher (Figure 3-34). Histological damage was again 
scored using the criteria of Bauer 91, which considers the loss of mucosal architecture and 
cellular infiltration (maximum score = 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
All DSS-treated groups showed statistically significant differences vs. 200ppm iron DSS-
untreated group. Interestingly, the 100ppm iron DSS-treated mice also showed a significant 
difference (P<0.01) compared with the 200ppm iron DSS-treated group.  
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Figure 3-34: Inflammation (colitis) scores for all groups DSS-treated and untreated (controls) mice 
on different iron diets (8-day course). Horizontal lines at the median. Differences tested by 
Kruskal– Wallis test followed by multiple comparisons Dunn’s test. ** P<0.01, *** P<0.001, **** 
P<0.0001 versus control (200ppm iron). 
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3.5.5 Assessing the degree of gut inflammation at the molecular level by measuring faecal 
calprotectin concentrations in DSS-treated and untreated mice during 10 and 8-day 
experiments  
 
All identically treated groups from each animal set (1 and 2) were combined to make the total 
number of samples per group as follows: DSS- treated groups’ 16 samples at day-1 and day-8 
then 8 samples at day-10 (each group). However, the untreated controls only had 8 samples 
at days-1, 8 and 10. Faecal calprotectin as with all previous work was measured using the 
S100A8/S100A9 ELISA kit. 
 
Faecal pellets were collected from the cages of each mouse in all groups at days-1, 8 and 10. 
The difference between samples taken at three different time points, day-1 at the start of diet 
and DSS treatment and days-8 and 10 when mice were killed can reflect the level of colitis in 
DSS-treated animals. However, any difference in untreated groups will explain the dietary 
effects on gut response as illustrated in Figure 3-35. 
 
In mice treated with DSS, faecal calprotectin concentrations were increased significantly at 
day-8 with each DSS-treated group. However, in those mice receiving 100 and 400ppm iron 
the difference in each case was P<0.001 (day-1 vs. day-8), whereas for mice receiving 200ppm 
iron P<0.05 (day-1 vs. day-8). No significant difference over time was observed in the 
untreated group as illustrated in (Figure 3-35). 
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Figure 3-7: Faecal calprotectin at three different time points (day-1, 8 and 10) for n=16 mice each 
of the three DSS-treated and n=8 mice of the untreated group. Data are presented as a mean ± 
standard error of the mean. Differences were tested by Kruskal– Wallis test followed by multiple 
comparison Dunn’s test. * P<0.05, *** P<0.001. 
 
 
 
Further analysis compared all groups together at individual time points namely at days-1, 8 
and 10. There were no any significant differences between the groups at day-1 and 10. 
However at day-8 the 400ppm iron (P<0.001) and 100ppm iron (P<0.01) DSS-treated groups 
were significantly different from the 200ppm iron untreated mice (Figure 3-36). 
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3.5.6 Measurement of total faecal iron concentration in DSS-treated and untreated mice 
during 10- and 8-day experiments  
  
All identical groups from each animal set (1 and 2) were combined to make the total number 
of samples per group as follows: DSS-treated groups 16 samples at days-1 and 8 then 8 
samples at day-10. Untreated controls had 8 samples at days-1, 8 and 10. The total faecal iron 
concentration was again measured using the iron immunoassay kit [MAK025, Sigma-Aldrich] 
where the final concentration was applied in ng/µl. Faecal pellets were collected from the 
cages of each mouse in all groups at day-1, 8 and day-10. To use the correct amount of sample 
a standard curve was run with every kit.  
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The difference between samples taken at three different time points on day-1 at the start of 
diet and DSS treatment and on days-8 and 10 when mice were euthanised can reflect colitis 
severity (luminal bleeding) in DSS-treated animals. However, any difference in untreated 
groups will explain the dietary effects of iron on gut response as illustrated in Figure 3-37. 
 
 
 
Figure 3-37: Faecal iron concentration at three different time points (day-1, 8 and 10) for four 
groups n=16 mice each for the three DSS-treated and n=8 mice for the untreated group. Data are 
presented as a mean ± standard error of the mean. Differences were tested by Kruskal– Wallis 
test followed by multiple comparison Dunn’s test. ** P<0.01, *** P<0.01 **** P<0.0001. 
 
 
 
 
Total faecal iron concentration was significantly increased in all DSS-treated mice compared 
to baseline at both 8 and 10-days. The highest significance in the 100 and 400ppm iron groups 
occurred at day-1 vs. day-8 (P<0.0001), whereas, for 200ppm iron DSS-treated mice the most 
significant difference was at day-1 vs. day-10 (P<0.001) (Figure 3-37). 
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 Further analysis compared all the groups at individual time points. At day-1 no significant 
difference was found, whereas at day-8 there was a similar difference (P<0.05) for both low 
and high iron (100 and 400ppm iron) DSS groups versus 200ppm iron untreated mice (Figure 
3-38). However, at day-10, total faecal iron concentration showed the same significant 
difference (P<0.05) for all DSS-treated mice versus untreated controls (Figure 3-38). 
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Figure 3-38: Faecal iron concentration at three 
different time points days-1, 8 and 10 
separately (a) faecal iron in each group at day-
1, (b) faecal iron in each group at day-8 where 
100 and 400ppm iron groups are equally 
statistically significant (c) faecal iron at day-10 
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significant in comparison with untreated mice. 
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3.6 Discussion 
 
Our hypothesis investigated whether that luminal iron can cause changes in gut microbiota in 
IBD patients as well as influence the nature of colitis. Data from this research shown that oral 
consumption of dextran sulphate sodium (DSS) (2%) in drinking water induced colitis in wild-
type C57BL/6 female mice, whereas changing the oral iron intake influenced the severity of 
colitis induced. However, DSS-treated mice lost body weight starting from day-6 and reaching 
the maximum body weight loss at day-8 predominantly for mice that received 100ppm iron 
than the other groups. In addition, high iron diet (400ppm iron group) came second after low 
iron mice in terms of exacerbated colitis. While untreated mice gained weight, Indeed control 
mice consuming the most iron gained the most weight. These observations agree with the 
findings of a study by Carrier et al. which emphasised the role of iron in changing 
inflammation, which appeared to be dependent on the amount of iron consumed, however, 
Carrier did not investigate low dose iron in her work 93. 
 
In the current study, any disruption of the intestinal mucosa or extensive infiltration by 
inflammatory cells was measured by a histological inflammatory scoring system (Table 3-1) 
91. The mice that received low iron diets (100ppm iron) showed more inflammation regarding 
mucosal ulceration, cellular infiltration and oedema within the lamina propria. This is also 
consistent with the previous study by Erichsen et al. which demonstrated that low-dose oral 
ferrous fumarate in rats with DSS-induced colitis increased intestinal inflammation 128. 
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In colitis, calprotectin is released by neutrophils that infiltrate inflamed tissues, raising faecal 
calprotectin levels 129. In the present study, all DSS-treated mice showed rises in faecal 
calprotectin concentrations by day-10, but this was only significant in the 200ppm iron group. 
However, when assessed at day-8, all DSS-treated groups showed more calprotectin at day-8 
vs. day-1, (P<0.001 for 100 and 400ppm iron and P<0.05 for 200ppm iron). This supports the 
view that both low and high doses of iron exacerbate the severity of DSS-colitis. 
 
Total faecal iron concentration was measured for all groups and compared at three different 
time points (days-1, 8 and 10). DSS-treated groups showed significant differences in total 
faecal iron levels between day-1 vs. day-8 and day-10 for each group individually. However, 
100 and 400ppm iron DSS groups showed a greater significance at day-8 (P<0.0001) than the 
200ppm iron group (P<0.01). However, at day-10 all DSS-treated mice had similar changes 
(P<0.001 for each group). This emphasises the contribution of bleeding to faecal iron loss: the 
amount of faecal iron was raised even in mice receiving 100ppm iron. The only controls that 
showed statistically significant differences were the 400ppm iron group with P<0.05.  
 
To conclude, in the present study, changes (increases or decreases) in the amounts of dietary 
iron appeared to enhance colonic inflammation in a DSS mouse model of inflammatory bowel 
disease. There appeared to be synergistic effects between iron and DSS on colonic 
inflammation and calprotectin levels. Inflammation, as well as oral iron increased faecal iron 
concentrations 127. This can explain the paradox in the low iron group where luminal bleeding 
during colitis caused an increase in the faecal iron concentration despite low levels of iron in 
the diet.  
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4 The influence of iron on gut microbial composition in 
a 10‐day DSS‐induced colitis experiment in wild‐type 
C57BL/6 mice 
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4.1 Introduction 
 
Inflammatory bowel disease (IBD) is associated with alterations in gut microbial communities 
and dysregulated mucosal immune responses 74. The vertebrate microbiota is extremely 
variable, especially at the lower taxonomic ranks. Although there are four dominant phyla: 
Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria, the Firmicutes and 
Bacteroidetes comprise >90% of the bacterial inhabitants in the colon, whereas 
Actinobacteria and Proteobacteria (Enterobacteriaceae) are present at 1%–5% 65.  
 
In patients with IBD, there is a reduction in microbial diversity and enhancement of some 
bacteria from the family Enterobacteriaceae and a decline in bacteria from the phyla 
Bacteroidetes and some Firmicutes 68. The mechanisms responsible for the development of 
this dysbiosis and its contribution to IBD are not well defined. Thus, defining which aspects 
of the gut microbiome change during relapse and remission may provide significant 
information with therapeutic potential.  
 
Murine models of IBD offer an opportunity to investigate bacteria and their pathways 
implicated in IBD and host–microbiota responses to treatments. This can be difficult to 
investigate in humans due to several factors such as genetic diversity and variability in 
environmental and treatment exposures 130. However, dysbiotic microbiota can induce 
murine colitis 131. 
 
  
166 
 
To identify approaches that promote and preserve beneficial intestinal microbes, a series of 
studies of the microbial community in colitis, with diets containing different amounts of iron, 
were undertaken as follows:  
 
1- Mice were treated with DSS dissolved in their drinking water, for 5 days, to induce colitis, 
followed by a recovery period, see Methods chapter. 
2- Dietary iron consumption was manipulated, see Methods chapter.  
3- Microbial DNA was prepared from the stool collected and was homogenised in stool 
stabiliser [PSP® Spin Stool DNA Plus Kit], for details on DNA extraction, see Methods chapter. 
4- 16S rRNA gene sequencing was performed: operational taxonomic unit (OTU) selection, 
microbial composition and community structure analyses and metagenome inference were 
undertaken in collaboration with CGR, see Methods chapter.  
5- Finally, statistical analysis in this chapter was undertaken by using the STatistical Analysis 
of Metagenomic Profiles (STAMP) software package for analysing metagenomic profiles, 
such as phylogenetic profiles. This represents the number of indicator genes allocated to 
different taxonomic units or functional outlines representing the number of sequences 
assigned to various subsystems or pathways 132. 
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4.2 Aims 
 
The aims were to: 
 
1- Analyse gut microbial communities following treatment of mice with DSS alongside dietary 
interventions (100, 200 and 400ppm iron). 
2- Investigate the effects of longer supplementation with various iron diets on the gut 
microbial structure. 
 
4.3 Bioinformatic and Statistical analysis of metagenomic profiles 
 
Initial processing and quality assessment of the sequence data was performed using an in-
house (CGR) pipeline. Briefly, basecalling and de-multiplexing of indexed reads was 
performed by CASAVA version 1.8.2 (Illumina) to produce 71 samples from the single flow 
cell, in fastq format. The raw fastq files were trimmed to remove Illumina adapter sequences 
using Cutadapt version 1.2.1 (Martin, 2011). The option “-O 3” was set, so the 3' end of any 
reads which matched the adapter sequence over at least 3 bp was trimmed off. The reads 
were further trimmed to remove low quality bases, using Sickle version 1.200 with a minimum 
window quality score of 20. After trimming, reads shorter than 10 bp were removed. If both 
reads from a pair passed this filter, each was included in the R1 (forward reads) or R2 (reverse 
reads) file. If only one of a read pair passed this filter, it was included in the R0 (unpaired 
reads) file. Figure 4-1 summarise the read counts before and after adapter and quality 
trimming. Figure 4-2 shows the read length distributions after adapter and quality trimming. 
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Later analysis used only R1 and R2 reads. Both Figures 4-1 and 4-2 indicate that only few 
samples matched to the expected number of reads, and that many samples should be 
excluded from the analysis. In particular, any samples with less than 100 read pairs were 
excluded from the analysed dataset. 
 
 
Figure 4-1: Diagram illustrating the total number of reads obtained for each sample. 
Note: all samples identifications are listed in appendix 10-1 
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Figure 4-2: Box plot showing the distribution of trimmed read lengths for the forward (R1), reverse (R2) and singlet (R0) 
reads. Note that it is common for a small number of reads to consist of mostly adapter-derived sequence, so it is expected 
that the distribution will show a long tail. (All samples identifications are listed in appendix 10-1) 
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For the bioinformatic analysis of microbiota data, Welch’s t-test was used in each group to 
compare day-1 vs. day-10. The false discovery rate (FDR) (multiple correction tests) was used 
to produce a prioritised list of OTUs that summarise observed differences between two user-
defined populations. The q-value is the adjusted p-value based on FDR calculation, where 
statistical significance was declared at P<0.05.   
 
 
In this chapter, we investigated the effects of different iron diet interventions on colitis status 
and gut microbial structure in wild-type mice. Using 16S ribosomal RNA (rRNA) gene surveys, 
we analysed gut microbial communities pre- and post-treatment with 2% DSS (100, 200 and 
400ppm iron) groups. Also, three control groups, fed 100-, 200- and 400-ppm iron from the 
start day of the experiment until the day of euthanasia, were studied (Section 3.3, Chapter 3). 
 
 
4.3.1 Bacterial diversity data analysis at phylum level (Summary and plot of the taxonomic 
content of each sample)  
 
The community composition of each sample for a given taxonomic rank (from Kingdom to 
Species) was summarised using Qiime. From these summaries, bar plots were generated. An 
example of such a bar plot, showing the relative abundance of different phyla among the 
samples, as it been shown in Figure 4-3. 
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Figure 4-3: Phylum‐level taxonomic composition of all samples (relative abundance). 
Note: all samples identifications are listed in appendix-1 and legend in appendix -2 
 
 
 
 
 
 
 
 
4.3.1.1 Alpha diversity estimation and alpha rarefaction analyses  
 
 
To negate the effect of sample size and to estimate species richness within each sample (alpha 
diversity), OTU tables were repeatedly sub‐sampled (rarefied). For each rarefied OTU table, three 
measures of alpha diversity were estimated: chao1, the observed number of species, and the 
phylogenetic distance. These estimates were plotted as rarefaction curves using Qiime (Figures 
4-4,-5 and -6 show the rarefaction plot). 
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Chao1 
 
Chao1 is a nonparametric estimator that predicts the minimum species richness of a sample. 
 
 
 
Figure 4-4: Rarefaction curves of the observed number of species metric for all samples (> 500 reads). The plot 
shows the average number of distinct OTUs found in sub‐samples of increasing number of sequences.  
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Observed species 
 
The observed number of species is defined as the number of distinct OTUs within a 
sample. 
 
 
 
Figure 4-5: Rarefaction curves of the observed number of species metric for all samples (> 500 reads). The plot 
shows the average number of distinct OTUs found in sub‐samples of increasing number of sequences.  
 
 
 
 
 
  
174 
 
 
PD (phylogenetic diversity)  
 
The PD metric represents the minimum total branch length that covers all taxa within the 
sample on a phylogenetic tree (Faith et. al., 1992). A smaller PD value therefore indicates a 
reduced expected taxonomic diversity whilst a large PD value indicates a higher expected 
diversity. 
 
 
Figure 4-6: Rarefaction curves of the PD metric represents the minimum total branch length that covers all taxa 
within the sample on a phylogenetic tree. The plot shows the average number of distinct OTUs found in sub‐
samples of increasing number of sequences.  
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4.3.1.2 Estimate beta diversity, generate UPGMA trees and 2D PCoA plots  
 
To allow inter‐sample comparisons (beta‐diversity), all datasets were sub‐sampled (rarefied) 
using the Qiime script. Rarefied OTU tables were used to calculate weighted and unweighted 
pair‐wise UniFrac matrices using Qiime. UniFrac matrices were then used to generate UPGMA 
(Unweighted Pair‐Group Method with Arithmetic mean) trees and 2D principal coordinates 
plots (PCoA). 
 
 
Figure 4-7: UPGMA (Unweighted Pair‐Group Method with Arithmetic mean) trees. 
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The multidimensionality of the data was reduced first by an OTU-based method-Principal 
Component Analysis (PCA) for each group separately. Principal component analysis was used 
to identify linear combinations of gut microbial taxa that were associated with duration on a 
diet. The phylogeny-based method UniFrac was applied to the data, where UniFrac accounts 
for the phylogenetic divergence between the OTUs. A clear overlap of samples was shown in 
PCA on unweighted (qualitative) UniFrac distances for the 100, 200 and 400ppm iron 
untreated iron groups and 100 and 200ppm iron DSS-treated mice (Figure 4-8: a-e). However, 
there was a clear separation of samples for the 400ppm iron DSS-treated group. In this group, 
there was good clustering of samples pre and post-DSS treatment (Figure 4-8: f).  
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Figure 4-8: PCA plots of the unweighted UniFrac distances of pre-and post DSS-intervention stool samples from DSS-
treated mice (b, d, and f) and (a, c and e) untreated mice at Phylum-level, phylogenetic classification of 16S rRNA gene 
sequences. Symbols represent data from individual mice, colour-coded by the indicated metadata. Statistical differences 
were assessed by Welch’s t-test followed by Storey’s FDR multiple test correction. 
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Heatmaps are extremely useful for the visual display of data from 16S rRNA high-throughput 
sequencing studies such as microbial analysis. Therefore, the heat map (Figure 4-9) below, 
represents the relative abundance (0.0-37.7%) of a collection of 12 phyla for 400ppm iron 
DSS-treated mice at day-1 vs. day-10. A noticeable reduction was observed in the proportion 
of Bacteroidetes and Firmicutes from day-1 to day-10. By contrast, a significant increase was 
demonstrated in the sequences assigned for other phyla (Proteobacteria and Actinobacteria) 
between these two-time points.  
 
 
Figure 4-9: Heat map at Phylum-level, phylogenetic classification of 16S rRNA gene sequences representing relative 
abundances for each pre- or post-DSS intervention for the 400ppm iron group. Statistical differences were assessed by 
Welch’s t-test followed by Storey’s FDR multiple test correction. 
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The extended error bar plot for the 400ppm iron DSS-treated group (Figure 4-10), illustrates 
the mean proportion of sequences assigned to each phylum at day-1 vs. day-10. This plot also 
indicates the difference in mean proportion between the two-time points along with the 
associated confidence interval of this effect size and the p-value of the specified statistical 
test. The error bars signify standard error of the mean (SEM). 
 
On the other hand, a significant statistical difference between day-1 and day-10 for all phyla 
was found. Whereas a reduction in Bacteroidetes and Firmicutes was noted, the opposite 
effect was observed for Proteobacteria, Actinobacteria and Fusobacteria, between day-1 and 
day-10. 
 
  
 
Figure 4-10: Extended error bar plot for the five phyla (Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria and 
Fusobacteria) that have a difference between the proportions of day-1 and day-10 for 400pm iron DSS-treated mice. Post-
hoc plot for each phylum indicating 1) the mean proportion of sequences at day-1 and-10, 2) the difference in mean 
proportions for each phylum comparing pre-and post-DSS treatment, and 3) a p-value indicating whether the mean 
proportion is equal for each time point. Statistical differences were assessed by Welch’s t-test followed by Storey’s FDR 
multiple test correction. 
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In the box plot graphs, the distribution of proportions (day-1 and day-10) within each phylum 
in the 400ppm iron DSS-treated group was indicated using a box-and-whiskers graphic (Figure 
4-11) to give a more concise summary of the allocation of the proportions. There was a 
variation in all phyla within the 400ppm iron DSS-treated group when comparing day-1 and 
day-10. There were differences between the pre- and post-DSS intervention: analysis of the 
experimental murine microbiota at the phylum level indicated that the proportion was 
reduced significantly at day-10 vs. day-1 for Bacteroidetes (P<5.98-e3) and Firmicutes (P<6.98-
e3). Conversely, greater proportions of Proteobacteria (P<1.38-e3), Fusobacteria (P<3.25-e3) 
and Actinobacteria (P<5.13-e3) were more frequently observed in day-10 samples as it 
presented in Figure 4-11.  
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Figure 4-11: Box plot showing the distribution in 
the proportion of five phyla (Firmicutes (a), 
Bacteroidetes (b), Proteobacteria (c), 
Actinobacteria (d), and Fusobacteria (e)) 
assigned to samples from 400ppm iron DSS-
treated mice. Boxes indicate the IQR (75th to 25th 
of the data). The median value is shown as a line 
within the box and the mean value as a star. 
Whiskers extend to the most extreme value 
within 1.5*IQR. Outliers are shown as crosses. 
Statistical differences were assessed by Welch’s 
t-test followed by Storey’s FDR multiple test 
correction. 
 
a b 
c d 
e 
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4.3.2 Bacterial diversity data analysis at family level 
 
Any variable region of a genome is good for distinguishing between closely related 
organisms.  If a region is not under strong negative selection (most mutations lethal or 
detrimental) the sequence drifts as mutations accumulate.  But many other considerations 
are also involved with choosing one variable region as being very good for identifying what 
type of organism is in your sample.  One of the considerations is having the variable region 
flanked by highly conserved regions so that it is easy to design PCR primers and sequencing 
primers that will work across a wide variety of organisms.  Another consideration is having a 
reasonable size of the variable region such as something between 50 and 1,000 bases length 
which makes PCR and sequencing inexpensive and reliable 133, 134.  
 
Plenty of 16S rRNA sequence data for microbial communities is provided by next-generation 
sequencing techniques with primers (e.g. V4). However, if we want to compare whether 
bacterial communities are different among samples, at what taxonomic level should we 
compare? Unfortunately, resolution based on amplification of the V4 16S region is not the 
best way to determine bacterial species with a high degree of confidence 134. However, it 
provides a useful tool to characterise microbial community structure based on a higher 
taxonomic level such as phyla or family. Though, if the project does not have sequence 
fragments larger than 1kb, the taxonomic assignation even at genus level will remain elusive. 
In our case, it was recommended to get the taxonomy at the family level thus providing results 
with a high degree of certainty for such identifications.  
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The community composition of each sample for a given taxonomic rank (from Kingdom to 
Species) was summarised using Qiime. From these summaries, bar plots were generated. An 
example of such a bar plot, showing the relative abundance of different families among the 
samples, is shown in Figure 4-12. 
 
 
 
 
Figure 4-12: Family‐level taxonomic composition of all samples (relative abundance). 
Note: all samples identifications are listed in appendix-1 and legends in appendix -3 
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the heat map (Figure 4-13) below, represents the relative abundance (0.0-39.4%) of a 
collection of 32 families for 400ppm iron DSS-treated mice at day-1 vs. day-10. A noticeable 
reduction was observed in the proportion of S24.7, Lachnospiraceae, Ruminococcaceae, and 
Lactobacillaceae. By contrast, a significant increase was demonstrated in the sequences 
assigned for other families (Cytophagaceae, Weekesllaceae and Alicyclobaciliaceae) between 
these two-time points.  
 
 
 
Figure 4-13: Heat map at Phylum-level, phylogenetic classification of 16S rRNA gene sequences representing 
relative abundances for each pre- or post-DSS intervention for the 400ppm iron group. Statistical differences were 
assessed by Welch’s t-test followed by Storey’s FDR multiple test correction. 
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4.3.2.1 Families belonging to Bacteroidetes phylum 
 
The mean proportion of sequences assigned to the four families (S24-7, Cytophagaceae, 
Weekesllaceae and Flavobacteriaceae) is represented in Figure 4‐7. A significant reduction in 
the S24-7 family was observed at day‐1 vs. day‐10 (P<2.15e‐3). By contrast, Cytophagaceae, 
Weekesllaceae and Flavobacteriaceae showed an increasing manner at day‐10 vs. day‐1. 
 
 
 
Figure 4-14: Extended error bar plot for the four families (S24-7, Cytophagaceae, Weekesllaceae and 
Flavobacteriaceae) that have a difference between the proportions of day-1 and day-10 for 400pm iron DSS-
treated mice. This Post-hoc plot for each family indicating 1) the mean proportion of sequences at day-1 and 
10, 2) the difference in mean proportions for each family comparing pre-and post-DSS treatment, and 3) a p-
value indicating if the mean proportion is equal for each time point. Statistical differences were assessed by 
Welch’s t-test followed by Storey’s FDR multiple test correction. 
 
 
 
 
4.3.2.2 Families belonging to Firmicutes phylum 
 
Five families in the Firmicutes phylum (Lachnospiraceae, Ruminococcaceae, 
Lactobacillaceae, Mogibacteriaceae and Clostridiaceae) showed a significant decline in their 
mean proportion of sequences (P<0.037, 0.017, 6.92e-3, 0.046 and 0.035 respectively). 
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However, the Alicyclobaciliaceae family increased at day-10 vs. day-1 (P<2.15e-3) as 
presented in Figure 4-15. 
 
 
 
Figure 4-15: Extended error bar plot for six families (Lachnospiraceae, Ruminococcaceae, Lactobacillaceae, 
Mogibacteriaceae, Alicyclobaciliaceae and Clostridiaceae) that have a difference between the proportions at day-
1 and day-10 for 400pm iron DSS-treated mice. This Post-hoc plot for each family indicates 1) the mean proportion 
of sequences at day-1 and-10, 2) the difference in mean proportions for each family comparing pre-and post-DSS 
treatment, and 3) a p-value indicating if the mean proportion is equal for each time point. Statistical differences 
were assessed by Welch’s t-test followed by Storey’s FDR multiple test correction. 
 
 
 
 
 
 
 
 
4.3.2.3 Families belonging to Actinobacteria phylum  
 
 
 
The mean proportion of sequences assigned to the six families (Microbacteriaceae, 
Nocardiaceae, Mycobacteriaceae, Sporichthyaceae, Nakamurellaceae and EB1017) is 
represented in Figure 4‐16 where a significant increase for all families at day‐10 vs. day‐1 was 
seen.  
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Figure 4-1: Extended error bar plot for the six Families (Microbacteriaceae, Nocardiaceae, Mycobacteriaceae, 
Sporichthyaceae, Nakamurellaceae and EB1017) that have a difference between the proportions of day-1 and 
day-10 for 400pm iron DSS-treated mice. This Post-hoc plot for each family indicates 1) the mean proportion of 
sequences at day-1 and 10, 2) the difference in mean proportions for each family comparing pre-and post-DSS 
treatment, and 3) a p-value indicating if the mean proportion is equal for each time point. Statistical differences 
were assessed by Welch’s t-test followed by Storey’s FDR multiple test correction. 
 
 
 
 
 
 
4.3.2.4 Families belonging to Fusobacteria phylum 
 
 
The families belonging to Fusobacteria were low in number (Fusobacteriaceae and 
Leptotrichiaceae). However, they showed a high percentage of sequences that were assigned 
to these families as represented in Figure 4‐17. A significant reduction was seen in the 
Fusobacteriaceae family at day‐1 vs. day‐10 (P<1e‐15), whereas Leptotrichiaceae displayed a 
significant increase (P<1e‐15) on day‐10 vs. day‐1. 
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Figure 4-2: Extended error bar plot for two families (Fusobacteriaceae and Leptotrichiaceae) that have a 
difference between the proportions of day-1 and day-10 for 400pm iron DSS-treated mice. This Post-hoc plot for 
each family indicates 1) the mean proportion of sequences at day-1 and 10, 2) the difference in mean proportions 
for each family comparing pre-and post-DSS treatment, and 3) a p-value indicating if the mean proportion is equal 
for each time point. Statistical differences were assessed by Welch’s t-test followed by Storey’s FDR multiple test 
correction. 
 
 
 
 
 
4.3.2.5 Families belonging to Proteobacteria phylum 
 
15 families were shown to have a significant increase in the mean proportion of sequences 
assigned to each family at day-1 vs. day-10 as demonstrated in Figure 4‐18. The highest most 
abundant three families were (Comamonadaceae, Acetobacteraceae and 
Sphingomonadaceae) with P<8.90e‐4 for each. 
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Figure 4-3: Extended error bar plot for 15 families (belong to Proteobacteria level), where, each family has a difference 
between the proportions of day-1 and day-10 for 400pm iron DSS-treated mice. This Post-hoc plot for each family 
indicates 1) the mean proportion of sequences at day 1 and 10, 2) the difference in mean proportions for each family 
comparing pre and post-DSS treatment, and 3) a p-value indicating if the mean proportion is equal for each time point. 
 
 
  
190 
 
4.4 Discussion 
 
Laboratory mice are frequently used as experimental models for diseases such as 
inflammatory bowel disease, where the gut microbiota composition, as well as function, has 
been found to be a significant contributory factor 135. Nevertheless, currently, there is a 
knowledge gap concerning the degree of similarity between the human and mouse gut 
microbiota particularly at the deeper levels of taxonomy such as genera and species 135. 
However, many gut microbiota associated illnesses have been related to bacterial dysbiosis 
on a higher taxonomic level, providing evidence for the efficacy of sequencing the gut 
microbiota to the Phylum and Family levels 136. 
 
Therefore, in this chapter, we analysed inter- and intragroup differences and similarities 
between the gut microbiota composition of 36 laboratory wild-type mice (6 mice per group). 
Qualitative and quantitative-based analysis of the faecal gut microbiota at two different time 
points (day-1 and day-10) for DSS-treated groups (100, 200 and 400ppm iron) and untreated 
mice (controls) on the same diets was undertaken. PCA revealed overlap of all microbial 
profiles, except for the 400ppm iron DSS-treated mice, which seemed to be the only group 
that had clear separation with significant differences observed (Figure 4-8). 
 
Previously the gut microbiota composition has been shown to be influenced by multiple 
factors including environmental factors and host genetics. Recently, researchers have 
suggested that diet is one of many environmental factors which strongly affects the 
composition of the gut microbiota 137. However, the mice used in this project received the 
same diet, except for its iron content. The effect was most notable after the DSS treatment. 
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Further analysis was applied to compare the day-10 data for different doses of iron. However, 
this analysis did not reveal any significant findings. 
 
Some studies have shown significant results indicating that a subset of CD and UC samples 
contain abnormal gut microbiotas, characterised by depletion of commensal bacteria, 
particular members of the phyla Firmicutes and Bacteroidetes and an increase in 
Proteobacteria 68. These results agreed with our project’s data analysis, where Proteobacteria 
increased by 1.62‐fold, Firmicutes levels decreased by 2.7‐fold and Bacteroidetes also reduced 
by 1.26‐fold on day‐10 vs. day‐1 in 400ppm iron DSS‐treated mice (Figure 4‐10). Although 
similar trends were found in the other groups of mice, without any no significance.  
 
The relative distribution of the gut microbiota in each group was calculated, combined, and 
summarised at the family level in OTU tables. Further statistical analysis was applied using 
STAMP software and various statistical tests for each group at day-1 vs. day-10. 
Correspondingly, only the 400ppm iron DSS-treated mice samples showed any significant 
differences and these were in families belonging to the phyla Bacteroidetes, Firmicutes, 
Proteobacteria, Actinobacteria and Fusobacteria. 
 
In conclusion, this chapter reports the use of high‐throughput 16S rRNA gene sequencing of 
the gut microbiome in mice treated with iron and or DSS. Increasing the iron content of the 
diet led to a change in the microbiota after colitis was induced with DSS: this was not observed 
in the normal or low‐iron diet groups of mice.  
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5 Induction of chronic intestinal inflammation using 
repeated cycles of dextran sulphate sodium (DSS)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
193 
 
5.1 Introduction 
 
Millions of people worldwide have been diagnosed with inflammatory bowel disease (IBD), 
which is considered to be a chronic inflammatory illness of the gastrointestinal tract. 
However, its pathophysiology remains unclear, and usually, IBD takes a relatively benign 
course with either a single attack or perhaps periods of long-term remission. The 
experimental models of colitis have contributed crucially to a better understanding of the 
disease (IBD), as well as the investigation of new therapies 138. Oral consumption of dextran 
sulphate sodium (DSS) in drinking water is widely used as a model to induce colitis in animals. 
DSS induction can cause both acute and chronic colitis in rodents by causing inflammation 
and the recruitment of immune cells, which are then activated directly via epithelial cell 
damage and macrophage function alterations 139. 
 
In chronic DSS-induced colitis, the induction phase is characterised by mild-moderate disease 
activity with significant colonic polymorph nuclear leucocyte infiltration 82. Variations in the 
composition of microbiota associated with IBD is recognised as dysbiosis. However, until now 
the mechanism by which IBD-associated dysbiosis develops is uncertain, and it is unclear 
whether this dysbiosis should be considered a cause or consequence of IBD 140. 
 
Over the past 20 years, many types of research have highlighted why the understanding of 
the IBD pathogenesis is imperative to the production of efficient and safe pharmacological 
treatments. In this chapter, some of the clinical, as well as molecular inflammatory actions, 
that occur during the acute and chronic stages as well as the remission period have been 
investigated using a widely employed experimental model of DSS-induced colitis. 
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5.2 Aims 
 
The aims were to: 
 
1- Investigate the effects of dextran sodium sulphate (DSS) on clinical, histological and 
molecular features during acute and chronic phases of colitis. 
 
2- Study the effect of iron on DSS-induced colitis, during both acute and chronic phases. 
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5.3 Induction of chronic colitis in three different iron diet groups  
 
The chronic DSS colitis model (3 cycles of 1.25% DSS (5-days), each followed by a 16-day 
recovery period (Figure 5-1)) has previously been established in our department and has been 
documented previously 83. 
 
 
 
 
Figure 5-1: Chronic DSS-induced colitis model 
 
 
 
48 individually-housed, wild-type C57BL/6 female mice aged 8-9 weeks were divided into six 
groups of 8 mice each. Group (A) mice were given 100ppm iron diet; Group (B) a 200ppm iron 
diet and Group (C) a 400ppm iron diet. All these groups were administered 3 cycles of 1.25% 
DSS treatment (Figure 5-1). Control mice were given distilled water without DSS. Of these, 
Group (D) had a 100ppm iron diet; Group (E) a 200ppm iron diet and Group (F) mice a 400ppm 
iron diet (Figure 5-2). 
•1.25% DSS for 5
days
•normal water 
for 16 days 
1st 
cycle
•1.25% DSS for 5
days
•normal water
for 16 days
2nd 
cycle
•1.25% DSS for 5
days
•normal water
for 16 days
3rd 
cycle
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Figure 5-2: Different diet groups with and without DSS treatment 
 
 
 
DSS treated animals (Group (A) 100ppm iron, (B) 200ppm iron and (C) 400ppm iron) were fed 
with their diet from day-1 until day-63. All mice were administered 1.25% DSS in distilled 
water as the sole source of drinking fluid for 5-days, and then normal drinking water for 16-
days. This 21-day period was defined as one cycle of acute DSS as illustrated in Figure 5-1. 
During the whole 63-day experiment, the mice were caged separately and placed on paper 
bedding, which was changed daily to collect fresh samples and observe any signs of rectal 
bleeding. Daily body weight was recorded as well as any clinical signs of colitis at the end of 
the experiment (day-63) when all mice were euthanised using a Home Office approved 
schedule 1 method. 
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5.3.1 The effect of repeated cycles of low dose (1.25%) dextran sulphate sodium (DSS) on 
the body weight of wild-type C57BL/6 mice supplemented with different iron diets 
 
The body weight of the DSS-treated mice was recorded daily to monitor the percentage of 
body weight change (weight loss) for each cycle as outlined in Figures 5-3, 5-4 and 5-5. In the 
first DSS cycle, all mice lost the most weight on day-8: 2.3%, 1% and 0.75% weight loss for 
mice taking 100ppm iron, 200ppm iron and 400ppm iron diets, respectively. In each group, 
this was followed by a steady increase in body weight during the 16-day recovery period 
(Figure 5-3). 
 
 
Figure 5-3: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red) and 400ppm iron (green)) 
during 1.25% dextran sulphate sodium-induced colitis. Data are presented as a mean ± standard error of the mean. 
Statistical differences were assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests. (n=8 
female mice per group).  
 
 
 
On the second DSS cycle, all mice again developed maximum weight loss at day-8: mice on 
the 400ppm iron diet, appeared as if they lost more weight than mice taking 100ppm iron and 
200ppm iron diets. From day-9 to day-21 of this cycle mice in all groups started to regain their 
body weight (Figure 5-4).  
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Figure 5-4: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red) and 400ppm iron (green)) 
during 1.25% dextran sulphate sodium-induced colitis. Data are presented as a mean ± standard error of the mean. 
Statistical differences were assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests. (n=8 
female mice per group).  
 
 
 
 
In the last (third) DSS cycle, the mice on the 100ppm iron diet lost most body weight followed 
by the 400ppm iron and 200ppm iron diet groups. However, the percentage of body weight 
loss was more than that lost in the previous two cycles for all animals. Again, from day-9 to 
day-21 of this cycle, all mice started to gain in their body weight (Figure 5-5).  
 
 
Figure 5-5: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red) and 400ppm iron (green)) 
during 1.25% dextran sulphate sodium-induced colitis. Data are presented as a mean ± standard error of the mean. 
Statistical differences were assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests. (n=8 
female mice per group).  
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Recurrent acute colitis was therefore induced in mice that received 1.25% DSS in their 
drinking water for 5-days, and this was followed by recovery in the following 16-days on plain 
drinking water. All DSS-treated mice lost body weight from day-6 with the maximal loss 
occurring on day-8 in each cycle. Group A (100ppm iron) mice appeared to lose more weight 
overall than the other groups, but this difference was not statistically significant (Figure 5-6).  
 
 
 
 
Figure 5-6: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red) and 400ppm iron (green)) during three cycles of 
1.25% dextran sulphate sodium-induced colitis during the 63-day period. Data are presented as a mean ± standard error of the mean. 
Statistical differences were assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests. (n=8 female mice per group).  
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5.3.2 The effect of different iron diets on the body weight of wild-type C57BL/6 mice without 
DSS treatment during a 63-day period 
 
Control mice (Groups D-F) were given drinking water without DSS, but with varying amounts 
of dietary iron, as described above. Daily observations and measures were completed in the 
same way as for the mice receiving DSS. At day-53 the control groups were divided further 
into 2 groups (consisting of 4 mice each). 3 groups (Group (G) 100ppm iron, (H) 200ppm iron 
and (I) 400ppm iron) had colitis induced with 2% DSS in a single acute cycle [2% DSS in drinking 
water for 5 days followed by another 5 days on plain drinking water]. The other three groups 
(D, E and F) were maintained on their diets for a total of 63-days. These mice increased in 
body weight in a dose-dependent manner, illustrating the importance of iron as a nutrient. 
Group (D) mice (100ppm iron) however gained significantly less weight between day-7-49 
than the other non-DSS-treatment groups. All mice were euthanised using a Home Office 
approved schedule 1 method on day-63 (Figure 5-7). 
 
Figure 5-7: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red) and 400ppm iron (green) without 
DSS treatment during the 63-day period. Data are presented as a mean ± standard error of the mean. Statistical differences 
were assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests (*P<0.05, **P<0.01). (n=8 until day-54, 
then 4 female mice per group).  
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5.3.3 The effect of a long period (53-days) on iron modification diets on the body weight of 
wild-type mice (C57BL/6) during the 10-day period of acute dextran sulphate sodium (DSS) 
induced colitis 
 
After feeding mice diets for 53 days an acute DSS cycle applied to mimic the human (IBD iron 
deficient patients) scenario. During the 10-day period, the body weight of the DSS-treated 
mice was recorded daily. All these DSS-treated mice developed colitis. There was an earlier 
onset of weight loss day-3 and greater magnitude of weight loss in group G (100ppm iron). 
Group H (200ppm iron) and the group I (400ppm iron) did not start to lose weight until day-5 
(Figure 5-8).  
 
 
Figure 5-8: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red) and 400ppm iron (green)) during 2% 
dextran sulphate sodium-induced colitis. Data are presented as a mean ± standard error of the mean. Statistical differences 
were assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests. (n=4 female mice per group).  
 
 
 
During this acute DSS cycle, the mice fed 100ppm iron lost more weight than other groups 
with significance difference observed from day-2 until day-8 as it illustrated in Figure 5-8. 
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5.4 Histopathological changes caused by colonic inflammation following 
repetitive cycles of Dextran Sulphate Sodium administration 
 
The colons of the mice were examined for features of colitis by light microscopy after staining 
with H & E as described in Chapters 2 and 3. 
 
5.4.1 100ppm iron diet DSS-treated mice displayed more colonic inflammation than mice on 
200ppm iron and 400ppm iron diets  
 
After 63-days, all mice were killed, and their colons examined, chronic DSS groups reflect mild 
colitis, and acute DSS reflects the sever colitis has been shown in Chapter 3, while controls 
demonstrate the longer effects of diets on mucosal tissues. H&E slides were observed under 
light microscopy. Untreated mice had no signs of colitis (Figure 5-9 IV, V and VI). On the other 
hand, all the mice treated with repeated cycles of 1.25% DSS developed features of mild 
colitis, but there was no mortality (Figure 5-9 I, II and III).  
 
Histological examination of colonic tissue sections from the mice treated with a single 2% DSS 
cycle (Groups G-I) also established the presence of moderate DSS-induced colitis, which as 
usual, was located in the distal part of the colon with areas of mucosal loss, increased muscle 
thickness, oedema and inflammatory cell infiltration (Figure 5-9 VII, VIII and IX).  
 
 
 
 
  
203 
 
 
 
 
 
     
     
     
Figure 5-9: Illustrative H&E-stained segments of distal colon from untreated (n=4), 1.25% (n=8) and 2% DSS-treated mice 
(n=4). Mice received either water (control) (IV, V, VI), 1.25% DSS for 5 days and full recovery period 16 days on normal 
water (I, II, III) or 2% DSS for 5 days and followed by another 5 days on plain drinking water before they were euthanised  
(VII, VIII, IX). Arrowheads highlight submucosal oedema; arrows highlight almost complete loss of colonic epithelium (20x 
magnification). 
 
 
 
The researcher assessed the degree of inflammation blinded to diets and treatment using the 
histological inflammatory scoring system (Table 5-1) 91.  
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Score Cell infiltration Tissue damage 
0 None None 
1 Focally increased numbers of 
inflammatory cells in the lamina 
propria 
Discrete epithelial lesions 
2 Confluence of inflammatory cells 
extending into the submucosa 
Mucosal erosions 
3 Transmural extension of the infiltrates Extensive mucosal damage and/or 
extension through deeper structures of 
the bowel wall 
 
Table 5-1: Colitis scoring system adapted from 90 
 
Mild inflammatory reaction occurred with every 1.25% DSS cycle as shown under the light 
microscope. Group B (200ppm iron and 1.25% DSS treatment) had significantly more 
moderate colitis than Group E (200ppm iron, no DSS). The colitis score was significantly 
greater than baseline for all three treated groups: the difference, compared to baseline, was 
greatest for the mice receiving 100ppm iron DSS-treated mice (Group A) (Figure 5-10).  
 
 
     
 
 
 
Iron (ppm iron) 100 200 400 100 200 400 
 DSS (1.25%) + + + - - - 
Figure 5-10: Inflammation (colitis) scores for all groups 1.25% DSS-treated and untreated (controls) 
mice on different iron diets. Horizontal lines at the median. Differences tested by Kruskal-Wallis test 
followed by multiple comparisons Dunn’s test. ** P<0.01, *** P<0.001 versus control (200ppm iron). 
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Acute 2% DSS caused severe colitis in all mice when delivered towards the end of the 63-day 
experiment. There was a significant difference in the colitis scores between the 200ppm iron 
DSS-treated and 200ppm iron DSS-untreated groups. The 100ppm iron and 400ppm iron DSS-
treated mice had more significant increases in intestinal inflammation similarly compared 
with DSS-untreated mice on the 200ppm iron diet. However, comparing 100 and 400ppm iron 
DSS-treated mice vs. 200ppm iron DSS-treated mice showed no significance difference (Figure 
5-11). 
 
 
 
 
 
 
 
 
Iron (ppm iron) 100 200 400 100 200 400 
 DSS (2%) + + + - - - 
Figure 5-11: Inflammation (colitis) scores for all groups 2% DSS-treated and untreated (controls) 
mice on different iron diets. Horizontal lines at the median. Differences tested by Kruskal– Wallis 
test followed by multiple comparisons Dunn’s test. *** P<0.001, **** P<0.0001 versus control 
(200ppm iron). 
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5.4.2 Analysis of intestinal fibrosis in chronic colitis in mice treated with repeated cycles of 
dextran sulphate sodium  
 
Masson’s trichrome staining was used to assess the degree of fibrosis following chronic DSS 
treatment. Collagen deposition was shown by blue staining in the mucosa and submucosa 
(Figure 5-12). 
                                                                                             
                                                                                                      
        
     
 
100ppm iron+ chronic DSS 
200ppm iron + chronic DSS 
400ppm iron + chronic DSS 
(b) 
(c) 
(d) 
 
Figure 5--12: Masson’s trichrome staining of the colonic tissues of (b) 100ppm iron; (c) 200ppm iron; (d) 400ppm iron 
mice with dextran sulphate sodium (DSS)-induced colitis at day-63, and 200ppm iron controls (a). The extracellular matrix 
is blue in colour in the mucosal and submucosal layers. Arrowheads (yellow) highlight submucosal fibrosis. (10x 
magnification). 
200ppm iron 
(a) 
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In chronic Crohn’s disease (CD) intestinal fibrosis may occur 124. In this research, we observed 
thickening of the colon of mice with chronic DSS-induced colitis. Masson’s trichrome staining 
was used to assess fibrosis (Table 5-2) 141 and slides were scored by a researcher blinded to 
the treatment group. 
 
 
 
Category Score Description 
Collagen 
(fibrosis) 0 No increase 
 1 Increased in the submucosa 
 2 Increased in the mucosa 
 3 
Increased in the muscularis mucosa; 
thickening/disorganisation  
of the muscularis mucosa 
 4 
Increased in the muscularis propria (evident increase in 
collagen fibrils for Sirius red) 
 5 
Gross disorganisation of muscularis propria; increased Sirius  
red/GFP or thickening of the serosa 
Percent 
involvement 1 1-25% of section 
  2 26-50% of section 
  3 51-75% of section 
  4 76-100% of section 
 
Table 5-2: Histological fibrosis scoring system adapted from Ding S. et al. 122 
 
 
 
Mice in the 100ppm iron DSS-treated group had significantly more fibrosis than the DSS-
treated mice receiving 200ppm iron and 400ppm iron diets (Figure 5-13). 
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Figure 5-13: Fibrosis scores for all groups of DSS-treated mice on different 
iron diets. Horizontal lines at the median. Data are presented as a mean ± 
standard error of the mean. Differences were tested by Kruskal–Wallis test 
followed by multiple comparison Dunn’s test. (P<0.05) 
 
 
5.5 Measuring the faecal calprotectin concentration in chronic DSS-treated 
wild-type (C57BL/6) mice at different time points during the 63-day course 
 
Faecal calprotectin concentrations were measured using the S100A8/S100A9 ELISA as 
described in Chapters 2 and 3. Faecal pellets were collected from the cage of each mouse in 
all groups at days-1, 21, 42 and 63. Faecal calprotectin concentration was measured and the 
difference between samples taken at different time points was used to assess the degree of 
inflammation in DSS-treated animals after each cycle. However, any difference in untreated 
groups will show whether the diet has any effect on intestinal cells and their response during 
the time course as shown in Figure 5-14.  
 
1
2
3
4
5
6
Fi
b
ro
si
s 
sc
o
re
Average of fibrosis in 
chronic DSS groups
*
  
209 
 
In mice treated with DSS, faecal calprotectin levels increased after each cycle of treatment in 
those receiving 100 and 400ppm iron, but not in those taking 200ppm iron. However, there 
was no any statistical significance between any of the groups as illustrated in Figure 5-14. 
 
 
 
 
Figure 5-14: Faecal calprotectin at four different time points (day-1, 21, 42 and 63) for six groups, three 
DSS-treated and three untreated controls. Data are presented as a mean ± standard error of the mean. 
Differences were tested by Kruskal– Wallis test followed by multiple comparison Dunn’s test. 
 
 
Comparison of faecal calprotectin concentration in each pair of groups taking similar diets 
(DSS-treated and untreated) showed the effects of DSS for a given amount of iron. Only the 
comparison in mice taking 400ppm iron showed a difference between day-21 and day-63 in 
the mice receiving DSS (Figure 5-15). 
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5.5.1 Evaluating gut inflammation at the molecular level by measuring faecal calprotectin 
in 2% DSS-treated (53-days on diets) and untreated mice during 10-day course  
 
Faecal calprotectin concentrations measured from samples taken at two different time 
points’ day-1 and day-10 for all groups. However, samples did not show any significant 
differences when comparing all groups together (Figure 5-16). However the study is likely to 
be underpowered. 
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(c) Figure 5-15: Faecal calprotectin concentration 
at four different time points day-1, 21, 42 and 
63 separately. (a) faecal calprotectin in 100ppm 
iron DSS-treated and untreated groups (b) 
faecal calprotectin in 200ppm iron DSS-treated 
and untreated groups (c) faecal calprotectin 
concentration in 400ppm iron DSS-treated and 
untreated groups. Data are presented as a 
mean ± standard error of the mean. Differences 
were tested by Kruskal– Wallis test followed by 
multiple comparison Dunn’s test. ** P<0.01 
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Figure 5-16: Faecal calprotectin at two different time points (day-1 and 10) for n=4 mice each group. 
Data are presented as a mean ± standard error of the mean. Differences were tested by Kruskal– 
Wallis test followed by multiple comparison Dunn’s test.  
 
 
 
However, comparing faecal calprotectin in each pair of groups taking similar diets (DSS-
treated and untreated) revealed that, the change in faecal calprotectin concentration from 
day-1 vs. day -10 was significant for each DSS-treated group. The 100ppm iron diet DSS-
treated mice had a greater difference between time points than that the other groups are 
receiving 200 and 400ppm iron (Figure 5-17). 
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5.6 The measurement of the total faecal iron concentration in chronic DSS-
treated and untreated mice during 63-day course at different time points 
 
Faecal iron was measured using the same kit [MAK025, Sigma-Aldrich] as described previously 
(Chapters 2 and 3). Faecal iron concentrations were measured at days-1, 21, 42 and 63. The 
difference between samples taken at these time points can reflect colitis severity (luminal 
bleeding) in DSS-treated animals. The difference in untreated mice can be used to indicate 
the effect of dietary iron consumption. However, by comparing all groups together, no 
statistical significance was shown (Figure 5-18). 
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(c) Figure 5-17: Faecal calprotectin concentration 
at two different time points day-1 and 10 
separately. (a) faecal calprotectin in 100ppm 
iron DSS-treated and untreated groups (b) 
faecal calprotectin in 200ppm iron DSS-treated 
and untreated groups (c) faecal calprotectin 
concentration in 400ppm iron DSS-treated and 
untreated groups. Data are presented as a 
mean ± standard error of the mean. Differences 
were tested by Kruskal– Wallis test followed by 
multiple comparison Dunn’s test. * P<0.05, ** 
P<0.01. 
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Figure 5-18: Faecal iron concentration at four different time points (day-1, 21, 42 and 63) for six 
groups, three DSS-treated and three untreated controls. Data are presented as a mean ± standard 
error of the mean. Differences were tested by Kruskal– Wallis test followed by multiple 
comparison Dunn’s test. 
 
 
Comparing faecal iron in each pair of groups taking similar diets (DSS-treated and untreated) 
showed the effects of DSS for a given amount of iron consumed. DSS-treated mice taking 
400ppm iron showed a difference between day-1 and day-63 only, while 100 and 200ppm 
iron mice receiving DSS both showed significant differences at day-1 vs. day-21, 42 and 63 
(Figure 5-19). A significant increase in faecal iron concentration was observed over the course 
of the experiment in control mice with fed 200ppm iron and 400ppm iron, but this was not 
seen in mice on 100ppm iron (Figure 5-19). 
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5.6.1 The measurement of the total faecal iron concentration in 2% DSS-treated and 
untreated mice (on diets 53-days) during 10 -day course  
  
The bar chart below illustrates the difference between samples taken at two different time 
points, day-1 at the start of 2% DSS treatment and day-10 when mice were euthanised and 
same points for the controls. When the DSS-treated and untreated groups were compared 
together, there was no any significant difference (Figure 5-20). However the study is likely to 
be underpowered.  
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(c) Figure 5-19: Faecal iron concentration at four 
different time points day-1, 21, 42 and 63 
separately. (a) Faecal iron in 100ppm iron DSS-
treated and untreated groups (b) faecal iron in 
200ppm iron DSS-treated and untreated groups 
(c) faecal iron in 400ppm iron DSS-treated and 
untreated groups. Data are presented as a 
mean ± standard error of the mean. Differences 
were tested by Kruskal– Wallis test followed by 
multiple comparison Dunn’s test. ** P<0.01. 
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Figure 5-20: Faecal iron concentration at two different time points (day-1 and 10) for six groups 
(n=4 mice each) three DSS-treated and three untreated controls. Data are presented as a mean ± 
standard error of the mean. Differences were tested by Kruskal– Wallis test followed by multiple 
comparison Dunn’s test.  
 
 
Once again, when all diet-matched groups were compared, DSS-treated mice showed 
significant differences between day-1 and day-10 for each group. This was more pronounced 
in the 400ppm iron group. Untreated mice did not reveal any differences apart from the 
400ppm iron group which has a statistical difference between day-1 and-10 (Figure 5-21). 
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(c) Figure 5-21: Faecal iron concentration at two 
different time points day-1 and 10 separately. 
(a) Faecal iron in 100ppm iron DSS-treated and 
untreated groups (b) faecal iron in 200ppm iron 
DSS-treated and untreated groups (c) faecal 
iron in 400ppm iron DSS-treated and untreated 
groups. Data are presented as a mean ± 
standard error of the mean. Differences were 
tested by Kruskal– Wallis test followed by 
multiple comparison Dunn’s test.  
* P<0.05, **** P<0.0001. 
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5.7 Discussion 
 
DSS-induced colitis in mice is a popular model for human ulcerative colitis. The mechanism by 
which DSS induces colitis is unclear. There are several theories including by direct toxic effects 
on colonic epithelial cells, by activation of macrophage inflammatory responses and by 
altering the gut microbiota 89. The majority of published work has used acute IBD animal 
models. But CD and UC are known as chronic pathologies. In 1990, Okayasu and colleagues 
described a model in which mice that were given DSS orally developed acute and chronic 
colitis similar to UC 89. 
 
DSS-induced colitis in mice is characterised by clinical and histological manifestations that are 
similar to those observed in humans. Therefore, it is important to induce a chronic intestinal 
inflammation model by administering repetitive cycles of DSS. This model allows observations 
about the adaptive immune system, mediators and cell Influx involved in the chronification 
process of IBD 142. 
 
Exposure to dextran sulphate sodium (DSS) induces acute colitis in mice, which usually 
resolves when DSS is stopped. In order to obtain the chronicity in DSS-induced colitis, mice 
are classically exposed to three to five cycles of DSS, followed by rest periods 124.  
 
This chapter presents data that clearly demonstrate the importance of both keeping mice 
longer on different iron diets and repeating DSS cycles to investigate the real influence of iron 
on chronic as well as acute colonic intestinal inflammatory responses (as it seen be in Figures 
5-10 & 5-11). Alterations to the iron level in standard chow diet (200ppm iron) resulted in 
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increased susceptibility of mice to developing DSS-induced colitis. In chronic DSS phase, 
100ppm iron diet DSS-treated wild-type mice showed more weight loss than other DSS-
treated mice (on 200 and 400ppm iron diets) at days-8 following DSS administration during 
the first and third DSS cycles (as it shown in Figure 5-6). However, in the second DSS cycle, the 
400ppm iron DSS group lost more weight than the other groups at the same time point (day-
8). However, administration of acute DSS treatment to mice that had been established on a 
100ppm iron diet for-53 days induced more significant colitis. Thus any modifications in iron 
consumption can potentially exacerbate the severity of DSS-induced colitis.  
 
The data show two forms of colitis, acute and chronic, as well as recovery phases. This 
classification is built on clinical symptoms and histopathological changes (epithelial 
architecture, type of inflammatory infiltrate, and fibrosis) 143. Microscopic examination 
revealed extensive damage and increased inflammatory cell infiltration (mononuclear cells 
(MNC)) in wild-type mice treated with 2% DSS (acute phase), especially the 100ppm iron 
group which showed worse colitis scores than the other mice. When looking at chronic colitis, 
after three cycles of 1.25% DSS, all mice exhibited mild-moderate colitis, as shown by weight 
loss. By histological examination, the colitis score was highest in the 100ppm iron DSS-treated 
group. Chronic intestinal inflammation resulted in fibrosis in submucosal tissue and the 
lamina propria as shown by Masson’s trichrome stain in all chronic DSS-treated mice 141. 
However, these fibrotic changes were more pronounced in the 100ppm iron groups followed 
by the 400ppm iron then 200ppm iron groups.  
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To increase the accuracy of this study, colitis was assessed by measuring faecal calprotectin 
concentrations. DSS-induced colitis leads to cell infiltration by mononuclear cells (MNC) which 
contain abundant calprotectin molecules. Therefore, when inflammation occurs neutrophils 
release calprotectin which can be used as an indicator of the degree of inflammation within 
tissues 129. The 2% DSS induction phase was characterised by an increase in faecal calprotectin 
concentration for each group which was significantly higher for those mice on the 100ppm 
iron diet. 
 
A correlation between the amount of dietary iron consumed and faecal iron excretion in 
healthy individuals has been proposed. In patients with IBD, faecal iron may also be increased 
as a result of luminal bleeding during flares of the disease 123. Iron has a role in intestinal 
inflammation by producing free radicals which can destroy DNA and damage cells 111. The iron 
assay kit gives the option to measure Fe3+, Fe2+ or total iron concentration. Therefore, total 
faecal iron was measured at the end of each DSS cycle to assess bleeding (luminal) as a feature 
of colitis and dietary iron consumed.  
 
To conclude, in the present chapter, changes in dietary iron intake enhanced both chronic 
and acute phases of colonic inflammation. The low iron diet had the most major effects on 
colitis courses (acute and chronic) in terms of body weight changes, histology (colitis and 
fibrosis) and faecal calprotectin concentration (acute course) in DSS-treated mice. The high 
iron diet also exacerbated colitis (acute and chronic) but had the most major effects on faecal 
calprotectin concentration and faecal iron concentration in the untreated control groups. 
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6 Longitudinal investigation of microbiota dynamics in 
a model of mild chronic DSS‐induced colitis in wild‐
type C57BL/6 mice receiving diets different with iron 
contents  
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6.1 Introduction 
 
Dextran sulphate sodium (DSS) may be used to study colitis in laboratory rodents. The severity 
of the colitis is influenced by many factors (DSS; MW, concentration, lenghth of exposure) 
and these may be used to induce different kinds of colitis (severe acute colitis, chronic or 
semi-chronic colitis). This model (DSS-induced colitis) of colitis has been used to translate 
murine data to human inflammatory bowel disease (IBD) 82.  
 
The intestinal pathology observed in the acute DSS model remain for a few days after the DSS 
treatment has been stopped. Therefore, they do not provide a subtle system to assess new 
therapeutics or the role of the numerous parameters that are involved in intestinal healing 
144. In contrast, the milder chronic DSS treatment model seems to be ideal for assessing the 
influence of drugs as well as the repair phase of colitis. Moreover, it is now clear that models 
characterised by mild intestinal damage are more accurate for studying the effects of several 
therapeutic agents 145. 
 
The importance of the microbiota in the pathogenesis of IBD is supported by the study of 
several animal models, where the severity of colitis depends on the commensal bacterial 
strains that are maintained in animals 146. DSS treatment is associated with a major shift in 
gut microbiota composition, which leads to an unhealthy state 147. The administration of 
antibiotics has been shown to improve both IBD and DSS-induced colitis, indicating the 
importance of the microbiota’s role in disease 148. This interpretation was supported by a 
group of researchers from North Carolina University who reported that the simple ingestion 
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of a lysate of bacterial cells belonging to the Firmicutes phylum (which is considered to be a 
healthy-type phylum), reduced the severity of DSS-induced experimental colitis in mice 149.  
 
In this chapter, we used a reproducible mild chronic colitis model, which allowed us to 
evaluate intestinal repair processes and the gut microbiota.  
 
6.2 Aims 
 
The aims were to: 
 
1- Characterise the inflammation and the gut microbiota dynamics longitudinally in a DSS-
induced murine model of chronic colitis using 16S ribosomal RNA (rRNA) gene surveys. 
 
2- Investigate the effects of long-term supplementation of various iron diets on chronic colitis 
as well as the gut microbial structure. 
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6.3 Murine and genomics methods 
 
Groups of C57BL/6 mice were repeatedly (3 cycles) treated with a small dose of DSS (1.25%) 
dissolved in their drinking water to induce colitis for 5-days, followed by a full (16-days) 
recovery period. After-53 days on a diet alone, the comparator control groups were divided 
into two. Four mice in each group continued as controls, and the other four were subjected 
to an acute (2%) DSS cycle for the last ten days of the chronic experiment (details provided 
in Chapter 5). Bacterial DNA was extracted from the stool (pellets) collected and 16S rRNA 
gene sequencing was performed. Operational taxonomic unit (OTU) selection, microbial 
composition and community structure analyses and metagenome inference were conducted 
in collaboration with the CGR. For details on DNA extraction and sequencing, see Methods 
chapter. Finally, statistical analysis in this chapter was undertaken in a similar way to that 
used for the microbiome data generated after acute DSS exposure (Chapter 4). 
 
6.4 Statistical analysis of metagenomic profiles for two as well as multiple 
groups 
 
The STatistical Analysis of Metagenomic Profiles (STAMP) software package was used for 
metagenomic profiles analysis. This generated phylogenetic profiles representing the number 
of indicator genes allocated to different taxonomic units or functional outlines representing 
the number of sequences assigned to various subsystems or pathways 132. The bioinformatic 
analysis of the microbiota data for chronic groups used Kruskal-Wallis H-test to compare day-
1, 21, 42 and 63 together. The false discovery rate (FDR) (multiple correction tests) was used 
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for all groups to produce a prioritised list of OTUs that summarise observed differences 
between user-defined populations. The q-value is the adjusted p-value based on FDR 
calculation, where differences were considered statistically significant at P<0.05. 
 
For paired-end sequence data, there are three sequence file types. The files labelled R1 and 
R2 contain the corresponding paired-end sequences. The singlet files contain sequences 
whose pair has been removed due to poor sequence quality or adapter contamination. If a 
sample has been sequenced several times, there will be several sets of sequence files in the 
sample directory. These will need to be concatenated before downstream analysis. (See 
Appendix-5 and-6). 
 
 
6.4.1 Bacterial diversity data analysis at phylum level (Summary and plot of the taxonomic 
content of each sample) for chronic experiments 
 
The intestinal microbiota of mice was characterised using the fully-validated 16S ribosomal 
RNA (rRNA) gene surveys. We investigated the effects of long-term adjustments to luminal 
iron content on mild-chronic as well as severe acute colitis status and gut microbial structure 
in wild-type mice.  A linear analysis was undertaken for gut microbial communities, pre- and 
post-treatment with three cycles of 1.25% DSS i.e. day-1, 21, 42 and 63 along with control 
groups at the same time points. 
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Figure 6-1: Phylum‐level taxonomic composition of all samples (relative abundance). 
Note: all samples identifications are listed in appendix -4 and legends in appendix -2 
 
 
 
6.4.1.1 Alpha diversity estimation and alpha rarefaction analyses  
 
To negate the effect of sample size and to estimate species richness within each sample (alpha 
diversity), OTU tables were repeatedly sub‐sampled (rarefied). For each rarefied OTU table, 
three measures of alpha diversity were estimated: chao1, the observed number of species, 
and the phylogenetic distance. These estimates were plotted as rarefaction curves using 
Qiime (Figures 6-2,-3 and -4). 
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Chao1 
 
Chao1 is a nonparametric estimator that predicts the minimum species richness of a sample. 
 
 
 
Figure 6-2: Rarefaction curves of the observed number of species metric for all samples (> 500 reads). The plot 
shows the average number of distinct OTUs found in sub‐samples of increasing number of sequences.  
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Observed species 
 
The observed number of species is defined as the number of distinct OTUs within a 
sample. 
 
 
Figure 6-3: Rarefaction curves of the observed number of species metric for all samples (> 500 reads). The plot 
shows the average number of distinct OTUs found in sub‐samples of increasing number of sequences.  
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PD (phylogenetic diversity)  
 
The PD metric represents the minimum total branch length that covers all taxa within the 
sample on a phylogenetic tree (Faith et. al., 1992). A smaller PD value therefore indicates a 
reduced expected taxonomic diversity whilst a large PD value indicates a higher expected 
diversity. 
 
 
Figure 6-4: Rarefaction curves of the PD metric represents the minimum total branch length that covers all taxa 
within the sample on a phylogenetic tree. The plot shows the average number of distinct OTUs found in sub‐
samples of increasing number of sequences.  
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6.4.1.2 Estimate of beta diversity, generate UPGMA trees and 2D PCoA plots  
 
To allow inter‐sample comparisons (beta‐diversity), all datasets were sub‐sampled (rarefied) 
using the Qiime script. Rarefied OTU tables were used to calculate weighted and unweighted 
pair‐wise UniFrac matrices using Qiime. UniFrac matrices were then used to generate UPGMA 
(Unweighted Pair‐Group Method with Arithmetic mean) trees and 2D principal coordinates 
plots (PCoA). 
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Figure 6-5: UPGMA (Unweighted Pair‐Group Method with Arithmetic mean) trees. 
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The multidimensionality of the data was reduced first by an OTU-based method - Principal 
Component Analysis (PCA) for each group separately. Principal component analysis was used 
to identify linear combinations of gut microbial taxa associated with the duration on a diet. 
The phylogeny-based method, UniFrac, was then applied, where UniFrac accounts for the 
phylogenetic divergence between OTUs. Our data showed an overlap in the samples of 100 
and 200ppm iron DSS-untreated and 200ppm iron DSS-treated mice in PCAs on unweighted 
(qualitative) UniFrac distances (Figure 6-6 a, c and d). There was clustering with little 
separation of samples pre and post-DSS treatment for 100 and the 400ppm iron DSS-treated 
groups as well as with control mice fed a 400ppm iron diet (Figure 6-6 b, e and f). Interestingly, 
the high iron diet disturbed the microbial community in both DSS-treated and untreated mice.  
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Figure 6-6: PCA plots of the unweighted UniFrac distances of pre-and post DSS-intervention stool samples from chronic 
(3 cycles) DSS-treated mice (b, d, and f) and (a, c and e) untreated mice at Phylum-level, phylogenetic classification of 16S 
rRNA gene sequences. Symbols represent data from individual mice, color-coded by the indicated metadata. Statistical 
differences were assessed by Kruskal-Wallis H-test followed by Storey’s FDR multiple test correction. 
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6.4.1.3 Increased bacterial diversity at phylum level for 100ppm iron DSS-treated mice 
 
Post-hoc test revealed the only significance difference in 100ppm iron chronic DSS-treated 
mice was for the phylum (Proteobacteria). The extended error bar plot for the 100ppm iron 
DSS-treated group (Figure 6-7), illustrates the mean proportion of sequences assigned to one 
phylum (Proteobacteria) within this group. Moreover, the graph shows the difference in mean 
proportion between the two-time points along with the associated confidence interval of this 
effect size and the p-value of the specified statistical test. There was a significant increase in 
day-63 vs. days-1 and 21 with P<0.05. 
 
 
 
 
Figure 6-7: Extended error bar plot for one phylum (Proteobacteria) that showed a difference between the proportions on 
days-1, 21 and day-63 for 100pm iron DSS-treated mice. This Post-hoc plot for this phylum indicates 1) the mean proportion 
of sequences at four-time points, 2) the difference in mean proportions for Proteobacteria comparing pre-and post-DSS 
treatment, and 3) a p-value indicating if the mean proportion is equal for each time point. Statistical differences were 
assessed by Kruskal-Wallis H-test followed by Storey’s FDR multiple test correction. 
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The box plot graph below (Figure 6-8) shows a concise summary of the allocation of the 
proportions of Proteobacteria at various time-points within the 100ppm iron DSS-treated 
group.  
 
There was a variation in assigned sequences for Proteobacteria within the 100ppm iron DSS-
treated group when comparing days-1, 21, 42 and 63 samples. There were differences 
between the pre and post-DSS intervention: analysis of the experimental murine microbiota 
at the phylum level indicated that the abundance was increased significantly at day-63 for 
Proteobacteria (P<0.017) as shown in Figure 6-8.  
 
 
 
Figure 6-8: Box plot showing the distribution in the proportion of Proteobacteria assigned to samples at 
day-1, 21, 42 and 63 from 100ppm iron DSS-treated mice. The boxes show the IQR (75th to 25th of the 
data), whiskers extend to the most extreme value within 1.5*IQR, and any outliers are shown as crosses. 
The median value appears as a line within the box and the mean value as a star. Statistical differences 
were assessed by Kruskal-Wallis H-test followed by Storey’s FDR multiple test correction. 
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6.4.1.4 The effect of high iron diet (400ppm iron) on gut microbiota composition 
 
The heat map is useful for the graphical display of data from 16S rRNA high-throughput 
sequencing studies such as microbial analysis. Therefore, the heat map (Figure 6-9) represents 
the relative abundance (0.0-1.3%) of 2 phyla (Proteobacteria and Actinobacteria) for 400ppm 
iron untreated mice at days-1, 21, 42 and 63. An increase is shown in the sequences assigned 
for Proteobacteria and Actinobacteria starting from day-1 until day-63 as it was shown by the 
post-hoc test. 
 
 
 
Figure 6-9: Heat map at Phylum-level, phylogenetic classification of 16S rRNA gene sequences representing relative 
abundances for the 400ppm iron group. Statistical differences were assessed by Kruskal-Wallis H-test followed by Storey’s 
FDR multiple test correction. 
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A post hoc test showing the mean proportion of sequences assigned only to Proteobacteria 
is represented in Figure 6‐10. This showed a significant rise in this phylum at day‐42 vs. day‐
21 (P<0.001) and day‐63 vs. day‐21 (P<0.05). 
 
 
 
 
Figure 6-10: Extended error bar plot for Proteobacteria that have a difference between the proportions of day-21, 42 
and 63 for 400pm iron untreated mice. This Post-hoc plot for Proteobacteria indicating 1) the mean proportion of 
sequences at day-21, 42 and 63, 2) the difference in mean proportions, and 3) a p-value indicating if the mean proportion 
is equal for each time point. Statistical differences were assessed by Kruskal-Wallis H-test followed by Storey’s FDR 
multiple test correction. 
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However, a clearer summary of the proportions for Proteobacteria and Actinobacteria in 
400ppm iron DSS-untreated mice is presented in the box plot graph (Figure 6-11), showing a 
variation in those two phyla comparing day-1, 21, 42 and 63 samples. Nevertheless, analysis 
of the experimental murine microbiota indicated that the proportion increased significantly 
over time-course for Proteobacteria and Actinobacteria with P<0.011 each. The significant 
differences were observed most in the day-63 samples as illustrated in Figure 6-11.  
 
 
 
     
Figure 6-11: Box plot showing the distribution in the proportion of two phyla (Actinobacteria (a) and Proteobacteria (b)) 
assigned to samples from 400ppm iron untreated mice. Statistical differences were assessed by Kruskal-Wallis H-test 
followed by Storey’s FDR multiple test correction. 
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6.4.1.5 Dysbiosis of microbiota composition at phylum level in 400ppm iron DSS- treated 
wild-type mice 
 
The analysis of faecal samples at day‐1, 21, 42 and 63 for mice in the 400ppm iron DSS‐treated 
group showed a big relative abundance range (0.0‐90.8%) as demonstrated in Figure 6‐12. 
However, the proportion of the sequences for the two phyla (Bacteroidetes and 
Proteobacteria) was increased from day‐1 until day‐63. 
 
 
 
 
 
Figure 6-12: Heat map at Phylum-level, phylogenetic classification of 16S rRNA gene sequences representing relative 
abundances for each pre- or post-DSS intervention for the 400ppm iron group. Statistical differences were assessed by 
Kruskal-Wallis H-test followed by Storey’s FDR multiple test correction. 
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In the box plot graphs below, the distribution of proportions at different time points for each 
phylum in the 400ppm iron DSS-treated group is indicated using a box-and-whiskers graphic 
(Figure 6-13). There were differences in Bacteroidetes and Proteobacteria comparing day-1, 
21, 42 and 63 within the 400ppm iron DSS-treated group. However the differences between 
the pre and post-DSS intervention samples indicated that the proportion was increased 
significantly with time for Proteobacteria (P<0.016), and decreased for Bacteroidetes 
(P<0.028) as shown in Figure 6-13.  
 
 
 
 
    
Figure 6-13: Box plot showing the distribution in the proportion of two phyla (Proteobacteria (a) and Bacteroidetes (b)) 
assigned to samples from 400ppm iron DSS-treated mice. Statistical differences were assessed by Kruskal-Wallis H-followed 
by Storey’s FDR multiple test correction. 
 
 
 
 
 
 
 
 
 
 
a b 
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6.4.2 Microbiota composition at taxonomic level (genus) lower than phylum level in faecal 
samples of chronic DSS experiments 
 
To further evaluate the performance of gut microbiota, we analysed high-throughput 16S 
amplicon reads data that were generated from sets of murine faecal samples by the Illumina 
MiSeq platform. Analysis of the bioinformatics data started from the Phylum taxonomic level 
and continued deeper to reach the lowest level that showed significance differences. 
Ultimately, we found that the number of genus level assignations was higher and statistically 
significant in both the 100ppm iron and 400ppm iron DSS-treated mice as well as in the 
400ppm iron untreated animals. 
 
The Kruskal-Wallis H-test post-hoc test along with effect size, and multiple test correction 
method (Storeys FDR) were used after quality filtering steps resulted in the identification of 
four phyla and 15 taxa (genera). Of the four phyla [Firmicutes, Bacteroidetes, Proteobacteria, 
and Actinobacteria], one phylum (Firmicutes) was highly abundant among all groups while the 
lowest abundance phylum was Actinobacteria. However, 100ppm iron and 400ppm iron DSS 
groups showed seven different genera apart from the three genera (Bacteroides, 
Lactobacillus and Bilophila) that they shared. The results of the relative abundances of various 
phyla and identified genera are summarised in Table 6-1, 2 and 3. 
 
STAMP encourages the use of effect sizes and confidence intervals in evaluating biological 
importance. Effect size is a simple method of quantifying the difference between groups, 
which has several advantages over the use of tests of statistical significance 150. 
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100ppm iron DSS-treated group 
Taxon p-values p-values (corrected) Effect size 
p_Bacteroidetes; g_Bacteroides 0.003 0.047 0.496 
p_Bacteroidetes; g_Odoribacter 0.002 0.04 0.620 
p_Bacteroidetes; g_Prevotella 0.0002 0.008 0.669 
p_Firmicutes; g_Clostridium 0.002 0.04 0.431 
p_Firmicutes; g_Dorea 0.003 0.047 0.138 
p_Firmicutes; g_Lactobacillus 0.00002 0.002 0.880 
p_Proteobacteria; g_Bilophila 0.0002 0.008 0.766 
 
Table 6-1: Genus-level taxonomic composition of faecal samples from 100ppm iron DSS-treated mice (Day-1 vs. 21, 42 and 
63 samples) 
 
 
400ppm iron DSS-treated group 
Taxon p-values p-values (corrected) Effect size 
p_Firmicutes; g_Lactobacillus 0.0001 0.01 0.74 
 
Table 6-2: Genus-level taxonomic composition of faecal samples from 400ppm iron DSS-treated mice (Day-1 vs. 21, 42 and 
63 samples) 
 
 
400ppm iron untreated group 
(Controls) 
Taxon p-values p-values (corrected) Effect size 
p_Actinobacteria; g_Adlercreutzia 0.002 0.04 0.49 
p_Bacteroidetes; g_Bacteroides 0.0005 0.02 0.68 
p_Firmicutes; g_Candidatus Arthromitus 0.003 0.04 0.54 
p_Firmicutes; g_Lactobacillus 0.0002 0.02 0.77 
p_Firmicutes; g_Oscillospira 0.001 0.03 0.61 
p_Firmicutes; g_Ruminococcus 0.002 0.04 0.46 
p_Proteobacteria; g_Bilophila 0.001 0.03 0.55 
 
Table 6-3: Genus-level taxonomic composition of faecal samples from 400ppm iron untreated mice (Day-1 vs. 21, 42 and 63 
samples) 
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6.5 The influence of long-term modification of the iron composition of diets on 
gut microbiota in a 10-day acute DSS (2%) experiment 
 
Here, we investigated the effects of 53-days alterations in dietary iron intake on acute DSS-
induced colitis: as described in Chapter 5. However, in this chapter, we have investigated the 
effects on gut microbial structure through 16S ribosomal RNA (rRNA) gene surveys. We 
analysed gut microbial communities, pre and post treatment with 2% DSS in 100, 200 and 
400ppm iron groups. These were compared with control groups (consuming 100, 200 and 
400ppm iron) on day-1 and day-10. 
 
The multidimensionality of the data was reduced first by an OTU-based method-Principal 
Component Analysis (PCA) for each group separately. Principal component analysis was used 
to identify linear combinations of gut microbial taxa that were associated with duration on a 
diet. The phylogeny-based method UniFrac was then applied to the data, where UniFrac 
accounts for the phylogenetic divergence between the OTUs. No separation of samples in PCA 
on unweighted (qualitative) UniFrac distances for all groups was seen (Figure 6-14 a, b, c, d 
and e). There were also no active features or degenerate plot (i.e. no PCA) for 200ppm iron 
control mice.  
 
As can be seen from the PCA plots in Figure 6-14, samples at day-1 clustered together in most 
of the groups, whereas samples at day-10 showed separation in all groups. However, the post-
hoc test did not show any significant differences between day-1 vs. day-10 for any of the six 
groups. 
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Figure 6-14: PCA plots of the unweighted UniFrac distances of pre-and post DSS-intervention stool samples from acute 
(2%) DSS-treated mice (b, c, and e) and (a, and d) untreated mice at Phylum-level, phylogenetic classification of 16S rRNA 
gene sequences. Symbols represent data from individual mice, color-coded by the indicated metadata. Statistical 
differences were assessed by Welch’s t-test followed by Storey’s FDR multiple test correction. 
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6.6 Discussion 
 
The incidence of IBD continues to increase in the developed world areas and is appearing in 
developing areas as a Westernised lifestyle is becoming implemented. However, despite 
significant advances in the understanding of the pathogenesis of IBD and the development of 
new treatments, a cure for IBD remains elusive. Taking into consideration the implications of 
the microbiota in intestinal inflammation, and the fact that diets play a major factor in 
recognition of bacterial influence and induction of inflammation, we, therefore, investigated 
the role of iron as an environmental factor in the pathogenesis of colitis and its effect on the 
composition of the gut microbiota.  
 
The dextran sulphate sodium (DSS) model involves damaging the mucosal epithelium during 
colitis. For that reason, it can be used as a model to examine the effect of environmental 
change on the commensal microbiota of the colon. Bacteria play a complex role in the 
commonly used acute model of DSS-induced colitis 151. Antibiotic treatment improves DSS-
induced colitis, suggesting that bacteria drive inflammation as well as epithelial damage 149.  
 
The use of repeated cycles of small doses of DSS (1.25%) provokes a mild form of colitis that 
replicates some features of human IBD, as shown in Chapter 5. We found that analysis of 
sequence pools revealed significant differences in microbial community composition at the 
phylum taxonomic level between the tested time points (days-1, 21, 42 and 63) in both the 
100 and 400ppm iron DSS-treated and 400ppm iron untreated groups of animals. However, 
according to a study done by Dirk Haller and his team, major alterations in microbial 
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composition occurred when mice received an iron depleted diet, whereas host genotype, 
inflammatory response, and systemic iron administration had smaller effects 152.  
 
However, in our study, principal component analysis (PCA), based on the normalised 
abundance of dominant bacterial phyla with a colour code according to iron and DSS 
treatment, illustrated the major separation of samples according to their collection time in 
100 and 400ppm iron DSS groups. Control group analysis indicated that a high iron diet 
(400ppm iron) led to most of the alterations in microbial population regardless of DSS 
treatment (Figure 6-6). These data were consistent with the results from a study of anaemic 
African children, which showed that iron fortification led to a potentially more pathogenic gut 
microbiota profile and gut inflammation 153. 
 
The population structure of the bacterial gut community and the intestinal ecosystem were 
affected by gut inflammation. In particular, intestinal pathogens (some types of 
Proteobacteria) appeared to take advantage of this shift (inflammation). This observation is 
in agreement with the ‘food hypothesis’ and ‘differential killing’ hypothesis: these two 
mechanisms are likely to contribute to the loss of colonisation resistance in the inflamed gut 
154. Nonetheless, the post-hoc analysis of our data revealed that one bacterial phylum 
(Proteobacteria) was increased significantly (P<0.01) in the 100ppm iron and 400ppm iron 
DSS-treated and 400ppm iron untreated groups (Figure 6-8, -11 (b) and -13 (a)). However, 
Actinobacteria were increased significantly (P<0.011) in the samples from 400ppm iron 
untreated mice (Figure 6-11 (a)), whereas Bacteroidetes decreased significantly (P<0.028) in 
the 400ppm iron DSS-treated group (Figure 6-13 (b)). 
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Dirk Haller and his team studied the depletion of luminal iron and its effects on the gut 
microbiota and how it prevents Crohn’s disease-like ileitis: the analysis revealed that eight 
bacterial families and nine bacterial genera were significantly (P<0.01) affected by the luminal 
iron (ferrous sulphate) deficiency. The genera Bifidobacterium (P<0.0018), Succinivibrio 
(P<0.0027), Turicibacter (P<0.0020) and Clostridium (P<0.0017) were significantly increased 
in mice supplemented with an iron depleted diet, whereas the genera Desulfovibrio 
(P<0.0001), Dorea (P<0.01) and Bacteroides related were greatly reduced. They concluded 
that all significant differences in bacterial abundance in wild-type mice appeared as a result 
of the interaction between treatment and Host-mediated inflammation 152.   
 
However, our analysis showed that seven genera were significantly different. We found 
reductions in Lactobacillus (P<0.002), Dorea, Clostridium, Bacteroides and Odoribacter 
(P<0.04), Bilophila (P<0.008), and an increase in (Prevotella P<0.008), all belonging to three 
phyla [Firmicutes, Bacteroidetes and Proteobacteria] in 100ppm iron DSS-treated mice (Table 
6-1). A significant reduction was shown in the Firmicutes with one genus (Lactobacillus 
P<0.01) in the 400ppm iron DSS group (Table 6-2). The only control group in which significant 
differences were found was the 400ppm iron group, where four phyla [Firmicutes, 
Bacteroidetes, Proteobacteria, and Actinobacteria] with seven genera showed statistically 
significant differences. Increases were shown in Lactobacillus (P<0.02), Oscillospira (P<0.03), 
Adlercreutzia and Candidatus Arthromitus (P<0.04) whereas, reductions occurred in 
Bacteroides (P<0.02), Bilophila (P<0.03) and Ruminococcus (P<0.04) (Table 6-3). 
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Our results suggest that any modifications of iron that is consumed in the diet can exacerbate 
colitis in mice and disturb the gut microbiota. Collectively these findings explore some 
mechanisms responsible for the disruption in intestinal epithelial homoeostasis and provide 
a new perspective on host-commensal symbiosis. 
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7 General discussion 
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IBD (ulcerative colitis and Crohn’s disease) is a long-term condition that damages the 
gastrointestinal tract. IBD is becoming a global problem which affects around 240,000 people 
in the UK 155. About one-third of IBD patients suffer from anaemia. Intestinal bleeding is a 
significant symptom in IBD, and a fall in the red blood cell count is common during relapse 156. 
Iron deficiency (ID) is the most frequent cause of anaemia in IBD. Therefore, intravenous iron 
and oral replacements are often used for the treatment of IDA 157. Regardless of the new 
recommendations by international expert guidelines, intravenous iron preparations are 
associated with safety issues and thus are widely considered as a last option 158. 
 
Iron is an essential requirement for most organisms, including bacteria. Unabsorbed iron from 
supplements and gastrointestinal bleeding puts iron into the colon and causes undesirable 
effects on the intestinal host–microbiota interface, which can excite the growth and virulence 
of some bacterial pathogens within the intestine and exacerbate inflammation in IBD 159. Any 
alterations of the gut microbial composition cause a condition called “dysbiosis”, which may 
contribute to the pathogenesis of IBD 160.  
 
We hypothesised that iron supplementation (and or bleeding) in IBD patients could change 
the composition of the gut microbiota and potentially influence the natural history of IBD. In 
this context, we assessed the intestinal microbiota in murine models (acute and chronic DSS) 
of inflammatory bowel disease, and in mice given different doses of iron supplements.  
 
Acute colitis was effectively induced in wild-type mice fed with different doses of iron (100, 
200 and 400ppm iron), by administering 2% DSS in drinking water for 5-days followed by 
another 3 or 5-days of plain drinking water. All DSS-treated mice started losing body weight 
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from day-6: the maximal weight loss occurred on day-8. Mice receiving 100ppm iron lost 
significantly more weight than other groups (Chapter 3). These findings were consistent with 
a study by a Norwegian group who found that intestinal inflammation in DSS-induced colitis 
in rats was aggravated by using low-dose oral ferrous fumarate 128. In the same study 128, there 
was an increase in histologic colitis scores in DSS-treated Wistar rats after receiving low-dose 
oral ferrous fumarate, while no changes were observed in control animals. Higher doses of 
iron caused an increase in histological intestinal inflammation 128. In our study, mice had 
significantly greater inflammation at day-10 after receiving 100ppm iron with DSS than DSS-
treated mice that received 200 or 400ppm iron.  
 
In humans, faecal calprotectin measurement is common for the assessment of IBD disease 
activity 161. We, therefore, measured faecal calprotectin concentrations to examine whether 
dietary iron affected inflammation by an additional technique. Interestingly, similar to the 
histological changes, faecal calprotectin levels were increased at day-8 compared to day-10 
and this occurred most prominently in the high- and low-iron DSS groups (P<0.001): these 
groups also had significantly (P<0.05) greater colitis score than the regular (200ppm iron) iron 
DSS group at day-10 (Figure 3-11 Chapter 3).  
 
Jaeggi et al.127 reported that oral iron supplementation had been associated with increased 
levels of faecal calprotectin (demonstrating augmented gut inflammation) and with an 
increased rate of diarrhoea 127. In contrast, a study by Kortman et al.162 showed that faecal 
calprotectin levels were not influenced by dietary iron intervention alone, but after enteric 
infection faecal calprotectin was significantly lower in mice on an iron-deficient diet. 
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Moreover, Kortman found that Enterorhabdus appeared only after enteric infection and its 
relative abundance and faecal calprotectin levels were highest in the regular iron group 162.  
 
Anaemia is a common clinical feature of IBD, whereas intestinal bleeding (either visible or 
occult blood) is a key symptom of IBD during a flare. We, therefore, measured total faecal iron 
concentrations in our mice. Our data showed a difference in total faecal iron concentration 
between samples taken at day-1 vs. day-10 which reflected colitis severity (luminal bleeding) 
in DSS-treated animals. The increase in faecal iron from day-1 to day-8 (the maximum weight 
loss point) was significant in the 100 and 400ppm iron groups (P<0.0001) as well as the 
200ppm iron DSS-treated groups (P<0.01). There was little change in faecal iron concentration 
in mice that did not receive DSS: P<0.05, only in mice receiving 400ppm iron (Chapter 3). 
 
In recent research, Kortman et al.162 investigated the effects of iron on pathology, host 
intestinal immune responses and gut microbiota composition in non-inflamed and inflamed 
colon mouse models. They reported that iron diets alone had a clear influence on luminal iron 
content and tissue iron stores, but found no effects on general health as reflected by body 
weight, immunological factors such as lipocalin-2 and calprotectin 162. In agreement with these 
results, we found that different amounts of iron in the diet alone did not affect body weight, 
histology or faecal calprotectin, in the absence of DSS (acute).  
 
However, as mentioned, the DSS-induced colitis groups showed an effect of the amount of 
iron in the diet on faecal iron concentration as demonstrated by the severity of inflammation 
where luminal iron was increased due to luminal bleeding. These results were highest at day-
8, when weight loss was greatest for low (100ppm iron) as well as high (400ppm iron) iron 
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groups. We have shown, therefore, that low, as well as high, iron diets, exacerbate the severity 
of colitis in the DSS murine model. 
 
Quantitative and qualitative changes in the composition of the intestinal microbial community 
(bacteria, viruses, yeast, and parasites) are referred to as a dysbiotic microbiota. The gut 
microbiota is susceptible to invasion and to blooms of pathogens affecting the niches that are 
left open after disturbances. So dysbiosis is considered as a potential trigger of disease and is 
commonly linked to other illnesses. For example, inflammatory bowel disease may arise as 
the result of inflammation that was caused by an altered immune response to the gut bacteria 
121, 163. 
 
Therefore, 16S sequencing of our samples (acute DSS-induced colitis) was performed. 
Bioinformatic analysis indicated that the only significant difference was for 400ppm iron DSS-
treated mice at day-1 vs. day-10, with significant reductions in the proportions of 
Bacteroidetes and Firmicutes (P<5.98e-3 and P<6.96e-3 respectively). In contrast, a significant 
increase was found in the sequences assigned to other phyla; Proteobacteria (P<1.38-e3), 
Actinobacteria (P<5.13-e3) and Fusobacteria (P<3.25-e3) (Chapter 4). Such findings were 
consistent with recent studies that have characterised the microbiota in IBD patients revealing 
that a reduction in the biodiversity of commensal bacteria has occurred, particularly in the 
phyla Bacteroidetes and Firmicutes 74. Also, recent research on rodents has also shown that 
bacterial compositional changes occur with colonic inflammation and/or infection 164. 
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Patterns of gut microbiome dysbiosis in the murine acute IBD model (DSS) vary among 
published studies. However, in our research, we used samples collected before and after DSS 
treatment and then studied the microbiome via 16S rDNA sequencing. An axis (luminal iron-
intestinal colitis) defined by an increased abundance of bacteria which include Proteobacteria, 
Actinobacteria and Fusobacteria and decreased abundance in Bacteroidetes and Firmicutes 
correlates strongly with disease status. 
 
Having already established the acute colitis mouse model, which allowed us to elucidate the 
impact of DSS-induced colitis on the intestinal microbiota and the proposed impact of iron on 
dysbiosis, we subsequently investigated a chronic DSS-induced colitis model to investigate the 
long-term effect of dietary iron consumption on the same parameters.  
 
Our data showed that chronic colitis was induced successfully in all mice that received 1.25% 
DSS as indicated by weight loss from day-6 and reaching a maximum at day-8 before mice 
started gaining weight throughout the recovery periods. However, body weight changes 
showed no statistically significant differences between DSS groups, although 100ppm iron 
treated mice appeared to lose more weight than other groups (Figure 5-6). In agreement with 
these data Erichsen et al. showed that a low dose of iron aggravated DSS-induced colitis in 
rats 128. Our untreated-DSS mice (controls) fed with different iron diets for a 63-day period 
showed increases in body weight in a dose-dependent manner (Figure 5-7). Therefore, these 
results demonstrate the importance of iron as a nutrient, and its level, in turn, affects the 
course of inflammation. 
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After 53-days on different diets, the control mice were split into six groups of four mice each. 
Three groups received 2% DSS to induce acute colitis and to investigate the influence of an 
extended period of iron depletion/supplementation upon the acute phase of colitis as well as 
on the microbiome, and the remaining mice continued as untreated controls. Surprisingly, our 
data showed significant differences in weight among all DSS-treated groups which developed 
colitis: weight loss was maximal at day-8 for all mice. However, the 100ppm iron DSS-treated 
mice again appeared to be the most severely affected group as shown by weight loss (Figure 
5-8). Our observations demonstrated the importance of luminal iron and inflammation, where 
low and high dietary iron administration for a longer period did exacerbate intestinal 
inflammation significantly, suggesting that the time of iron supplementation may be crucial in 
aggravating colitis. 
 
Histologically, mild inflammation occurred after three cycles of 1.25% DSS. Inflammation was 
significantly increased in 100ppm iron (P<0.001), 200ppm iron (P<0.01) and 400ppm iron 
(P<0.01) DSS-treated mice vs. untreated animals. These findings demonstrate first that the 
DSS model had successfully worked to induce colitis, and secondly that a low iron diet 
(100ppm iron) resulted in the highest histological inflammation score. Such results imply that 
the degree of inflammation in the low iron group was worse than in the higher and regular 
iron diet groups; this is consistent with the weight chart results.  
 
However, inducing colitis with 2% DSS (severe colitis) after a prolonged period on different 
doses of oral iron was associated with significantly more histological colitis than occurred 
during the chronic colitis regimen. Acute DSS-treatment after the prolonged dietary 
manipulation resulted in colitis scores that were significantly greater (P<0.0001) in those mice 
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taking 100ppm iron and 400ppm iron and (P<0.001) for 200ppm iron DSS-treated groups vs. 
untreated 200ppm iron group. Accordingly, histological changes reflected the level of 
inflammation, as noted for the weight change. 
 
In this research, we identified the degree of thickening (fibrosis) in the colon of mice after 
chronic DSS-colitis was induced by staining the tissues with Masson’s trichrome 141. All slides 
were treatment and group blinded to the researcher to assess fibrosis using a histological 
fibrosis score (Table 5-2 Chapter 5). The results revealed fibrosis in all DSS-treated sections 
with statistical significance (P<0.05) between the 100ppm iron and 200ppm iron DSS-treated 
mice. However, the fibrotic score median value was higher for the low iron group followed by 
the high iron group then the standard iron group (5, 4 and 3.5 respectively).  
 
Collectively, all parameters established that low iron (100ppm iron) mice suffered from more 
colitis followed by high iron (400ppm iron) mice then regular iron diet (200ppm iron). This is 
in agreement with data reported by Erichsen et al. and his group which showed that a low iron 
diet aggravated colitis regarding body weight and histology 128. 
 
Our statistics showed no significant differences in faecal calprotectin levels in chronic DSS-
treated mice. However, the calprotectin level appeared to increase gradually after each cycle 
of DSS treatment in mice receiving 100 and 400ppm iron, but not in those taking 200ppm iron. 
Comparison of the samples taken at day-21 vs. day-63 in DSS-treated mice consuming 400ppm 
iron showed a significant difference (P<0.01) (Figure 5-17). Once more, calprotectin signified 
the presence of more faecal neutrophils, i.e. more inflammation in mice that were receiving 
high iron diets 129. No differences were noted in the untreated chronic groups. 
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The levels of faecal calprotectin in mice fed long term 100ppm iron and 400ppm iron diets 
followed by acute DSS (2%) were consistent with our acute DSS experimental results (reported 
in Chapter 3) where faecal calprotectin day-1 vs. day-10 showed significant differences in each 
DSS-treated group. However, the highest difference was for 100ppm iron diet DSS-treated 
mice. 
 
We measured total faecal iron concentrations to assess the level of inflammation by using the 
presence of luminal bleeding 111. Data in this research showed that all DSS-treated group 
revealed a significant difference between cycles. However, the 400ppm iron group had lower 
significance than those with 100 and 200ppm iron groups. In contrast, untreated mice 
receiving 200 and 400ppm iron showed significant differences (P<0.01) and not in those taking 
100ppm iron (Figure 5-19 Chapter 5).  
 
After 63-days on diets, the samples were taken from mice that received 2% DSS displayed a 
significant difference (day-1 vs. 10) reflecting the severity of colitis. The 400ppm iron group 
showed the most significant difference (P<0.0001) whereas the 100ppm iron and 200ppm iron 
DSS groups had a difference of similar significance (P<0.01). However, faecal iron 
concentration data for untreated mice were only significant in the mice supplemented with 
400ppm iron which was statistically significant (P<0.05) (Figure 5-21 Chapter 5). 
 
Microbiome analysis for chronic DSS samples was carried out using the same technique and 
software employed in the acute DSS experiments (Chapter 4). Chronic samples were taken at 
four different time points (days-1, 21, 42 and 63) which represented the beginning and the 
end of each DSS cycle. Thorough analysis started at an upper taxonomic level such as phylum 
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with principal component analysis (PCA) for each group separately to identify linear 
combinations of gut microbial taxa that were associated with the duration on a diet. A clear 
separation was seen for the samples from 100ppm iron and 400ppm iron DSS-treated groups 
as well as from 400ppm iron control mice. Thus, high dietary iron disturbs the microbial 
community in both DSS-treated and untreated mice, while low dietary iron only affects gut 
microbiota in the presence of colitis (DSS-induce). 
  
Further post hoc tests applied to each group showed that the mean proportion of sequences 
was significantly assigned to Proteobacteria in 100ppm iron DSS group with an increase in day-
63 vs. day-1 and 21 (P<0.05). This suggests that at the end of each DSS cycle, the level of 
inflammation was associated with an increase in Proteobacteria. In a study, Proteobacteria 
appeared to have a growth advantage from this shift (low iron) 154. These observations are in 
agreement with our other findings (weight loss, histology, calprotectin and microbiome 
analysis), proposing that a low iron diet exacerbates colitis and causes dysbiosis. 
 
The data from research on anaemic African children where iron fortification in their food was 
applied, revealed that a pathogenic intestinal bacterial profile and gut inflammation were 
increased as a result of extra iron in the diet 153. This is consistent with our findings in which 
the 400ppm iron DSS-treated group had significantly reduced Bacteroidetes (P<0.078) and 
increased Proteobacteria (P<0.016), where the difference between each pre and post-DSS 
intervention was observed in day-63 samples.  
 
However, the only DSS-untreated group that showed a significant difference in the phyla was 
the 400ppm iron group: these mice showed an increase in both Proteobacteria and 
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Actinobacteria (P<0.011 each). Nevertheless, the increase in Proteobacteria was significant at 
day‐42 vs. 21 (P<0.001) and day‐63 vs. 21 (P<0.05). However the changes seen in the gut 
microbiome in this group are contrary to data reported by Dirk Haller and his team: they found 
that a depleted iron diet caused significant dysbiosis without a major effect on host genotype, 
inflammatory response and systemic iron application 152. 
 
When studying probiotics and IBD, Toumi et al.165 stated that administration of some strains 
of Lactobacillus and Bifidobacterium had not only beneficial effects on maintenance of the 
integrity of the epithelial barrier and tissue repair but also had anti-inflammatory effects and 
improved DSS-induced colitis 165. Devkota et al.166 also demonstrated that diet could alter the 
intestinal microbiota which contributes to the development of colitis in mice, and any 
reduction in bacteria Bilophila wadsworthia could increase the incidence of colitis 166.  
 
These results support our data. When a further lower taxonomic analysis was done, seven 
genera belonging to three phyla were significantly different in 100ppm iron DSS-treated and 
400ppm iron DSS-untreated mice. Three of these genera reduced over time and were present 
in both groups (Lactobacillus, Bacteroides and Bilophila). However, the differences were 
changed in the low iron DSS-treated mice for Lactobacillus (P<0.002) and Bilophila (P<0.008) 
than in untreated fed with a high iron diet (Lactobacillus (P<0.02) and Bilophila (P<0.03)). 
 
As previously mentioned iron is an essential nutrient for various gut bacteria that compete for 
unabsorbed dietary iron. Iron acquisition plays a key role in determining the virulence and 
colonisation of the majority of enteric Gram-negative bacteria (e.g. Shigella, Salmonella and 
pathogenic Escherichia coli) 76. Other commensal gut bacteria belonging to the genera 
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Lactobacillus and Bifidobacterium play a major role (barrier effect) against colonisation by 
such pathogens. Interestingly Lactobacilli do not require iron but instead, use manganese 167.  
 
The Bifidobacterium species (Bifidobacterium breve) can sequester luminal iron. However, the 
majority of Bifidobacterium species do not produce siderophores or other active iron carriers. 
Therefore, unabsorbed dietary iron may modify the colonic microbiota equilibrium and help 
the growth of pathogenic strains more than healthy ‘barrier’ strains. 
 
Interestingly, the 400ppm iron DSS group had only one phylum (Firmicutes) with one genus 
that showed a statistically significant difference (Lactobacillus P<0.01). These data suggest 
that 400ppm iron led to a relative suppression of Lactobacilli. Also, in a recent study by Werner 
T et al. data analysis found that depleted luminal iron only significantly affected a few genera, 
for example, Clostridium (P<0.0017) 152. This was also consistent with our findings where 
100ppm iron DSS-treated mice showed a significant reduction in Clostridium (P<0.04).  
 
In the case of high grades of inflammation and infection, iron absorption is likely to be even 
lower, as inflammation results in elevated circulating hepcidin and this further reduces iron 
absorption 168. So, in DSS-induced colitis, the level of absorbed iron was probably decreased. 
This leads to an increase in pathogenic bacteria and reduced immunity against infection. 
 
In this project, we investigated the effects of different dietary iron interventions (for 53-days) 
on the severity of acute DSS-induced colitis and its impact on the gut microbial structure in 
wild-type mice. However, the bioinformatics analysis at day-1 vs. day-10 for each group 
showed no significance. The inflammation was severe as shown by colitis scores (Chapter 5) 
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as a result of 2% DSS-induced colitis. The absence of difference may, therefore, be due to the 
small sample size (n=4) and also due to a failure to obtain bacterial DNA: the latter may be a 
result of DSS in the sample or disruption of the microbiome. However the study is also likely 
to be underpowered 
 
7.1 Potential medical implications  
 
Certainly, there is evidence to support the notion that the quality of life in anaemic IBD 
patients can be very poor and that treatment of anaemia will improve this 38. The best therapy 
for anaemia of chronic disease (ACD) is curing the underlying illness, and treating anaemia 
might be a therapeutic target for treating IBD. However, a cure may not be possible 35. Oral 
iron supplementation is often preferred by clinicians to treat IDA because of its relative safety, 
efficacy, and cost. Common oral iron preparations that are used to treat iron deficiency in IBD 
patients such as ferrous salts e.g.; sulphate, fumarate and gluconate, however, have multiple 
gastrointestinal side effects 34. Recent studies have also shown that oral iron supplements can 
increase intestinal tissue injury by catalysing the production of reactive oxygen species (ROS) 
and can affect the immune system as well as intestinal inflammation in IBD 38. Moreover, 
advanced molecular techniques have illustrated changes in the gut microbiota (dysbiosis) in 
IBD patients 68. 
 
To provide a more rational approach, it is essential to distinguish between the role of iron in 
aggravating intestinal inflammation and the inflammation-associated dysbiosis. The data in 
this thesis have shown differential and unique influences of different iron diets upon murine 
models of colitis and colitis-associated microbiota. It is too early for our results to suggest that 
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reducing the amount of consumed (luminal) iron to the optimal range may be a promising 
novel strategy to manage IBD and minimise the risk of dysbiosis in these patients. Therefore, 
we need to extend these observations toward a prospective study in humans (IBD patients) 
comparing faecal samples before and after taking iron supplements. 
 
7.2 Future research directions  
 
Numerous potential future experiments have already been discussed with my supervisor and 
carrying out these experiments could help to answer several important research questions 
and explain the molecular mechanisms responsible for the different intestinal responses to 
injury that were observed among animals consuming different amounts of iron in their diet. 
Data in this thesis have demonstrated that modifications of standard iron diet can exacerbate 
DSS-induced colitis as well as the balance of the intestinal microbial community in wild-type 
(C57BL/6) mice. It is well documented that NF-kB signalling pathways make important 
contributions to inflammatory responses. Pritchard et al.169 demonstrated that NF-κB2-
mediated signalling seems to be critical for DSS-induced colitis 169. Consequently, it would be 
interesting to investigate the effect of administering a different range of iron diets on the 
development of DSS-induced colitis in NFκB null mice as well as study the consequences of 
deleting various NFκB family members on gut microbiota. 
 
Ferric maltol is a new oral iron treatment containing a stable complex of ferric iron (Fe3+) with 
maltol. This preparation allows ferric iron to be absorbed properly by enterocytes at relatively 
low dose levels enabling IBD patients to be treated with iron deficiency 170. Also, ferric maltol 
has good tolerability and has less impact on inflammatory bowel disease severity 171. 
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Therefore, it would be interesting to look at (1) the effect of ferric iron supplementation upon 
murine colitis, by assessing the severity of colitis and dysbiosis, and (2) the impact of ferric 
iron on the microbiota of humans with IBD. 
 
The fundamental aim of our studies was to increase understanding of the pathogenesis of 
inflammatory bowel disease and its associated dysbiosis. Thus, it is now necessary to extend 
these studies to more types of murine IBD models along with further manipulations in iron 
diets. Several IBD models such as TNBS colitis have previously been established and can be 
used to study colitis in mice. Moreover, some bacteria have been associated with iron 
concentrations and inflammation development in this research, so in vitro experiments using 
techniques such as cell culture could also be used to assess the function of a particular 
organism (S. Typhimurium) in response to iron. This could provide another window to look 
through on the pathogenesis of inflammatory bowel disease and dysbiosis. 
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7.3 Limitations of presented studies  
 
Iron concentrations in animals are controlled by regulation of intestinal iron absorption. 
Haemochromatosis is considered when total body iron is widely increased due to 
inappropriately high levels of intestinal iron absorption 172. In contrast, low levels of intestinal 
iron absorption cause iron deficiency (ID) with or without anaemia. In this research, diets low 
(100ppm iron) and high (400ppm iron) in iron were formulated according to literature and 
previous studies in this area. The low iron diet (100ppm iron) was the lowest that we could 
obtain based on the standard chow (200ppm iron) already used in maintaining animals and 
high iron diet (400ppm iron) was created by doubling the standard chow (200ppm iron) iron 
content to prevent hemochromatosis. This apparent limitation, however, allows for 
investigating the iron influence on the study of colitis in both acute as well as chronic 
experiments. 
 
The majority of the ingested iron (ferrous) passes unabsorbed on to the ileum and colon, 
where sites of inflammation in Crohn’s disease (CD) and ulcerative colitis (UC) occur, before 
appearing in the stool. Iron attaches to the intestinal surface (ulcerated), increasing the local 
production of reactive oxygen species (ROS) and thus augmenting inflammation 173. We 
suggested that the immunoassay technique may be required for assessing faecal iron 
concentrations using the best commercially available iron assay kit (as it described in Chapter 
2), which is a cheap, simple and relatively consistent way to measure luminal iron i.e. from 
food and any intestinal bleeding, but other methods such as Coulter counter may be 
preferable to assess iron deficiency anaemia (IDA) or Hem-occult test (Beckman Coulter, Inc., 
Fullerton, CA) to detect any intestinal bleeding, however the Biomedical Services Unit (BSU) 
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lack of such tool. As discussed in previous chapters, particular time points (pre and post-DSS 
treatment) utilised to address these important research questions.  
 
The successful and reproducible induction of DSS-induced colitis was achieved in this project 
and allowed us to obtain faecal samples to assess microbiota disturbances at various time-
points. During DSS-induced colitis day-8 was the showed the most weight loss and histological 
changes (as it described in Chapter 3). However, we could not study the microbiota at this 
stage as the PCR appeared to be inhibited, perhaps by DSS. It would, therefore, be helpful to 
find other means of assessing the microbiota at this time point.  
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7.4 Conclusions  
 
In this thesis, I have demonstrated that dietary iron plays a role in DSS-induced colitis and 
intestinal responses to various types of inflammation. Low iron was clinically (body weight and 
histology) significantly worsened colitis while high iron had a great impact on intestinal 
microbiota disturbance as summarised in Table 7.1. Although we do not have an ultimate 
explanation for this observation, it could reflect the consequences of differences in blood loss 
from the inflamed colon, differences in food intake or the influence of iron regulating 
mechanisms. In the setting of inflammation, any modifications of iron in the diet exacerbated 
the severity of experimental acute and chronic colitis in wild-type mice. However, long-term 
high iron diet (400ppm iron) resulted in increased inflammation associated with dysbiosis 
induced by DSS and dysbiosis with diet alone as summarised in Table 7.2. These findings how 
oral iron supplements exacerbate IBD. 
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 Acute DSS-induced colitis 
 
100ppm iron 200ppm iron 400ppm iron 
DSS Ctr. DSS Ctr. DSS Ctr. 
Body weight           
Histology (colitis)       
Faecal calprotectin       
Faecal iron       
Microbiome significance       
 
Table 7-1: Summary of the main observations from acute 2% DSS-induce colitis experiments. Ctr. (control), the dash (   ) no 
change and microbiome significance represent statistical significance. 
 
 
 
 Chronic DSS-induced colitis 
 
100ppm iron 200ppm iron 400ppm iron 
DSS Ctr. DSS Ctr. DSS Ctr. 
Body weight           
Histology (colitis)       
Histology (fibrosis)       
Faecal calprotectin       
Faecal iron       
Microbiome significance       
 
Table 7-2: Summary of the main observations from chronic 1.25% DSS-induce colitis experiments. Ctr. (control), the dash  
 (    ) no change and microbiome significance represent statistical significance. 
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8 Publications arising from this thesis 
 
8.1 List of published abstracts 
 
1. Mahalhal A., Campbell B., Pritchard D.M., Probert C. Influence of Iron Supplementation on 
The Natural History of Colitis. BSG 2016 Liverpool. Gut 2016; 65: A244. PTH-051 (abstract of 
distinction) (poster of distinction). 
2. Mahalhal A., Campbell B.J., Pritchard D.M., Probert C. Influence of iron supplementation on 
gut microbiota and the natural history of colitis. European Microbiome Congress, 18-19 
November 2015 (Poster of distinction).  
3. Mahalhal A., Aggio R., Reade S., Campbell B., Pritchard D.M., Probert C. The influence of 
iron supplementation on the severity of a murine model of colitis. ITM research day July 6, 
2015, University of Liverpool. S1-P06 (Poster of distinction). 
4. Mahalhal A., Reade S., Campbell B., Pritchard D.M., Probert C. The influence of iron 
supplementation on the severity of a murine model of colitis. DDF 2015 conference London. 
Gut 2015; 64: A92. PTU-072 (poster). 
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10 Appendices 
 
Appendix 1- Samples identifications (Chapter 4) 
 
Sample ID 
According to 
96 well plate 
Barcode 
Sequence 
Linker 
Primer 
Sequence 
Treatment DOB Description 
A1   Control 25/02/2014 Control mouse, colon 
content –I.D MA01,1,CC 
A2   Control 25/02/2014 Control mouse, colon 
content –I.D MA01,2,CC 
A3   Control 25/02/2014 Control mouse, colon 
content –I.D MA01,3,CC 
A4   Control 25/02/2014 Control mouse, colon 
content –I.DMA01,4,CC 
A5   Control 25/02/2014 Control mouse, colon 
content –I.D MA01,5,CC 
A6   Control 25/02/2014 Control mouse, colon 
content –I.D MA01,6,CC 
A7   DSS/low iron diet 25/02/2014 DSS/low iron mouse, 
colon content –I.D 
MA03,1,CC 
A8   DSS/low iron diet 25/02/2014 DSS/low iron mouse, 
colon content –I.D 
MA03,2,CC 
A9   DSS/normal diet 25/02/2014 DSS normal diet mouse, 
colon content –I.D 
MA02,1,CC 
A10   DSS/normal diet 25/02/2014 DSS normal diet mouse, 
colon content –I.D 
MA02,2,CC 
A11   DSS/normal diet 25/02/2014 DSS normal diet mouse, 
colon content –I.D 
MA02,3,CC 
A12   DSS/normal diet 25/02/2014 DSS normal diet mouse, 
colon content –I.D 
MA02,4,CC 
B1   DSS/normal diet 25/02/2014 DSS normal diet mouse, 
colon content –I.D 
MA02,5,CC 
B2   DSS/normal diet 25/02/2014 DSS normal diet mouse, 
colon content –I.D 
MA02,6,CC 
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B3   DSS/low iron diet 25/02/2014 DSS/low iron mouse, 
colon content –I.D 
MA03,3,CC 
B4   DSS/low iron diet 25/02/2014 DSS/low iron mouse, 
colon content –I.D 
MA03,4,CC 
B5   DSS/high  iron 
diet 
25/02/2014 DSS/high iron mouse, 
colon content –
I.DMA04,1,CC 
B6   DSS/high  iron 
diet 
25/02/2014 DSS/high iron mouse, 
colon content –
I.DMA04,2,CC 
B7   DSS/high  iron 
diet 
25/02/2014 DSS/high iron mouse, 
colon content –
I.DMA04,3,CC 
B8   DSS/high  iron 
diet 
25/02/2014 DSS/high iron mouse, 
colon content –
I.DMA04,4,CC 
B9   DSS/high  iron 
diet 
25/02/2014 DSS/high iron mouse, 
colon content –
I.DMA04,5,CC 
B10   DSS/high  iron 
diet 
25/02/2014 DSS/high iron mouse, 
colon content –
I.DMA04,6,CC 
B11   DSS/low iron diet 25/02/2014 DSS/low iron mouse, 
colon content –I.D 
MA03,5,CC 
B12   DSS/low iron diet 25/02/2014 DSS/low iron mouse, 
colon content –I.D 
MA03,6,CC 
C1   Low iron diet 25/02/2014 low iron mouse, colon 
content –I.D MA05,1,CC 
C2   Low iron diet 25/02/2014 low iron mouse, colon 
content –I.D MA05,2,CC 
C3   Low iron diet 25/02/2014 low iron mouse, colon 
content –I.D MA05,3,CC 
C4   Low iron diet 25/02/2014 low iron mouse, colon 
content –I.D MA05,4,CC 
C5   Low iron diet 25/02/2014 low iron mouse, colon 
content –I.D MA05,5,CC 
C6   Low iron diet 25/02/2014 low iron mouse, colon 
content –I.D MA05,6,CC 
C7   High iron diet 25/02/2014 high iron mouse, colon 
content –I.D MA06,1,CC 
C8   High iron diet 25/02/2014 high iron mouse, colon 
content –I.D MA06,2,CC 
C9   High iron diet 25/02/2014 high iron mouse, colon 
content –I.D MA06,3,CC 
C10   High iron diet 25/02/2014 high iron mouse, colon 
content –I.D MA06,4,CC 
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C11   High iron diet 25/02/2014 high iron mouse, colon 
content –I.D MA06,5,CC 
C12   High iron diet 25/02/2014 high iron mouse, colon 
content –I.D MA06,6,CC 
D1   Control 25/02/2014 Control mouse, Faecal 
pellet day 0–I.D 
MA01,1,P0 
D2   Control 25/02/2014 Control mouse, Faecal 
pellet day 0–I.D 
MA01,2,P0 
D3   Control 25/02/2014 Control mouse, Faecal 
pellet day 0–I.D 
MA01,3,P0 
D4   Control 25/02/2014 Control mouse, Faecal 
pellet day 0–I.D 
MA01,4,P0 
D5   Control 25/02/2014 Control mouse, Faecal 
pellet day 0–I.D 
MA01,5,P0 
D6   Control 25/02/2014 Control mouse, Faecal 
pellet day 0–I.D 
MA01,6,P0 
D7   DSS/normal diet 25/02/2014 DSS mouse, Faecal 
pellet day 0–I.D 
MA02,1,P0 
D8   DSS/normal diet 25/02/2014 DSS mouse, Faecal 
pellet day 0–I.D 
MA02,2,P0 
D9   DSS/normal diet 25/02/2014 DSS mouse, Faecal 
pellet day 0–I.D 
MA02,3,P0 
D10   DSS/normal diet 25/02/2014 DSS mouse, Faecal 
pellet day 0–I.D 
MA02,4,P0 
D11   DSS/normal diet 25/02/2014 DSS mouse, Faecal 
pellet day 0–I.D 
MA02,5,P0 
D12   DSS/normal diet 25/02/2014 DSS mouse, Faecal 
pellet day 0–I.D 
MA02,6,P0 
E1   DSS/low iron diet 25/02/2014 DSS low iron mouse, 
Faecal pellet day 0–I.D 
MA03,1,P0 
E2   DSS/low iron diet 25/02/2014 DSS low iron mouse, 
Faecal pellet day 0–I.D 
MA03,2,P0 
E3   DSS/low iron diet 25/02/2014 DSS low iron mouse, 
Faecal pellet day 0–I.D 
MA03,3,P0 
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E4   DSS/low iron diet 25/02/2014 DSS low iron mouse, 
Faecal pellet day 0–I.D 
MA03,4,P0 
E5   DSS/low iron diet 25/02/2014 DSS low iron mouse, 
Faecal pellet day 0–I.D 
MA03,5,P0 
E6   DSS/low iron diet 25/02/2014 DSS low iron mouse, 
Faecal pellet day 0–I.D 
MA03,6,P0 
E7   
 
DSS/high  iron 
diet 
25/02/2014 DSS high iron mouse, 
Faecal pellet day 0–I.D 
MA04,1,P0 
E8   DSS/high  iron 
diet 
25/02/2014 DSS high iron mouse, 
Faecal pellet day 0–I.D 
MA04,2,P0 
E9   DSS/high  iron 
diet 
25/02/2014 DSS high iron mouse, 
Faecal pellet day 0–I.D 
MA04,3,P0 
E10   DSS/high  iron 
diet 
25/02/2014 DSS high iron mouse, 
Faecal pellet day 0–I.D 
MA04,4,P0 
E11   DSS/high  iron 
diet 
25/02/2014 DSS high iron mouse, 
Faecal pellet day 0–I.D 
MA04,5,P0 
E12   DSS/high  iron 
diet 
25/02/2014 DSS high iron mouse, 
Faecal pellet day 0–I.D 
MA04,6,P0 
F1   Low iron diet 25/02/2014 Low iron mouse, Faecal 
pellet day 0–I.D 
MA05,1,P0 
F2   Low iron diet 25/02/2014 Low iron mouse, Faecal 
pellet day 0–I.D 
MA05,2,P0 
F3   Low iron diet 25/02/2014 Low iron mouse, Faecal 
pellet day 0–I.D 
MA05,3,P0 
F4   Low iron diet 25/02/2014 Low iron mouse, Faecal 
pellet day 0–I.D 
MA05,4,P0 
F5   Low iron diet 25/02/2014 Low iron mouse, Faecal 
pellet day 0–I.D 
MA05,5,P0 
F6   Low iron diet 25/02/2014 Low iron mouse, Faecal 
pellet day 0–I.D 
MA05,6,P0 
F7   High iron diet 25/02/2014 High iron mouse, Faecal 
pellet day 0–I.D 
MA06,1,P0 
F8   High iron diet 25/02/2014 High iron mouse, Faecal 
pellet day 0–I.D 
MA06,2,P0 
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F9   High iron diet 25/02/2014 High iron mouse, Faecal 
pellet day 0–I.D 
MA06,3,P0 
F10   High iron diet 25/02/2014 High iron mouse, Faecal 
pellet day 0–I.D 
MA06,4,P0 
F11   
 
High iron diet 25/02/2014 High iron mouse, Faecal 
pellet day 0–I.D 
MA06,5,P0 
F12   High iron diet 25/02/2014 High iron mouse, Faecal 
pellet day 0–I.D 
MA06,6,P0 
G1   - - -VE control 
G2, G3   - - -VE control 
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Appendix 2- Phyla (legends) Chapter 4 and 5 
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Appendix 3- Families (legends) Chapter 4 
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Appendix 4- Samples identifications (Chapter 6) 
 
  Sample Plate  
Plate 1 Name Location 
9676_1 Chronic DSS, 100, d1,1 A1 
9676_2 Chronic DSS, 100, d1,2 A2 
9676_3 Chronic DSS, 100, d1,3 A3 
9676_4 Chronic DSS, 100, d1,4 A4 
9676_5 Chronic DSS, 100, d1,5 A5 
9676_6 Chronic DSS, 100, d1,6 A6 
9676_7 Chronic DSS, 100, d1,7 A7 
9676_8 Chronic DSS, 200, d1,1 A8 
9676_9 Chronic DSS, 200, d1,2 A9 
9676_10 Chronic DSS, 200, d1,3 A10 
9676_11 Chronic DSS, 200, d1,4 A11 
9676_12 Chronic DSS, 200, d1,5 A12 
9676_13 Chronic DSS, 200, d1,6 B1 
9676_14 Chronic DSS, 200, d1,7 B2 
9676_15 Chronic DSS, 400, d1,1 B3 
9676_16 Chronic DSS, 400, d1,2 B4 
9676_17 Chronic DSS, 400, d1,3 B5 
9676_18 Chronic DSS, 400, d1,4 B6 
9676_19 Chronic DSS, 400, d1,5 B7 
9676_20 Chronic DSS, 400, d1,6 B8 
9676_21 Chronic DSS, 400, d1,7 B9 
9676_22 Chronic control, 100, d1,1 B10 
9676_23 Chronic control, 100, d1,2 B11 
9676_24 Chronic control, 100, d1,3 B12 
9676_25 Chronic control, 100, d1,4 C1 
9676_26 Chronic control, 100, d1,5 C2 
9676_27 Chronic control, 100, d1,6 C3 
9676_28 Chronic control, 100, d1,7 C4 
9676_29 Chronic control, 200, d1,1 C5 
9676_30 Chronic control, 200, d1,2 C6 
9676_31 Chronic control, 200, d1,3 C7 
9676_32 Chronic control, 200, d1,4 C8 
9676_33 Chronic control, 200, d1,5 C9 
9676_34 Chronic control, 200, d1,6 C10 
9676_35 Chronic control, 200, d1,7 C11 
9676_36 Chronic control, 400, d1,1 C12 
9676_37 Chronic control, 400, d1,2 D1 
9676_38 Chronic control, 400, d1,3 D2 
9676_39 Chronic control, 400, d1,4 D3 
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9676_40 Chronic control, 400, d1,5 D4 
9676_41 Chronic control, 400, d1,6 D5 
9676_42 Chronic control, 400, d1,7 D6 
9676_43 Chronic DSS, 100, d21,1 D7 
9676_44 Chronic DSS, 100, d21,2 D8 
9676_45 Chronic DSS, 100, d21,3 D9 
9676_46 Chronic DSS, 100, d21,4 D10 
9676_47 Chronic DSS, 100, d21,5 D11 
9676_48 Chronic DSS, 100, d21,6 D12 
9676_49 Chronic DSS, 100, d21,7 E1 
9676_50 Chronic DSS, 200, d21,1 E2 
9676_51 Chronic DSS, 200, d21,2 E3 
9676_52 Chronic DSS, 200, d21,3 E4 
9676_53 Chronic DSS, 200, d21,4 E5 
9676_54 Chronic DSS, 200, d21,5 E6 
9676_55 Chronic DSS, 200, d21,6 E7 
9676_56 Chronic DSS, 200, d21,7 E8 
9676_57 Chronic DSS, 400, d21,1 E9 
9676_58 Chronic DSS, 400, d21,2 E10 
9676_59 Chronic DSS, 400, d21,3 E11 
9676_60 Chronic DSS, 400, d21,4 E12 
9676_61 Chronic DSS, 400, d21,5 F1 
9676_62 Chronic DSS, 400, d21,6 F2 
9676_63 Chronic DSS, 400, d21,7 F3 
9676_64 Chronic control, 100, d21,1 F4 
9676_65 Chronic control, 100, d21,2 F5 
9676_66 Chronic control, 100, d21,3 F6 
9676_67 Chronic control, 100, d21,4 F7 
9676_68 Chronic control, 100, d21,5 F8 
9676_69 Chronic control, 100, d21,6 F9 
9676_70 Chronic control, 100, d21,7 F10 
9676_71 Chronic control, 200, d21,1 F11 
9676_72 Chronic control, 200, d21,2 F12 
9676_73 Chronic control, 200, d21,3 G1 
9676_74 Chronic control, 200, d21,4 G2 
9676_75 Chronic control, 200, d21,5 G3 
9676_76 Chronic control, 200, d21,6 G4 
9676_77 Chronic control, 200, d21,7 G5 
9676_78 Chronic control, 400, d21,1 G6 
9676_79 Chronic control, 400, d21,2 G7 
9676_80 Chronic control, 400, d21,3 G8 
9676_81 Chronic control, 400, d21,4 G9 
9676_82 Chronic control, 400, d21,5 G10 
9676_83 Chronic control, 400, d21,6 G11 
9676_84 Chronic control, 400, d21,7 G12 
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9676_85 Chronic DSS, 100, d42,1 H1 
9676_86 Chronic DSS, 100, d42,2 H2 
9676_87 Chronic DSS, 100, d42,3 H3 
9676_88 Chronic DSS, 100, d42,4 H4 
9676_89 Chronic DSS, 100, d42,5 H5 
9676_90 Chronic DSS, 100, d42,6 H6 
9676_91 Chronic DSS, 100, d42,7 H7 
9676_92 Chronic DSS, 200, d42,1 H8 
9676_93 Chronic DSS, 200, d42,2 H9 
9676_94 Chronic DSS, 200, d42,3 H10 
9676_95 Chronic DSS, 200, d42,4 H11 
9676_96 Chronic DSS, 200, d42,5 H12 
 
 
  Sample Plate  
Plate 2 Name Location 
9676_97 Chronic DSS, 200, d42,6 A1 
9676_98 Chronic DSS, 200, d42,7 A2 
9676_99 Chronic DSS, 400, d42,1 A3 
9676_100 Chronic DSS, 400, d42,2 A4 
9676_101 Chronic DSS, 400, d42,3 A5 
9676_102 Chronic DSS, 400, d42,4 A6 
9676_103 Chronic DSS, 400, d42,5 A7 
9676_104 Chronic DSS, 400, d42,6 A8 
9676_105 Chronic DSS, 400, d42,7 A9 
9676_106 Chronic control, 100, d42,1 A10 
9676_107 Chronic control, 100, d42,2 A11 
9676_108 Chronic control, 100, d42,3 A12 
9676_109 Chronic control, 100, d42,4 B1 
9676_110 Chronic control, 100, d42,5 B2 
9676_111 Chronic control, 100, d42,6 B3 
9676_112 Chronic control, 100, d42,7 B4 
9676_113 Chronic control, 200, d42,1 B5 
9676_114 Chronic control, 200, d42,2 B6 
9676_115 Chronic control, 200, d42,3 B7 
9676_116 Chronic control, 200, d42,4 B8 
9676_117 Chronic control, 200, d42,5 B9 
9676_118 Chronic control, 200, d42,6 B10 
9676_119 Chronic control, 200, d42,7 B11 
9676_120 Chronic control, 400, d42,1 B12 
9676_121 Chronic control, 400, d42,2 C1 
9676_122 Chronic control, 400, d42,3 C2 
9676_123 Chronic control, 400, d42,4 C3 
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9676_124 Chronic control, 400, d42,5 C4 
9676_125 Chronic control, 400, d42,6 C5 
9676_126 Chronic control, 400, d42,7 C6 
9676_127 Chronic DSS, 100, d63,1 C7 
9676_128 Chronic DSS, 100, d63,2 C8 
9676_129 Chronic DSS, 100, d63,3 C9 
9676_130 Chronic DSS, 100, d63,4 C10 
9676_131 Chronic DSS, 100, d63,5 C11 
9676_132 Chronic DSS, 100, d63,6 C12 
9676_133 Chronic DSS, 100, d63,7 D1 
9676_134 Chronic DSS, 200, d63,1 D2 
9676_135 Chronic DSS, 200, d63,2 D3 
9676_136 Chronic DSS, 200, d63,3 D4 
9676_137 Chronic DSS, 200, d63,4 D5 
9676_138 Chronic DSS, 200, d63,5 D6 
9676_139 Chronic DSS, 200, d63,6 D7 
9676_140 Chronic DSS, 200, d63,7 D8 
9676_141 Chronic DSS, 400, d63,1 D9 
9676_142 Chronic DSS, 400, d63,2 D10 
9676_143 Chronic DSS, 400, d63,3 D11 
9676_144 Chronic DSS, 400, d63,4 D12 
9676_145 Chronic DSS, 400, d63,5 E1 
9676_146 Chronic DSS, 400, d63,6 E2 
9676_147 Chronic DSS, 400, d63,7 E3 
9676_148 Chr.ctr.d63,acute DSS d1, 100, 1 E4 
9676_149 Chr.ctr.d63,acute DSS d1, 100, 2 E5 
9676_150 Chr.ctr.d63,acute DSS d1, 100, 3 E6 
9676_151 Chr.ctr.d63,acute ctr. d1, 100, 1 E7 
9676_152 Chr.ctr.d63,acute ctr. d1, 100, 2 E8 
9676_153 Chr.ctr.d63,acute ctr. d1, 100, 3 E9 
9676_154 Chr.ctr.d63,acute ctr. d1, 100, 4 E10 
9676_155 Chr.ctr.d63,acute DSS d1, 200, 1 E11 
9676_156 Chr.ctr.d63,acute DSS d1, 200, 2 E12 
9676_157 Chr.ctr.d63,acute DSS d1, 200, 3 F1 
9676_158 Chr.ctr.d63,acute ctr. d1, 200, 1 F2 
9676_159 Chr.ctr.d63,acute ctr. d1, 200, 2 F3 
9676_160 Chr.ctr.d63,acute ctr. d1, 200, 3 F4 
9676_161 Chr.ctr.d63,acute ctr. d1, 200, 4 F5 
9676_162 Chr.ctr.d63,acute DSS d1, 200, 1 F6 
9676_163 Chr.ctr.d63,acute DSS d1, 200, 2 F7 
9676_164 Chr.ctr.d63,acute DSS d1, 200, 3 F8 
9676_165 Chr.ctr.d63,acute ctr. d1, 200, 1 F9 
9676_166 Chr.ctr.d63,acute ctr. d1, 200, 2 F10 
9676_167 Chr.ctr.d63,acute ctr. d1, 200, 3 F11 
9676_168 Chr.ctr.d63,acute ctr. d1, 200, 4 F12 
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9676_169 Acute DSS d10, 100, 1 G1 
9676_170 Acute DSS d10, 100, 2 G2 
9676_171 Acute DSS d10, 100, 3 G3 
9676_172 Control d63,d10, 100, 1 G4 
9676_173 Control d63,d10, 100, 2 G5 
9676_174 Control d63,d10, 100, 3 G6 
9676_175 Control d63,d10, 100, 4 G7 
9676_176 Acute DSS d10, 200, 1 G8 
9676_177 Acute DSS d10, 200, 2 G9 
9676_178 Acute DSS d10, 200, 3 G10 
9676_179 Control d63,d10, 200, 1 G11 
9676_180 Control d63,d10, 200, 2 G12 
9676_181 Control d63,d10, 200, 3 H1 
9676_182 Control d63,d10, 200, 4 H2 
9676_183 Acute DSS d10, 400, 1 H3 
9676_184 Acute DSS d10, 400, 2 H4 
9676_185 Acute DSS d10, 400, 3 H5 
9676_186 Control d63,d10, 400, 1 H6 
9676_187 Control d63,d10, 400, 2 H7 
9676_188 Control d63,d10, 400, 3 H8 
9676_189 Control d63,d10, 400, 4 H9 
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Appendix 5- Total number of reads (Chapter 6) 
 
 
Diagram illustrating the total number of reads obtained for each sample. 
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Diagram illustrating the total number of reads obtained for each sample. 
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Appendix 6- Distribution of trimmed read lengths (Chapter 6) 
 
Box plot showing the distribution of trimmed read lengths for the forward (R1), reverse (R2) and 
singlet (R0) reads. 
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Box plot showing the distribution of trimmed read lengths for the forward (R1), reverse (R2) and 
singlet (R0) reads. 
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Box plot showing the distribution of trimmed read lengths for the forward (R1), reverse (R2) and 
singlet (R0) reads. 
